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Abstract 
 
Pfn2 is a brain specific actin binding protein involved in actin dynamics. The Pfn2 knock-out mouse 
model shows an autistic-like phenotype with all of the features commonly reported in autism patients 
such as social and communicational impairment, repetitive behavior and epileptic seizures. The role(s) 
and function(s) of Pfn2 in this striking phenotype are not understood completely. A first step in 
understanding these roles is investigating the expression pattern of Pfn2 in the brain to shed light on 
the different neuronal systems that could potentially contribute to the many aspects of the autistic-like 
and epileptic phenotypes. 
 
A Profilin2-GFP fusion protein knock-in mouse model was used in this thesis to investigate the 
expression of Pfn2 in neuronal cell subtypes that could possibly contribute to the autistic-like 
phenotype. Pfn2 has been found expressed in glutamatergic, dopaminergic, serotonergic, adrenergic 
and cholinergic neurons, both pre- and post-synaptically, while GABAergic neurons showed a complex 
subtype specific expression pattern dependent on the respective brain area. Pfn2 was missing from all 
glial cell subtypes. Neural stem cells expressed Pfn2, but stem cell-derived progenitor cells were 
devoid of Pfn2, but it is re-expressed upon their differentiation into post-mitotic neurons. 
 
The P2-GFP fusion protein is expressed in the knock-in mouse model at reduced levels (app. half) 
compared to the wt in heterozygous animals. P2-GFP also showed a minor impairment in poly-L-
proline binding efficiency (app. 75% of Pfn2), but no changes in G-actin binding efficiency. 
Nevertheless, P2-GFP was able to bind to nearly all ligands that Pfn2 could interact with including a 
novel interaction partner, cortactin. The P2-GFP KI mouse model is therefore validated to study Pfn2 
trafficking and function in vivo.  
 
Finally, comparative analysis of wt and Pfn2 KO primary hippocampal neuron cultures as a model 
system revealed that Pfn2 also has a role during neuronal development. Pfn2 KO neurons showed an 
accelerated neuronal development, reaching each developmental stage faster than wt cells, possibly 
due to altered actin dynamics. The P2-GFP KI model was then employed to produce mature 
hippocampal neuron cultures and the trafficking of Pfn2 following different stimulation protocols was 
studied. Upon application of various stimulants, Pfn2 mostly re-localized into post-synaptic terminals, 
as previously described, but also into pre-synaptic terminals and, to a lesser extent, into axons. The 
view of Pfn2 and its function possibly involved in actin-dependent mechanisms during neuronal 
development as well as during induced synaptic activity requires further studies, but a complex role of 
Pfn2 in these processes has been discovered with the help of the P2-GFP mouse model as a valuable 
tool. 
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1.1 Actin and actin polymerization 
 
Networks of filaments of several kinds can be found in every eukaryotic cell. They are 
essentially divided into three subtypes: microtubules, intermediate filaments and actin 
filaments. 
Microtubules consist of α- and β-tubulin dimers and can form long filaments of app. 
25 nm in diameter. Microtubules provide stability to the cell and are important for e.g. 
spindle formation during cell division or neurite outgrowth and elongation. 
Intermediate filaments are composed of protein that can build filaments up to 10 nm 
in diameter. Intermediate filaments are involved in several processes ranging from 
structural support of the cell to anchoring of subcellular structures. Most famous 
constituents of intermediate filaments are the nuclear envelope lamins, the neuronal 
proteins nestin and the neurofilaments, the typical astrocytic protein GFAP, which will 
be described further in this study, as well as the mesenchymal marker protein 
vimentin. 
The smallest filaments in terms of their average diameter, but also the most important 
for this thesis, are the actin filaments, with app. 7 nm thickness. Actin filaments are 
constituents of the cytoskeleton of the cell and necessary for a variety of cellular 
processes including cell movement, cytokinesis, membrane trafficking and many 
related mechanisms. 
Actin filaments consist of actin monomers (G-actin = globular actin) with a molecular 
weight of 42 kDa that polymerize to form a double helical structure called F-actin 
(filamentous actin).  
Actin is encoded by different highly conserved gene families (α-, β- and γ-actin). 
Each gene encodes a different isoform of actin, often expressed in distinct tissues. 
Three isoforms of α-actin are commonly known (skeletal, cardiac and smooth), 
primarily expressed in the respective type of muscle cells. Additionally one γ-actin 
isoform, γsmooth-actin, is expressed in smooth muscle enteric cells. The other γ-actin 
isoform and the most abundantly found β-actin variant are expressed most 
prominently in non-muscle cells (Perrin and Ervasti, 2010; Pollard et al., 1994). Actin 
is also highly conserved among species to a degree that in in vitro assays it is 
interchangeable (Kron et al., 1992; Nefsky and Bretscher, 1992). 
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The globular and filamentous forms are present in the cell in a reversible equilibrium. 
Actin filaments can be polymerized de novo from a nucleation complex by 
incorporation of G-actin monomers, loaded with ATP, in a unidirectional elongation 
process.  
F-actin filaments are polar molecules with the elongation process taking place mainly 
at the so-called “barbed end” (or plus (+) end) of the filament. Actin monomers are in 
general continuously removed at the so-called “pointed end” (or minus (–) end) (Fig. 
1). This happens, because the critical concentration of the actin monomer in order to 
polymerize is lower at the barbed end (Cc = app. 0.1 µM for purified actin in vitro) and 
much higher at the pointed end of a filament. Monomers can be removed when the 
intrinsic ATPase activity of actin has catalyzed the slow transition from the bound 
ATP to ADP, changing the biochemical and binding properties of the filament.  
 
Fig. 1 The actin polymerization cycle 
Depicted is the polymerization cycle of actin- filaments. A cell maintains a pool of G-actin bound to 
profilin, which loads it with ATP. Upon nucleation of app. 3 G-actin monomers with the help of 
nucleation factors like the Arp2/3 complex an F-actin filament can grow, elongating spontaneously or 
catalyzed by proteins like formins. Apart from straight elongation, an F-actin filament can also be 
branched mainly by the action of the Arp2/3 complex. The elongation process can be stopped by 
capping of an F-actin filament e.g. by binding of CapG to the tip of a filament. F-actin filaments are 
also frequently severed by proteins like gelsolin or the ADF/cofilin family of proteins, which leads to 
either depolymerization of the filaments or further elongation from the new ends of the previous 
filament. After depolymerization of an F-actin filament into G-actin monomers, these are available 
again in the G-actin pool for the next polymerization cycles.  
ATP
ADP
ADP
ADP
ATP ATP
ATP
ATP
ATP
ADP
ADP
ADP
elongation
ADP
ATP
ATP
depolymerization
depolymerization
ADP
ADP
ADP
nuc
lea
tio
n
ATP
ATP
ATP
branching ATP
ATP
ATP
ATP
capping 
& severing
1. Introduction 
 
4 
The circularity depicted in Fig. 1 occurs when the cytosolic concentration of the actin 
monomer subunit is maintained between the Cc+ and Cc- ends with the help of various 
actin binding proteins. This process is defined as actin treadmilling, in which there is 
growth at the positive end, and shrinkage at the negative end. 
 
1.2 Actin binding proteins  
 
Actin binding proteins (ABPs) are regulatory proteins that participate in actin 
dynamics (Winder, 2005) enhancing or inhibiting specific processes during actin 
polymerization. The proteins functioning as actin nucleators are the Arp2/3 complex, 
formins and WH2- (WASP-homology-2 also verproline-homology) domain containing 
actin nucleators (spire, cordon-bleu and leiomodin) (Fig. 2).  
 
 
Fig. 2 Actin nucleator classes 
Three classes of actin nucleators can be distinguished based on their mode of action.  
Class 1 Arp2/3 complexes work in synchrony with a nucleation-promoting factor, such as N-WASP, 
which provides an actin monomer via its WH2-domain in order to form a trimer of actin and actin-like 
structures with the actin-related subunits 2 and 3 of the Arp2/3 complex, which serves as a 
polymerization start point. Formins are class 2 actin nucleators, which are able to stabilize 
spontaneously occurring actin dimers or even trimers. Upon actin nucleation, formins remain attached 
to the barbed end of the actin filament further helping to accelerate the elongation process. All three 
class 3 actin nucleators form actin nuclei stabilized in different modes. Domains of various lengths 
have a linker function in between the WH2-domains of either Spire, Cobl or Lmod (modified from 
Chesarone and Goode, 2009). 
1. Introduction 
 
5 
The function of actin nucleators is to help the G-actin nucleation process, which is 
needed to initiate the polymerization of an actin filament (Ahuja et al., 2007; 
Campellone and Welch, 2010; Chesarone and Goode, 2009; Kunda et al., 2003; 
Quinlan et al., 2005). These proteins help to stabilize or create a nucleus of two to 
four G- actin monomers from which the filament elongation process can start (Fig. 2). 
The Arp2/3 complex is the most studied actin nucleator so far (Chesarone and 
Goode, 2009; Goley and Welch, 2006; Mullins et al., 1997; Welch et al., 1997). It was 
first purified by its binding capacity to profilin-beads (Machesky et al., 1994) and has 
since been shown to have a crucial role in the formation of branched actin filament 
networks during diverse processes. Arp2 and Arp3 are components of this 
heptameric complex that mimic the structure of an actin monomer. Arp2/3 requires 
activation from a nucleation promoting factor (NPF) such as WASP, N-WASP and the 
WAVE complex (Fig. 2).  
Another highly conserved class of actin nucleators is named formins (Fig. 2). This 
protein family consists of over 15 members in mammals (Faix and Grosse, 2006) but 
is also present in all eukaryotes examined until now. Formins function as 
homodimers, are inhibited by an autoinhibitory domain and this default inhibition is 
relieved by RhoA/Cdc42 signaling. They contain one FH2 (formin-homology-2) 
domain, which stabilizes the first nucleus of two actin monomers, and one FH1 
(formin-homology-1) domain, which can bind to profilactin complexes (see 1.3) and 
deliver the bound G-actin to the barbed end of the growing filament (Paul and 
Pollard, 2008). Remaining at the barbed end of an actin filament, formins can 
compete with capping protein binding, resulting in longer actin filaments compared to 
those generated by Arp2/3, Spire or Cobl (Fig. 2). 
Their function of actin nucleators is important not only for stress fiber formation, but 
also for filopodia and adherent junction formation in mouse and human cell lines, as 
well as cell polarity and cytokinesis in lower eukaryotes (Chesarone and Goode, 
2009; Imamura et al., 1997).  
To form e.g. stress fibers, additional proteins are needed to cross-link F-actin 
filaments and stabilize larger and more complex actin structures. This protein family 
includes α-actinin, fimbrin, spectrin and dystrophin.  
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To stop an actin filament from elongating, capping proteins (CapG, CapZ) are 
needed in the cell, which bind to the barbed end of an actin filament and prevent 
further monomer attachment. 
The disassembly of actin filaments is mediated by actin severing proteins such as 
gelsolin or the ADF/cofilin family of proteins. These proteins sever actin filaments to 
generate new endings and nuclei for extended actin polymerization in the cell as well 
as provide new actin monomers to the G-actin pool.  
G-actin monomers are bound by actin sequestering proteins, such as profilin or 
thymosin-β4. They are highly abundant proteins with opposing roles in the cell of 
promoting and inhibiting actin polymerization. Profilins are able to sequester ADP-G-
actin from the actin monomer pool, on which they can act as an ADP-ATP exchange 
factor, loading G-actin with ATP and supplying it further to the polymerization cycle. 
Thymosin-β4 on the other hand sequesters ATP-G-actin away from the 
polymerizable G-actin pool and therefore inhibits actin polymerization (Safer and 
Nachmias, 1994). 
 
1.2.1 The WAVE complex 
 
The WAVE (Wasp-family verproline-homologous protein) complex is a hetero-
pentameric complex (Eden et al., 2002) that is able to activate the Arp2/3 complex to 
enhance actin polymerization. In mammals, besides one of the three WAVE isoforms 
(WAVE 1-3) that have a different tissue expression, the complex contains CyFIP1-2 
(cytoplasmic Fragile-X mental retardation protein-interacting protein), Nap1 (Nck- 
associated protein-1), Abi 1-2 (Abl-Interactor) and HSPC300/Brick (hematopoietic 
stem cell progenitor protein) (Fig. 3). WAVE1 is highly expressed in brain but at lower 
levels also in other tissues and various cell lines. WAVE3 is nearly exclusively 
expressed in brain. WAVE2 is expressed ubiquitously (Takenawa and Miki, 2001). 
Similarly, CyFIP1 is expressed ubiquitously, while CyFIP2 has a very high expression 
in brain and a marginal expression in other tissues. Much less is known about the 
expression pattern of Abi isoforms. This not always overlapping tissue distribution of 
the components´ isoforms leaves doubts on the effective composition of the WAVE 
complex in vivo. 
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The WAVE complex is 
activated by Rac1, a small 
GTPase which induces the 
exposure of the VCA domain 
of the WAVE proteins by a 
transient interaction with 
CyFIP1 (Chen et al., 2010; 
Steffen et al., 2004, Fig. 3). 
The acidic domain of the 
VCA can bind to and thus 
activate the Arp2/3 complex, 
bringing Arp2 and Arp3 in 
proximity in order to start 
actin filament polymerization 
(Egile et al., 2005). The two 
subunits in turn will bind the G-actin monomer provided by the WH2/verprolin 
homology domain of WAVE producing the trimeric nucleus essential for actin filament 
elongation. 
 
1.3 Profilin 
 
An intrinsic ATPse activity of actin is responsible for the hydrolysis of ATP to ADP in 
actin filaments over time and is also allowing for a preferential binding of ABPs to 
ATP- or ADP-bound actin. 
A very important ABP binding preferentially to ADP-G-actin is profilin, whose study is 
the subject of this thesis. Profilin is known to bind actin to form a 1:1 complex, from 
which it was first isolated (profilactin), and to catalyze the exchange of ADP to ATP 
on the bound G-actin monomer with up to 1000-fold higher efficiency than 
spontaneous exchange (Goldschmidt-Clermont et al., 1992) before releasing it in 
response to a membrane signal via PIP2 (phosphatidylinositol-4,5-bisphosphate). The 
ATP-loaded G-actin can then be incorporated into the barbed end of a growing actin 
filament. Profilin can in turn be bound by a variety of proteins including the WAVE 
 
Fig. 3 The WAVE complex 
Shown here is a model of the crystal structures of the WAVE 
complex. The WAVE complex is a heteropentameric complex 
consisting of one WAVE isoform (WAVE1-3), Nap1, one CyFIP 
isoform (CyFIP1-2), one Abi isoform (Abi1-3) and HSPC300. 
CyFIP and Nap1 form a large scaffolding surface to which Abi, 
WAVE and HSPC300 dock on the side of CyFIP (Chen et al., 
2010). 
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complex, formins and other actin binding proteins, delivering the ATP-G-actin 
required by profilin ligands for actin polymerization. 
The ligand binding cleft of profilin is located opposite to the actin binding site,  
produced by two juxtaposed N- and C-terminal helices, and specifically binds to poly-
L-proline (PLP) stretches (Fig. 4) (Lu and Pollard, 2001; Mahoney et al., 1999). 
This PLP-binding site resembles an SH3 (Src-homology-3) domain, common to many 
other proteins, and can possibly compete with it for poly-L-proline binding. Certain 
ligands bound to the PLP-binding domain of profilins (e.g. dynamin1) are released 
together with G-actin, when a phosphoinositide (in particular, phosphatidylinositol-
4,5-bisphosphate, PIP2) binds to its binding site located on the ends of the N- and C- 
terminal helices, which are 
also involved in PLP-binding 
(Gareus et al., 2006; 
Gieselmann et al., 1995; 
Lassing and Lindberg, 1985; 
Machesky et al., 1994) (Fig. 
4).  
 
It is possible to speculate that 
profilins are translocated close 
enough to the membrane by 
their ligands and there, 
induced by PIP2 binding, they 
release ATP-G-actin to 
accelerate actin polymerization that is canonically happening in proximity of the cell 
membrane. 
 
1.3.1 Profilin isoforms 
 
Profilins were mentioned first in 1977 and are one of the earliest ABPs researched on  
(Carlsson et al., 1977). Profilins are highly expressed in all eukaryotes to a cellular 
concentration of up to 10 µM (Mogilner and Edelstein-Keshet, 2002) with the 
exception in certain algae according to a recent study (Aumeier et al., 2015). 
Fig. 4 Crystal structure of Pfn2 with peptides of a) VASP 
and b) mDia1 
The crystal structures of mouse a) Pfn2-VASP and
b) Pfn2–mDia1 PLP peptide complexes are shown. Ribbons 
represent α-helices, flat arrows β-sheets. Peptides are shown 
as stick and ball structures (modified from Kursula et al., 
2008). 
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The importance of profilins function and therefore their evolutionary conservation can 
be seen from the list of the many model organisms in which profilin function was 
already investigated. 
Profilins are important in bacterial motility, for example in the actin-based Listeria 
movement within infected cells (Geese et al., 2000; Laurent et al., 1999; Theriot et 
al., 1994). Knock-out of both profilin isoforms in Dictyostelium discoideum results in a 
decrease of F-actin content with impairments in migration and cytokinesis (Haugwitz 
et al., 1994). In Drosophila melanogaster, chickadee, the orthologue of profilin, 
controls oogenesis, spermatogenesis, cell migration, bristle and eye formation 
(Cooley et al., 1992; Verheyen and Cooley, 1994). Pfn1 in Zebrafish (Danio rerio) is 
important for gastrulation (Lai et al., 2008) and XPfn2 (Xenopus leavis Pfn2), in 
addition to gastrulation, is also regulating cell polarization and axial alignment 
(Khadka et al., 2009). Birds express PFN1 and PFN2 ubiquitously, except for skeletal 
muscle, and PFN2 plays a role in focal contact formation, cell adhesion and 
spreading (Murk et al., 2009). Some of the many plant profilin isoforms are also 
reported to be major pollen allergens (Ruiz-García et al., 2011; Santos and Van Ree, 
2011; Smith, 2002; Valenta et al., 1991). Even some types of viruses like Vaccinia 
virus (Blasco et al., 1991), and all orthopoxviruses (Butler-Cole et al., 2007) as well 
as certain cyanobacteria (Guljamow et al., 2007) contain profilin homologs. 
In humans and mice, the profilin protein family so far consists of 4 distinct profilin 
isoforms. Pfn1 is ubiquitously expressed in all tissues, except skeletal muscle and 
heart (Witke, 2004; Witke et al., 1998, 2001). Pfn2 is essentially neuron-specific, 
although expression in other tissues can be detected at much lower levels (Witke et 
al., 1998, 2001). Pfn3 and 4 are expressed specifically in mouse and human testis 
(Behnen et al., 2009; Hu et al., 2001; Obermann et al., 2005). 
The amino acid sequence is not very well conserved among the paralogs, for 
example human PFN1 and PFN2 are only 65% identical and the degree of identity is 
similar in the mouse. Even greater differences are found in lower eukaryotes (35% 
homology in Dictyostelium) and in plants (20% homology). Nevertheless, their 
structural domains and basic functions are well conserved (Gieselmann et al., 1995; 
Lambrechts et al., 1997). 
Both profilin 1 and profilin 2 genes consist of 3 exons with introns of varying lengths 
in between the coding regions. The exon-intron boundaries are conserved among the 
isoforms, but the Pfn2 gene additionally comprises a fourth alternative coding exon in 
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the 3´UTR in exon3. The alternative exon4 can be included in the ORF of Pfn2 
instead of exon3, leading to two alternative splice variants, Pfn2a and Pfn2b, in 
mouse and humans (Di Nardo et al., 2000), which differ in their C-terminal structures. 
In this study I will refer, if not specifically mentioned otherwise, to the splice variant 
Pfn2a as Pfn2, since it is the isoform involved in actin dynamics and is by far the 
dominant isoform in terms of expression level in the brain (95% Pfn2a) (Lambrechts 
et al., 2000; Di Nardo et al., 2000). Pfn2b does not bind actin and the poly-L-proline 
binding efficiency is reduced in comparison to Pfn2a. 
Mouse Pfn2 is predominantly localized to the cytoplasm but has been observed to be 
able to enter the nucleus. The profilactin complex is specifically transported out of the 
nucleus by its interaction with Exportin6 (Stüven et al., 2003). It has been observed 
that Pfn2 trafficking into the nucleus can be NMDA-dependent (Birbach et al., 2006). 
There is evidence of a nuclear fraction also for Pfn1 (Lederer et al., 2005), which 
could be recruited to the nucleus by the transcription factor p42POP that also was 
reported to bind to Pfn2. 
Pfn1 and Pfn2 share several ligands, even though with varying binding efficiencies: 
G-actin for example has a higher binding efficiency for Pfn1, while Mena, VASP and 
mDia are bound to Pfn2 with a higher efficiency than to Pfn1. But profilin isoforms 
also have specificity for certain ligands with only Pfn2 binding to dynamin 1, 
synapsins, ROCK and components of the Wave complex (CyFIP/POP, HEM2/Nap1) 
(Witke, 2004; Witke et al., 1998). Due to these differences it is still unclear whether 
Pfn1 and Pfn2 are interchangeable in vivo. The KO phenotype of the two profilins in 
the mouse is indeed very different, with the Pfn1 KO being early embryonic lethal 
before reaching the blastocyst stage (Witke et al., 2001) while the Pfn2 KO is viable 
with behavioral abnormalities (Pilo Boyl et al., 2007) (see 1.4.3). The reason for the 
different impact of Pfn1 and Pfn2 deletion in vivo could be rooted in their different 
embryonic expression patterns, since Pfn1 is expressed throughout embryonic 
development starting from the gamete stages, while the expression of Pfn2 at the 
embryonic level appears to begin around embryonic day 10 (E10) with the 
specification of the neuroectoderm (Witke et al., 2001). Both profilin isoforms could 
also play different roles, assuming the differences in e.g. binding partners of profilins 
could account for different functions of the proteins. Certainly these aspects of 
expression and function of profilins require further investigation.  
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1.3.2 Profilin 2 
 
The major neuronal profilin isoform is profilin 2 (Pfn2), whose expression in other 
tissues is several fold less (Witke et al., 1998). 
Pfn2 has specific functions that differ from Pfn1, as results from the work of several 
groups investigating the role of Pfn2 in different organisms and cell lines. A negative 
role of Pfn2 in neuronal clathrin-mediated vesicle endocytosis through the binding to 
dynamin 1 was shown in cultured neurons devoid of Pfn2 (Gareus et al., 2006). More 
recently a repressive role for glutamatergic vesicle exocytosis was also demonstrated 
in the Pfn2 KO mouse model (Pilo Boyl et al., 2007). An exocytosis impairment of 
kainate glutamate receptor 2b (GluK2b) was reported in COS-7 cells and Pfn2 knock-
out cultured hippocampal neurons transfected with Pfn2, suggesting a specific role of 
Pfn2 in negatively regulating receptor exocytosis (Mondin et al., 2010). 
Pfn2 can be phosphorylated by ROCK2 (Rho-associated coiled-coil kinase 2), but the 
relevance of Pfn2 phosphorylation has not been extensively investigated so far. A 
negative regulatory effect of Pfn2 on neuritogenesis, the first step in neuronal 
differentiation, was shown by inhibiting the ROCK2-dependent phosphorylation of 
Pfn2 in primary hippocampal neuron cultures (Da Silva et al., 2003).   
Importantly, the specific expression pattern of Pfn2 in mouse brain has not been 
thoroughly investigated yet and needs to be elucidated. Published work has shown 
the expression and a role in glutamatergic neurons, but other neuronal subtypes 
were hitherto not investigated and might therefore contribute specific functions in the 
intricate neuronal network constituting the peripheral and central nervous system. 
 
1.3.3 The Pfn2 knock-out mouse model 
 
A Pfn2 knock-out (KO) mouse was generated by heterologous gene transfer, 
integrating the lacZ gene fused to the coding region of Pfn2 exon3 by homologous 
recombination and resulting in a complete loss of Pfn2 expression. Pfn2 KO mice are 
viable and display a neuronal specific phenotype (Pilo Boyl et al., 2007). They have 
behavioral impairments such as hyperactivity and hyperexcitability, but no learning 
deficits (Pilo Boyl et al., 2007). Higher brain functions, such as social behavior and 
communication, are also impaired leading to an autism-like phenotype (Pilo Boyl, 
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unpublished). The major physiological defect observed in the Pfn2 KO mouse is a 
loss of regulation of glutamatergic vesicle exocytosis, possibly due to impaired 
synaptic fast actin polymerization, accompanied by an increased post-synaptic 
density (PSD) length. Yet it is unclear if other neuronal systems are also affected by 
Pfn2 loss and what is their contribution to the phenotype. 
 
1.3.4 The phenotype of Pfn2 KO mice and its implications in autism 
spectrum disorder 
 
The Pfn2 knock-out mouse shows behavioral abnormalities reminding of autism-like 
behavior including deficits in social interaction and communication, hyperexcitability, 
repetitive behavior, coordination impairments and epileptic seizures (Pilo Boyl, 
unpublished). 
Autism is a very complex disorder with many syndromes closely related to it, which 
are commonly summarized in the term autism spectrum disorder (ASD). 
The human autism phenotype has been described first in 1943 by Leo Kanner 
(Kanner, 1943), who first defined two features that were commonly present in autism 
spectrum disorders: 1.) “living in your own world” and 2.) “resistance to change”. This 
“resistance to change” manifests itself very often as stereotypical, repetitive behavior 
and hyperexcitability upon novel stimuli from the environment. Social and language 
impairment often associated with mental retardation were later defined as two distinct 
traits in autism spectrum disorders (Rutter, 1978; Rutter and Schopler, 1987). The 
incidence of autism is progressively increasing to now 13/10,000 children (in one 
study of US children even 110/10,000) (Kogan et al., 2009), with the earliest cases 
reported at only two years of age, while there is still no pharmacological cure or 
therapy (Chakrabarti and Fombonne, 2005; Fombonne, 2003, 2008; Kim, 2015; Pinto 
et al., 2010), therefore research on autism is of dire importance.  
Autism disorders are highly heritable (app. 90%) and associate frequently with other 
medical conditions like Fragile X syndrome (FXS), tuberous sclerosis (TSC), Prader-
Willi syndrome, Angelman syndrome, phenylketonuria (PKU), Rett´s syndrome and 
others (Folstein and Rosen-Sheidley, 2001; Tsai, 1999; Veenstra-VanderWeele et 
al., 2002; Zafeiriou et al., 2007). Moreover, seizures occur in app. 30% of the patients 
(Gillberg, 2000). An interesting observation is that the incidence of ASD is 3-5 times 
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higher in males than in females, which would imply a linkage to the X-chromosome, 
but the results are non-conclusive so far. Chromosome abnormalities in general were 
observed for several distinct gene loci, but the correlation to the neurodevelopmental 
phenotype in ASD is not yet fully understood.  
Physiologically, alterations in the excitation/inhibition ratio in the brain were observed 
in patients and mouse models affected by different mutations. Concomitant 
impairment of different neuronal circuitries, most often in the form of an excess of 
excitation (shift in the excitation/inhibition ratio) as well as single molecule defects are 
considered the basic cause of the autistic phenotype. 
Concerning the genetic variations implicated in ASD, many gene mutations are 
known to induce an autistic phenotype. Naturally occurring mutations in the three 
neurexin and four neuroligin genes (app. 50 known mutations for each gene family) 
as well as the post-synaptic scaffolding proteins Shank2 and Shank3 can cause 
forms of ASD (Bang and Owczarek, 2013; Pinto et al., 2010; Tabuchi et al., 2007). 
The three neurexin genes give rise to α- and β-isoforms with 6 canonical alternative 
splice sites each, which would yield theoretically app. 2000 splice variants, while the 
four neuroligin genes are also alternatively spliced without a complete mapping of the 
resulting isoforms (Bang and Owczarek, 2013; Treutlein et al., 2014). The role of 
these proteins in vivo is to bridge pre- and post-synaptic terminals via trans-synaptic 
interactions of pre-synaptic neurexins with post-synaptic neuroligins. The neuroligin-3 
gain-of-function mutation R451C observed in ASD patients leads to enhanced 
inhibitory synaptic transmission in mice (Bang and Owczarek, 2013; Tabuchi et al., 
2007) causing a mild behavioral deficit in social interactions and enhanced spatial 
learning. This mutation can serve as an example for the shift in the excitation/ 
inhibition balance in ASD, which is affected by alterations in either excitatory or 
inhibitory synaptic transmission (Anderson et al., 2012; Tabuchi et al., 2007). Several 
mouse models have been generated in recent years to study syndromic autism, for 
example FMRP (fragile X mental retardation protein) or MeCP2 (methyl CpG binding 
protein 2) knock-out mice are common models for the autistic phenotype related to 
Fragile X syndrome (FXS) and Rett syndrome, respectively. 
A wide range of mouse models has been described that show only a subset of 
endophenotypes of ASD and are listed in the autism research database AutDB 
(http://www.mindspec.org/autdb.html). 
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Pfn2 is therefore a very promising candidate gene for autism research, since it is 
involved in synaptic vesicle endo- and exocytosis (Gareus et al., 2006; Mondin et al., 
2010; Pilo Boyl et al., 2007) and synaptic plasticity via its function through the 
interaction with the WAVE complex, several other actin nucleators, gephyrin as well 
as synapsins. Pfn2 could play a role in a vast number of neuronal systems and 
circuits leading to the autistic-like phenotype of Pfn2 KO mice. If this specific role of 
Pfn2, however, is restricted to certain subpopulations of neurons and neuronal 
circuits, the key impact of the deletion for the autism-like phenotype could be 
unraveled.  
 
1.4 The nervous system 
 
The brain is the most complex organ imaginable with an immense amount of 
research trying to understand the underlying mechanisms that regulate the intricate 
connection circuits of this unique structure.  
The nervous system can be subdivided into the central nervous system (CNS), which 
summarizes the whole brain and spinal cord system. In contrast, the peripheral 
nervous system (PNS) mainly comprises the different nerve fibers for sensory 
information and neuromuscular junctions.   
Neural tissue is composed of neurons and glial cells. These cells are tightly 
connected together, with the glial cells supporting the integrity and functionality of the 
neuronal cells, which are in turn the basis of brain function.  
 
1.4.1 Neurons and synaptic transmission 
 
Neurons are asymmetrical cells, featuring two kinds of processes with different 
functions (Fig. 5). Neurons extend thin (app. 1-3 µm in diameter), long (app. 100-500 
µm) and highly branched processes called dendrites, which differ in their complexity 
depending on the cell type and neuronal system they belong to. Dendrites are the 
major recipient of synaptic input to a neuron through post-synaptic terminals that, in 
case of excitatory synapses, develop into dendritic spines (Fig. 6), small, actin-rich 
protrusions emerging from the dendritic shaft. The input signals can be relayed and 
further transmitted to muscles or other neurons via the second kind of process, the 
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axon, on average even thinner (0.1-0.5 µm) and longer (up to 1 m) than dendrites, 
extending thousands of pre-synaptic terminals (boutons, Fig. 6) to the target cells 
(Debanne et al., 2011). When a neuron receives an excitatory input, sodium channels 
at the plasma membrane open, decreasing the normally negative membrane 
potential (depolarization), which ultimately leads to a spike of the membrane potential 
called an action potential. 
 
Fig. 5 Neuronal morphology 
Neuronal cells show a polar morphology with specialized 
projections emerging from their cell bodies. Most projections 
arising from neurons are called dendrites, which feature 
protrusions called dendritic spines on their shafts (especially 
excitatory synapses), which receive synaptic signals from 
contacting neurons. Spines are therefore targeted by the second 
type of neuronal projections, the axons. Axons also form 
protrusions on their shafts, so-called boutons, which contact the 
dendritic spines and transmit information by releasing 
neurotransmitters via synaptic vesicles exocytosis.  
 
Neurons form these projections upon guidance cues 
or stimuli during development in a process called 
neuritogenesis. Neuritogenesis is characterized by 
breakage of the symmetry of the cell towards finally 
polarized structures, which emerge from the cell soma as neurites and form the 
future dendrites and axons (Bradke and Dotti, 1997, 1999; da Silva and Dotti, 2002; 
Stiess and Bradke, 2010; Tahirovic and Bradke, 2009; Witte and Bradke, 2008). 
 
The ultrastructure of synapses is under growing investigation aiming to understand 
the basic principles of synaptic function, such as pre-synaptic vesicle exocytosis 
upon changes in the intracellular ion concentration and resulting changes in the 
membrane potential of the effector cells. Synaptic vesicles (SV), enveloping the 
neurotransmitters, are present in pre-synaptic terminals of axonal projections in pools 
of distinct localization (Fig. 6). SVs are mostly accumulated in the reserve pool (RP), 
located distally from the site of vesicle exocytosis, which is the active zone and 
comprises the readily releasable pool (RRP) of SVs. The SVs in the RP are isolated 
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from the active zone by an actin network, which dynamically regulates the transition 
of SVs from the RP to the RRP, where SVs are exocytosed and neurotransmitter is 
released into the synaptic cleft. For an SV to be able to be released it needs to be 
docked to the synaptic membrane and primed for the fusion process. Priming is 
dependent on SNARE-complex formation between the SV and the synaptic 
membrane. The primed vesicles can fuse with the membrane upon action 
potential/depolarization-dependent Ca2+ influx and the released neurotransmitter 
reaches the post-synaptic site of a synapse of a neighboring neuron. In the case of 
an excitatory synapse, a dendritic spine protrudes from the shaft, while inhibitory 
synapses form small enlargements on the dendritic shaft. In spines, neurotransmitter 
receptors are anchored to an electron-dense, actin-rich structure exactly opposed to 
the active zone called the post-synaptic density (PSD, Fig. 6).  
 
Binding of the neurotransmitter to these receptors leads to changes in the membrane 
potential due to the ion influx, as described earlier and can generate an action 
potential, which can propagate in turn to the pre-synaptic boutons to induce 
neurotransmitter release to further neurons. Neurons express several kinds of ion 
channels, such as ligand-gated ionotropic receptors and voltage-gated ion channels, 
mediating the influx of Na+, K+, Cl- and Ca2+ ions (Fig. 7). The most prominent 
neurotransmitter in the CNS is glutamate, an excitatory neurotransmitter, and its 
receptors are divided into two classes: ionotropic receptors, such as the NMDA (N-
methyl-d-aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) 
and kainate families of receptors, and metabotropic (mGluR) receptors (Cingolani 
and Goda, 2008) (Fig. 7). Ionotropic glutamate receptors are ligand-gated ion 
channels, whereas metabotropic receptor activation leads to a G-protein-coupled 
second messenger cascade regulating the influx of cations through the ion and 
receptor channels. Glutamate can be further used to synthesize GABA (γ-
aminobutyric acid), which is the primary inhibitory neurotransmitter of the nervous 
system. GABA receptors are also subdivided in ionotropic (GABAA) and metabotropic 
(GABAB) receptors (Fig. 7). The many subtypes of the mentioned receptors are 
differentially expressed in different neuronal systems and even in distinct cell types 
belonging to the same neuronal system (Biggin, 2002; Cingolani and Goda, 2008; 
Dutta et al., 2007; Ennis et al., 2001; Greengard et al., 1999; Levey et al., 1993; Lévi 
et al., 2004; Winters and Bussey, 2005; Xiao et al., 2007). 
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Fig. 6 Schematic overview of an excitatory synapse 
Shown here is the schematic view of an excitatory synapse and the distribution of actin filaments 
(brown helixes), SVs (green circles) and receptors (see in the legend) in its pre- and post-synaptic 
terminals. Synaptic vesicles of the reserve pool (RP) are held back from the readily releasable pool 
(RRP) by an actin meshwork. Upon vesicle exocytosis, neurotransmitters are released into the 
synaptic cleft and are able to bind to post-synaptic receptors  anchored to the post-synaptic density 
(PSD) via different sets of molecules including a dense actin network (from Cingolani and Goda, 
2008). 
 
Other neurotransmitters released by neurons of different neuronal systems can have 
excitatory effects like acetylcholine or noradrenaline or play both excitatory and 
inhibitory roles depending on the post-synaptic receptor subtype, such as dopamine 
or serotonin. The flexibility of neuronal transmission is therefore even extended with 
the same neurotransmitter system also being able to act differently on the post-
synaptic target cells depending on their intrinsic molecular composition.  
 
This complexity can also be further emphasized, when neurotransmitter co-
expression is taken into account. A few neuronal cell types, in fact, were shown to 
express two types of neurotransmitters, for example the olfactory short axon cells, 
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which release dopamine and GABA, or the dopaminergic neurons of the VTA, which 
co-express small amounts of glutamate.  
 
Neurons often are also associated with the expression of neuromodulatory 
substances with functions distinct from those of neurotransmitters. The most common 
neuromodulators are predominantly co-expressed in certain types of GABAergic 
neurons, such as somatostatin (SOM or SST), substance P (SP), vasoactive 
intestinal peptide (VIP) or neuropeptide Y (NPY). These neuromodulators often act 
as peptide hormones mostly with an inhibitory function on their post-synaptic 
recipient. 
 
Fig. 7 Schematic representa-
tion of the different types of 
glutamate and GABA recep-
tors localized to distinct syn-
aptic compartments 
Glutamate released from 
synaptic vesicles of the pre-
synaptic terminal can bind post-
synaptic ionotropic NMDA, 
AMPA or kainate receptors as 
well as pre- and post-synaptic 
metabotropic receptor types 
(mGluRs). The activation of 
these receptors induces a 
change of the post-synaptic 
potential due to Na+ and Ca2+ 
influx leading to the excitation of 
the post-synaptic cell. GABA-mediated inhibition of post-synaptic targets can act through ligand-gated 
ionotropic GABAA-receptors, by Cl- influx, or G-protein coupled metabotropic GABAB-receptors,. The 
concentration of free neurotransmitters in the synaptic cleft is modulated by neurotransmitter 
transporters, e.g. glutamate transporter (EAAT), especially concentrated on glial cell membranes, and 
diffusion (modified from Swanson et al., 2005). 
 
All of these excitatory or inhibitory stimuli are acting on synaptic plasticity, inducing 
changes in synaptic strength and therefore increasing or decreasing performance of 
individual synapses. Upon repeated high excitatory input, synapses are strengthened 
1. Introduction 
 
19 
by a process termed long-term potentiation (LTP), in which dendritic spine 
morphology is altered by enlargement of the spine head and concomitant increase in 
receptor density leading to enhanced synaptic performance. The opposite alterations 
(spine shrinkage, reduced synaptic performance) are produced during long-term 
depression (LTD), when sustained weak inputs are received by post-synaptic 
terminals (Bellot et al., 2014; Bosch et al., 2014; Chen et al., 2007a; Hering and 
Sheng, 2001; Dubinsky, 1993; Kim and Lisman, 1999; Krucker et al., 2000; Lee et 
al., 1998; Oberman and Pascual-Leone, 2013; Shehata et al., 2012; Zhou et al., 
2009). 
 
1.4.2 Glial cells 
 
The most abundant type of glial cells in the CNS are astrocytes, who owe their name 
to the star-shaped appearance in vivo (Fig. 8A). Astrocytes are responsible for 
stabilizing the neurons, providing them with growth factors and nutrients, as well as 
modulating synaptic transmission (Bergles et al., 2010).  Moreover, the clearance of 
neurotransmitters from the synaptic cleft is highly increased by astrocytes, since 
excess of neurotransmitters (especially glutamate) in the extracellular matrix can lead 
to excitotoxic effects. An important function of astrocytes is also the invasion into 
lesion sites after nervous tissue injury, forming the so called glial scars (Ertürk et al., 
2012). 
 
Another type of glial cells are oligodendrocytes, which are important for a fast signal 
transduction along axons, since they provide the myelin-sheath coating around the 
axons of neurons in the CNS (Fig. 8B). Impulse transmission is accelerated due to 
myelination of the axons, since it decreases ion leakage and membrane capacitance. 
Myelination of axonal projections is not uniform, but leaves small spaces at the nodes 
of Ranvier to provide a mode of saltatory propagation of action potentials. A loss of 
oligodendrocytes is associated with diseases like multiple sclerosis and 
schizophrenia.  
The brain is only partially connected to the rest of the body due to the blockage of 
e.g. cell migration through the blood-brain-barrier (BBB). The brain therefore is in 
need of an additional defense mechanism against infections, which is provided by the 
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microglia type of glial cells (Fig. 8C). Microglial cells are responsible for clearing 
nervous tissue from pathogens and toxic material, while malfunctioning of microglia 
contributes to neuronal cell death, since inflammatory responses to pathogens from 
the immune system of the remaining body are not facilitated. 
 
Fig. 8 Types of glial cells in the CNS 
The cells supporting the neurons are called glial cells. Four major types of glial cells can be 
distinguished in the CNS. The role of the respective glial cell type differs profoundly. Astrocytes (A, 
identified by staining for GFAP). are star-shaped cells supporting neurons not only structurally but also 
by providing nutrients. In addition they are able to clear neurotransmitters from the synaptic cleft to 
avoid spill over to neighboring synapses and cytotoxic effects on the neurons. Structural support and 
most importantly insulation of neuronal axons is provided by oligodendrocytes (B, identified by staining 
for CNPase). Synaptic transmission is greatly accelerated by the axonal insulation via myelin-sheaths 
produced by oligodendrocytes. The brains immune cells are called microglia (C, identified by staining 
for Iba1), permanently scanning for pathogens and clearing the brain from toxic material. The role of 
the fourth type of glial cells, the NG2 cells (D, identified by staining for NG2), is not defined yet, but 
they are believed to be able to provide lesion sites with newly generated oligodendrocytes, since they 
were found to act as oligodendrocyte precursor cells (OPCs).  
 
A special type of glial cells are NG2 cells (also called synantocytes or 
polydendrocytes), which are small, abundant glial cells with an astrocytic appearance 
and expression of the NG2 surface proteoglycan (Fig. 8D). They are believed to be 
able to give rise to oligodendrocytes (and possibly astrocytes or even neurons) and 
are therefore considered oligodendrocyte precursor cells (OPCs), but might also 
have distinct roles in the CNS (Bergles et al., 2010). These cells receive synaptic 
input with a low threshold and express AMPA receptors but are devoid of kainate or 
NMDA receptors. GABAergic signaling in these cells is still under debate as well as 
their role in other neuronal processes and modulation. 
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1.4.3 Neuronal circuitry 
 
Neuronal systems are immensely interconnected via distinct types of connections 
and several different pathways. Compromising one system often leads to alterations 
and secondary effects in other systems as well. 
Understanding the effects of distinct circuits on each other could shed light on 
neurological phenotypes, which may originate from one system but affect another via 
the immense interconnectivity of the brain. Pharmacological treatments, for example, 
are typically targeting individual symptoms of neurological disorders often neglecting 
the causative source, which could reside in different systems that indirectly modulate 
the symptoms. 
 
The GABAergic system, for example, features the highest diversity of neuronal cell 
subtypes. Those subtypes can be distinguished from one another by their distinct 
location, biochemical characteristics, morphological appearance and 
electrophysiological properties. Increasing amount of data regarding the specific 
functions of these cells has led to new insights into synaptic circuits and their 
properties under various states of stimulation. 
 
Several classical circuitries were part of the investigation in this thesis, but only the 
key circuits also involved in ASD and/or epilepsy are described further in the 
following chapters. 
 
1.4.3.1 Hippocampal circuitry 
 
The best studied structure in the rodent brain is the hippocampus. The hippocampal 
formation is responsible for many higher brain functions such as learning and 
memory, relaying sensory information from various sources, emotion and several 
types of behavioral responses. 
Several distinct pathways compute information in the hippocampus. The main input 
comes from the entorhinal cortex (EC) but also several other regions contribute to 
hippocampal input including the thalamus, hypothalamus, amygdala, deep cerebellar 
nuclei (glutamatergic systems), the raphe nuclei (serotonergic system), the locus 
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coeruleus (noradrenergic system) and the substantia nigra and the ventral tegmental 
area (dopaminergic systems).  
 
The efferents from the entorhinal cortex target mainly dentate gyrus (DG) granular 
cells and distal dendrites of CA3 pyramidal neurons (perforant path, Fig. 9) leading to 
weak, mostly sub-threshold excitation (Yu et al., 2010). DG granular neurons send 
projections (mossy fibers, Fig. 9) to CA3 pyramidal neurons, whose axons target the 
CA1 neurons (Schaffer collaterals, Grateron et al., 2003, Fig. 9). CA1 pyramidal 
neurons mediate the output of the hippocampus through the subiculum back to the 
entorhinal and neocortex. In addition, CA1 pyramidal neurons receive direct input 
from the entorhinal cortex (layer III) via the temporoammonic pathway (Fig. 9) while 
DG granule cells receive feed-back from mossy cells and hilar interneurons 
originating in the dentate gyrus hilus (Deng et al., 2010).  
 
 
 
Fig. 9 Hippocampal circuitry 
Depicted is a map of the neuronal connectivity of the mouse hippocampus. In brief, dentate gyrus 
(DG) granular neurons and CA3 pyramidal cells receive input from the entorhinal cortex (EC) via the 
medial and lateral perforant pathways (MPP, green fibers and LPP, pink fibers). DG granular neurons 
send mossy fibers to the CA3 pyramidal neurons (red fibers), which in turn target CA1 neurons via 
Schaffer collaterals (blue fibers), which send efferents back to the entorhinal cortex (EC, pink fibers). 
CA1 pyramidal cells receive additional input from the entorhinal cortex via the temporoammonic 
pathway (orange fibers) (modified from Deng et al., 2010) 
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The effects of LTP and LTD mechanisms upon changes in synaptic activity can 
typically be observed in pyramidal neurons of the hippocampus. Inhibition in the 
hippocampus is mediated by GABAergic neurons that mostly form local inhibitory 
connections, but some form huge networks with several layers.These vast 
connections lead to a very complex circuitry (Fig. 9) with intrinsic feed-back signaling 
to efficiently counteract firing/timing/synchrony errors or noise (Kim and Lisman, 
1999). 
 
 
1.4.3.2 Basal ganglia 
 
The basal ganglia system comprises a combination of several interconnected brain 
areas performing tasks involving movement and cognition in a collaborative fashion. 
The striatum, consisting of the dorsal caudate putamen (CPu) and the ventral 
nucleus accumbens (NAc), the subthalamic nucleus (STN), the globus pallidus (GP), 
the entopeduncular nucleus (EP) and the substantia nigra (SN) together form the 
basal ganglia nuclei (Prescott et al., 2003). 
 
The key structure in the basal ganglia circuitry is the striatum. Several cell types are 
present, with app. 98% GABAergic neurons (mostly medium spiny neurons, MSNs, 
and few interspersed aspiny neurons) and cholinergic interneurons. Excitatory 
signals are the prevalent input to the striatum originating from the cortex, thalamus, 
Raphe nuclei, substantia nigra and ventral tegmental area (VTA) (Fig. 11). These 
input projections can be distinguished not only by the neurotransmitters being 
released but also by the distinct pathways in which they act. Dopamine is released in 
the striatum to modulate motor function by different mechanisms. Substantia nigra 
(especially the pars compacta, SNpc) neurons send efferents to dorsal MSNs 
through the nigrostriatal pathway, which controls motor function via the direct 
pathway.  
 
Dopaminergic innervations coming from the VTA, on the other hand, target the 
ventral striatum MSNs through the mesolimbic pathway, which preferentially 
modulate motor activity through the indirect pathway (Fig. 11) (Calabresi et al., 2014). 
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Both direct and indirect pathways act through disinhibition of cortical neurons and 
therefore activate motor function, but are differentially regulated by dopaminergic 
input, since dopamine can facilitate neuronal excitability through activation of G-
coupled dopamine D1 receptors or repress neuronal excitability via dopamine D2 
receptors (Ena et al., 2011; Perreault et al., 2010, 2011; Rubenstein and Merzenich, 
2003; Sano et al., 2003; Tan et al., 2003).  
Abnormalities in these circuits are associated with movement disorders, 
schizophrenia as well as neurodegenerative disorders like Parkinson´s and 
Huntington´s diseases (Galvan et al., 2015; Prescott et al., 2003). 
 
 
 
 
 
 
 
Fig. 11 Schematic overview of the various neurotransmitter systems modulating the basal 
ganglia pathways  
Different neurotransmitter systems mediate the computation of diverse information in two separate 
striatal pathways. Depicted in the mouse brain scheme (saggital view) is the mesolimbic pathway 
originating from dopaminergic neurons of the ventral tegmental area (VTA, green fibers) projecting to 
the ventral striatum (nucleus accumbens, NAc) to regulate motor function. This pathway is additionally 
modulated by glutamatergic innervations (red fibers) and by feed-back mechanisms through the 
involvement of GABA (blue fibers) (modified from Russo and Nestler, 2013). 
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1.4.3.3 Cerebellar circuitry 
 
A conserved structure of the CNS throughout species is the cerebellum. It is located 
distinct from the cerebrum near the brainstem and is part of the rhombencephalon 
(hindbrain).  
 
The cerebellum consists of central fibers (white matter), the deep cerebellar nuclei 
and the cerebellar cortex (grey matter), a three-layered structure consisting of the 
granular layer, the Purkinje cell layer and the molecular layer (Fig. 12). The functions 
of the cerebellum are mostly restricted to several aspects of motor control, especially 
motor coordination, precision, timing and motor learning. Also functions in regulating 
language as well as fear and pleasure responses have been described for cerebellar 
signaling computation. Interestingly, the cerebellar circuits are similar across 
vertebrates with increased mass of the cerebellum compared to the cerebrum in 
higher organisms (fish, reptiles, birds, mammals).  
 
Sensory information from the spinal cord (motor feed-back, proprioception), the 
brainstem, the trigeminal nerve (sensation of chewing, biting, etc.), and the visual and 
auditory systems is processed in the cerebellum. 
All major excitatory systems send their axons to the cerebellum (glutamatergic, 
dopaminergic, cholinergic, serotonergic and adrenergic systems), but two main 
classes of input fibers can be clearly differentiated, which are the mossy and the 
climbing fibers. Mossy fibers originating from several brain regions terminate in the 
granular layer and excite small, densely packed granule cells, which send 
unmyelinated axons through the Purkinje layer to the molecular layer, where they 
branch at right angles to form the parallel fibers, which in turn relay the information 
further to the dendrites of the Purkinje cells (Fig. 12). The Purkinje cells are large, 
GABAergic neurons featuring vast dendritic arborizations, which receive parallel fiber 
input but also additional excitatory input from the climbing fibers originating from the 
inferior olivary nucleus of the brainstem. Purkinje cells transmit the rather weak 
excitation from parallel and powerful excitation from the climbing fibers further mainly 
to the deep cerebellar nuclei (DCN), which are located in the center of the cerebellum 
(Fig. 12). 
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Fig. 12 Schematic view of the cerebellar circuitry 
Signal input in the cerebellum begins with innervations by 
excitatory (+) mossy fibers (mf, yellow) and climbing fibers 
(cf, red) originating from the inferior olivary nucleus (IO). 
Mossy fibers mainly target granule cells (GrC, light 
orange), while climbing fibers mainly innervate Purkinje 
cells (PC, orange). Granule cells form parallel fiber (pf, 
light orange) connections with Purkinje cells but also Golgi 
cells (Goc, blue), basket cells (BC, blue) and stellate cells 
(SC, blue), which are responsible for local inhibition of 
granule and Purkinje neurons. Purkinje cells form the sole 
cerebellar output forming synapses on neurons of the deep 
cerebellar nuclei (DCN, pink), which further send the 
signals to the rest of the brain (modified from D’Angelo and 
Casali, 2012). 
 
The deep cerebellar nuclei are mostly comprised 
of large glutamatergic projection neurons that 
spontaneously fire at high frequencies enhanced 
by mossy and climbing fiber input unless otherwise regulated by the Purkinje cell 
inhibition (Leto and Rossi, 2011; Uusisaari and Knöpfel, 2012). DCN neurons 
mediate the sole output from the cerebellum into the rest of the brain.  
Purkinje cell activity can furthermore be modified by GABAergic stellate and basket 
neurons located in the molecular layer of the cerebellar cortex (Fig. 12). Both stellate 
and basket cells locally inhibit Purkinje cells, while Golgi cells, which can be found 
sparsely in the granular layer of the cerebellum (Golgi, 1883), relay input from mossy 
and parallel fibers to locally inhibit the granule cells modifying cerebellar transmission 
(Sillitoe et al., 2008). 
 
1.4.3.4 Olfactory sensory system circuitry 
 
The sensory systems mediate the environmental input, with stimuli of different kinds 
(light, odors, tactile sensation, etc.), and their representation in the brain.  
Especially the olfactory system is of raising interest in neurological disorders, since 
odor information is extensively computed in a very conserved structure throughout 
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species called the olfactory bulb (OB) (Cave and Baker, 2009; Song and Leonard, 
2005) and only one single output pathway reaches the main telencephalon.  
 
Odor information from environmental inputs is received by excitatory receptor 
neurons located in the olfactory epithelium of the nose (Fig. 10), which send their 
axons to the OB (the most rostral part of the brain) or, more specifically, to spherical 
structures (app. 50-150 µm in diameter) called glomeruli. In the glomerular layer, the 
initial information processing is mediated by microcircuits of several cell types 
surrounding the glomeruli. This glomerular circuitry is signaling to Mitral cells and 
external tufted cells (ETC) in the Mitral cell and external plexiform layer, which 
facilitate the sole output of the OB via the lateral olfactory tract (LOT) mainly to the 
piriform as well as entorhinal cortex and the amygdala (Fig. 10).  
 
 
 
Fig. 10 Schematic representation of the olfactory projection circuitry 
Odor recognition is carried out by olfactory receptor neurons (RC) in the nasal cavity, which send 
efferents to the olfactory bulb and more specifically to the glomeruli. Surrounding the glomeruli three 
types of cells can be found (short axon cells (SAC), periglomerular cells (PG) and external tufted cells 
(ETC)), which receive and compute the sensory input and transmit it further to the Mitral cells (MC). 
ETC and Mitral cells mediate the sole output of the olfactory bulb via the lateral olfactory tract (LOT) 
and are additionally inhibited by granule cells (GC). 
Green= dopamine, red= GABA, blue= glutamate (modified from Cave and Baker, 2009) 
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The representation and relay of the sensory information in the OB is generated by 
various cell types in several layers of the OB using several pathways of modulation 
by feed-back and feed-forward inhibition (Fig. 10). 
In the glomerular layer information is processed by three types of neurons 
surrounding a glomerulus, which are ETCs, short axon cells (SACs) and 
periglomerular cells (PGs). All three cell types receive glutamatergic input from the 
olfactory nerve terminals via the neuropil in the core of a glomerulus structure.  
 
The interglomerular circuit is comprised of local inhibition of ETCs by GABAergic 
periglomerular cells (Murphy et al., 2005) and by GABA and dopamine co-expressing 
SACs, whichtune down presynaptic olfactory nerve terminal glutamate release via 
dopamine receptor D2-dependent inhibition (Ennis et al., 2001; Liu et al., 2013), 
while forming inhibitory dendro-dendritic contacts with Mitral and external tufted cell 
dendrites (Cave and Baker, 2009) even between distant glomeruli (Aungst et al., 
2003). ETCs also feature a feed-forward excitatory pathway to the Mitral cells (Hayar 
et al., 2004; De Saint Jan et al., 2009).  
 
1.4.4 Neural stem cells 
 
Neurogenesis during embryonic development is largely based on neural stem cells 
(NSCs) proliferation and differentiation into the respective cell types. Furthermore, 
the pool of neuronal and glial cells is constantly replenished also in adult nervous 
tissue, which is mediated by adult neural stem cells (aNSCs).  
The most studied structure during embryonic neurogenesis is the formation of the 
neopallial cortex by neural stem cells located in the subventricular zone (SVZ) of the 
lateral ventricle (LV). A part of embryonic neural stem cells of the SVZ leave the 
repeating cycle of self-renewal app. at embryonic day 10-12 (E10-E12) and start 
dividing asymmetrically. NSCs begin to change their morphology, extending radial 
fibers along the newly forming cortex, along which progenitor cells can migrate, 
therefore the stem cells are also called radial glia (RG). The newly generated 
neurons form the cortical layers in an inside-out pattern with each new generation of 
neurons travelling through the existing layers towards the pial surface of the cortex 
(Ayala et al., 2007). The differentiation of NSCs progresses sequentially through 
transiently amplifying progenitor cells and intermediate progenitor cells (IPCs) to 
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neuroblasts and further into immature neurons or glial precursors (Ma et al., 2009; 
Mamber et al., 2010). Also other neuronal lineages are generated during 
embryogenesis, such as dopaminergic neurons, which derive from the 
mesencephalic NSCs or GABAergic neurons, which emerge from the medial and 
lateral ganglionic eminences (MGE, LGE) (Ayala et al., 2007; Di Cristo, 2007; Faux et 
al., 2012). 
The adult brain still features two niches for adult neural stem cells, which are the 
remnants of the aforementioned radial glia, one in the SVZ and a second niche in the 
hippocampal dentate gyrus subgranular zone (SGZ) (Goldman, 1998; Landgren and 
Curtis, 2011). Adult NSCs, like embryonic NSCs, can generate progenitor cells, even 
though at a slower rate. These are further able to differentiate into neurons at their 
final destination. Adult neural stem cells of the SGZ slowly replenish mostly the pool 
of dentate granular neurons, while aNSCs of the SVZ can form cortical neurons as 
well as GABAergic neurons of the olfactory bulb (Gage, 2000; Gensert and Goldman, 
2001). The progenitor cells that are destined to the olfactory bulb travel long 
distances through the brain in the rostral migratory stream (RMS) in a state, where 
mostly migratory and few differentiation processes occur. The final differentiation step 
of precursor cells migrating along the RMS towards mature neurons is induced in the 
immediate proximity of the olfactory bulb before the newly arriving neurons can be 
integrated into the existing olfactory network. 
The functionality but also the complexity of neuronal circuits, therefore, also depends 
on newly generated neuronal and glial cells derived from neural stem cells. 
 
1.4.5 Implication of neuronal systems in neurological diseases 
 
Several neuronal systems, including those described previously, are implicated in 
various neurological disorders, such as the aforementioned autism spectrum disorder 
(ASD, see 1.3.4) but also others like epilepsy, mood disorders, Alzheimer´s dementia 
(AD), Parkinson´s disease (PD), Huntington´s disease (HD) and many more. 
 
The neuropathology of ASD includes forebrain neurons developmental delay, loss of 
Purkinje cells and age-dependent changes in size and number of neurons in the 
diagonal band of Broca, the deep cerebellar nuclei and the inferior olive (Kemper and 
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Bauman, 1998). Some of these changes concern the cerebellar circuits (see 1.4.3.3), 
which are involved in several processes, such as motor control, attention, language, 
and fear as well as pleasure responses. Alterations in this system could therefore 
have an impact in the language deficits and hyperexcitability phenotypes in ASD 
even though classically cerebellar disturbances are linked to autism, Alzheimer´s 
dementia and other neurological disorders by the occurrence of ataxia, essential 
tremors and motor coordination deficits. These effects could originate from alterations 
in the glutamatergic system, since in postmortem human autistic cerebellar brain 
tissue genes involved in glutamatergic synaptic transmission were found to be 
upregulated (EAAT1 and AMPA subunits), which could account for the changes in 
the excitation/inhibition ratio often associated with ASD (Purcell et al., 2001). 
 
Alterations in neuronal circuitry leading to problems with cognition and motor function 
are common features of neurological diseases. Parkinson´s disease is characterized 
by loss of motor function often associated with essential tremors caused by 
neurodegeneration of dopaminergic neurons especially of the substantia nigra, which 
are consequently no longer able to innervate the striatal circuits that are fundamental 
components of the motor control system. 
 
A key observation in Huntington´s disease (HD), in contrast to Parkinson´s disease, 
is an alteration of the dopaminergic system leading to an increase of dopamine 
released in the striatum (Chakraborty et al., 2014a; Napolitano et al., 2004; Pandey 
et al., 2009). HD is a neurodegenerative disorder caused by the mutation of the CAG 
repeat length in the huntingtin gene (htt, it15). Apart from the impact on the 
dopaminergic system, Ca2+ homeostasis (Hansson et al., 2001; Maciel et al., 2004), 
mitochondrial dysfunctions (Chakraborty et al., 2014b; Pandey et al., 2008, 2010) 
and excitotoxicity (Tabrizi et al., 1999) are associated with the pathology of HD. The 
excitotoxic effect of elevated dopamine release in the striatum via the striatonigral 
pathway may also lead to the observed loss of dendritic spines (Chakraborty et al., 
2014a; Pandey et al., 2009; Tabrizi et al., 1999) and the resulting defects in the direct 
and indirect pathways ultimately cause motor phenotypes. 
The variation of neurotransmitter levels can also cause multiple forms of mood 
disorders, which are often coincidental with an imbalance not only in the 
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dopaminergic but also in the serotonergic and noradrenergic systems (Nakatani et 
al., 2007). 
 
It is also well-established that abnormal cortical and hippocampal circuit activity can 
cause epilepsy. Epilepsy is mostly due to hyperactivation of hippocampal pyramidal 
neurons by intrinsic hyperexcitability or due to a disinhibition by GABAergic 
interneurons (Abrahams and Geschwind, 2008; Alarcón et al., 2008; Cobos et al., 
2005; Di Cristo, 2007; Peñagarikano et al., 2011).   
 
An example for a rare neurodegenerative disease is amyotrophic lateral sclerosis 
(ALS), which is associated with the progressive loss of motor neurons in the 
corticospinal tract, the brainstem and the anterior horn of the spinal cord (Charcot, 
1874; Daoud et al., 2013). This neuron loss results in muscle atrophy, progressive 
paralysis and ultimately death. Single gene alterations in 13 genes have been 
identified (including SOD1, TDP-43, FUS, ANG, OPTN and PFN1) accounting for 
only 10% of ALS cases (Boopathy et al., 2015; Daoud et al., 2013; Figley et al., 
2014; Ingre et al., 2013; Kiernan et al., 2011; Smith et al., 2015; Tiloca et al., 2013; 
Wu et al., 2012). Excitotoxicity induced by hyperactivation of the glutamatergic 
system and the involvement of astrocytes as well as microglia in dysregulated 
neurotrophic and neurotoxic factor release have been proposed to cause the loss of 
motor neurons (Kiernan et al., 2011). Protein aggregates, especially of TDP-43, FUS 
and mutant form of PFN1, were found in patients with ALS (Boopathy et al., 2015; 
Figley et al., 2014; Del Poggetto et al., 2015a, 2015b; Tiloca et al., 2013; Wu et al., 
2012). Patients suffering from this neurological disease are also showing altered 
growth cone morphology in motor neurons (Wu et al., 2012) and a change in actin 
levels (Tiloca et al., 2013), which might be associated with the phosphorylation-
dependent interference on actin binding of PFN1 (Ingre et al., 2013).  
The only therapy is a treatment targeting the glutamatergic system by use of the 
glutamate release inhibitor riluzole, but a treatment could be developed by restoring 
actin dynamics consequently to resolving stress granule protein aggregation 
produced by certain mutations of PFN1 (Figley et al., 2014; Kiernan et al., 2011). 
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1.5 The P2-GFP knock-in mouse model 
 
The work for thesis work will take advantage of a novel mouse model generated in 
the lab expressing a Pfn2-EGFP fusion protein (P2-GFP) in addition to the previously 
described Pfn2 KO mouse model. The mouse models have been back-crossed into 
the C57 Bl/6 N background. 
 
To generate the P2-GFP mouse, the CDS of the enhanced green fluorescent protein 
(EGFP) was fused to the C-terminus of the Pfn2 CDS in exon3 with a 14 aa linker 
peptide in between (Fig. 13) without any additional alteration of the Pfn2 genomic 
locus. The targeting construct was transferred to ES cells (129/Sv) by homologous 
recombination and the cells were injected into blastocysts that were implanted in 
pseudo-pregnant female mice. 
 
 
 
Fig. 13 Pfn2 and P2-GFP alleles  
A Pfn2 allele (wt) 
B P2-GFP allele with the GFP gene inserted at the C-terminus of Pfn2. 
 
P2-GFP expressing mice are viable in homozygosity and show mild behavioral 
alterations such as jumping phenotype and a low incidence of seizures with rising 
susceptibility with aging. 
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1.6 Aim of the thesis 
 
Pfn2 knock-out mice show a complex phenotype including autistic-like behavior and 
epileptic seizures. This could be of high relevance for the corresponding human 
disorders. Yet it is still unclear how the Pfn2 knock-out phenotype arises, whether the 
dysfunction of the glutamatergic system is sufficient or other neurotransmitter 
systems are involved and are contributing to it as well. The essential problem is that it 
is still unknown in which cell types of the nervous system Pfn2 is expressed and what 
functions it might have in different neuronal circuits. 
 
In this thesis the specific expression pattern of Pfn2 in neuronal and non-neuronal 
cell subtypes of the nervous system in adult as well as embryonic mice is examined 
using a profilin 2-EGFP fusion protein mouse model. For this purpose, co-
immunofluorescence stainings of P2-GFP with marker proteins for subtypes of 
various neuronal cells, glial cells, neural stem cells, precursor cells and synaptic 
subcompartments are performed on tissue sections as well as cultured hippocampal 
neurons from the P2-GFP KI mouse model and imaged using conventional widefield 
and laser-scanning confocal fluorescence microscopy. 
 
In addition, the expression level of the P2-GFP fusion protein in comparison to wt 
Pfn2 is studied, evaluating the binding efficiencies of different anti-Pfn2 antibodies 
using Strep-tagged variants of P2-GFP and Pfn2 and calculating the expression level 
in tissue extracts of homozygous and heterozygous P2-GFP mutant mice. The 
biochemical properties of P2-GFP in comparison to Pfn2 are also evaluated by 
performing binding assays to poly-L-proline beads and by co-immunoprecipitation 
experiments, in order to validate the P2-GFP mouse model for future in vivo studies. 
 
In the last part of the thesis, the roles and functions of Pfn2 employing cultured 
primary hippocampal neurons derived from both P2-GFP KI and Pfn2 KO animals are 
studied during neuronal development and its trafficking is visualized following the 
application of various chemical stimuli. 
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2.1 Analysis of the expression pattern of Pfn2 in the nervous 
system  
 
The loss of Pfn2 in the brain is responsible for complex phenotypes that phenocopy 
human autism in most of its aspects (see 1.3.4). The molecular and physiological 
origin of autism is still very unclear, and it is not known which neurotransmitter 
system is mainly involved, although genes encoding proteins specific for different 
neuronal subtypes and neurotransmitter systems have been found mutated or 
inactivated in patients with ASD (see 1.3.4). From this respect, knowing in which 
neuronal subtypes Pfn2 is expressed and therefore which circuits could be affected 
by its removal, could shed light on the physiological origin of ASD. 
For this purpose the P2-GFP mouse model (see 1.5) was created and has been used 
in this study to co-localize P2-GFP expression with specific markers for the different 
neuronal subtypes and neuronal compartments. Where a co-expression of the 
marker and the P2-GFP was observed, it was possible to determine that Pfn2 is 
expressed in the corresponding neuronal subtype. 
 
Extensive attempts in defining classes or subtypes of neurons have been made 
throughout the decades, but the wealth of cell types with distinct molecular, 
morphological and electrophysiological features made these attempts extremely 
difficult and as yet incomplete. Especially GABAergic neurons show an immense 
variety of cell types with very specific and often not yet well understood functions 
(Ascoli et al., 2008; Battaglia et al., 2013).  
Identification of the different cell types in the brain is largely based on their location, 
morphology, molecular composition and electrophysiological properties. Using high-
resolution microscopy, the first three traits (location, morphology, molecular 
composition) can be used to identify the cell types under investigation.  
 
In this thesis, whole mouse brains were dissected from P2-GFP knock-in 
homozygous mice (G/G), Pfn2 KO and wild type controls and sectioned sagittally or 
coronally using a vibratome with a thickness of 20 µm (see 4.3.2), which corresponds 
to approximately 2 cell layers. High-resolution confocal laser-scanning microscopy 
2. Results 
 
 
 
36 
(see 4.3.5) was applied to visualize neurons and neuronal structures in the brain with 
the best possible signal-to-noise ratio in order to reach the light-microscopy lateral 
resolution limit of 250-500 nm. 
 
P2-GFP was additionally labelled with an anti-GFP antibody and a secondary Alexa 
Fluor 488-coupled antibody, since tissue fixation with formaldehyde markedly 
reduces the fluorescence efficiency of the GFP moiety. Neuronal subtypes were 
identified by fluorescently labelling marker proteins with the corresponding specific 
primary antibodies and secondary antibodies conjugated with Alexa Fluor 555 or 
CF633 dyes for the respective emission channels. A nuclear DNA staining substance 
was also applied to aid the identification of certain brain structures (DAPI and Draq5 
dyes). 
In order to control for non-specific signals in every emission channel, serial scans 
with all available lasers over the whole visible spectrum (“lambda stacks”) using the 
same settings as for the specifically stained sample were obtained for control slides 
missing one staining component (primary and/or secondary antibody) from P2-GFP 
KI, wild type and Pfn2 KO sections.  
 
 
2.1.1 All excitatory neuronal systems express Pfn2 at varying levels 
 
The most widely used mode of synaptic transmission is mediated by excitatory 
neurotransmitters such as glutamate, dopamine, noradrenaline, serotonin and 
acetylcholine (see 2.1.1.1- 2.1.1.5).  
 
The excitatory neuronal systems will be discussed in the order of their expression 
level of Pfn2 (see Fig. 21 for an overview). In general, all excitatory neuronal systems 
expressed Pfn2, but interesting observations concerning the expression level and the 
cell type as well as the subcellular localization of the protein lead to a more distinct 
and complex picture of the role of Pfn2 in neuronal networks and its potential role in 
neurological diseases. 
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2.1.1.1 Glutamatergic neurons display the highest expression of 
Pfn2  
 
The most common neurotransmitter in the brain is glutamate. Many areas in the brain 
feature at least some glutamatergic neuron types, but they are mostly enriched in the 
cortex, the hippocampus and the cerebellum. In the latter especially small, densely 
packed granule neurons are the most numerous neuronal type, while most 
glutamatergic neurons in the cortex and the hippocampal CA regions are described 
as pyramidal or principal neurons based on their common features in terms of 
morphology and strong excitatory output. 
 
Glutamatergic neurons are included in several neuronal circuits: many cortical 
pathways, the hippocampal perforant path, mossy fibers and Schaffer collaterals (see 
1.4.1.1), as well as olfactory (see 1.4.1.2) and cerebellar (see 1.4.1.3) circuitries.  
In order to identify glutamatergic neurons specifically, neurogranin (Nrgn) was used 
as a marker, a protein exclusively present in the glutamatergic system. Neurogranin 
is a post-synaptically localized calmodulin-binding protein involved in synaptic 
plasticity and a known biomarker for glutamatergic neurons, which was also found to 
be up-regulated in Alzheimer´s disease and mesial temporal lobe epilepsy (MTLE) 
(Díez-Guerra, 2010; Hoffman et al., 2014; Höglund et al., 2015; Singec et al., 2004; 
Wu et al., 2015). Nrgn staining is prominent in the cell bodies and dendrites of 
glutamatergic neurons. 
 
Previous work has already shown Pfn2 to be expressed in certain glutamatergic 
neurons (Pilo Boyl et al., 2007), but only few neuronal circuits were analyzed leaving 
most areas and cell types to be investigated. 
Pfn2 was found to be expressed in all glutamatergic neurons in varying amounts (see 
also Fig. 21). The highest expression in the brain was featured by two large neuronal 
types, the CA2 pyramidal neurons of the hippocampus (Fig. 14A), and the Mitral cells 
of the olfactory bulb (data not shown).  
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High expression of Pfn2 could be observed in pyramidal neurons of the hippocampal 
formation extending their dendrites towards the stratum radiatum (Fig. 14A, 
schematized in Fig. 14B). The dentate gyrus granular neurons, on the other hand, 
show interestingly low expression of Pfn2 in their cell bodies (Fig. 14B) but high 
expression in their mossy fiber processes (data not shown). 
Most neurons of the cortex are glutamatergic featuring an equal expression of Pfn2 
throughout the cortical layers (Fig. 14C). A similar distribution was found in the 
thalamus and the cerebellum.  
Pfn2 can also be found in axons, pre-synaptic boutons and spines by co-localization 
stainings of P2-GFP with pre- and post-synaptic markers (data not shown).  
The control stainings of wildtype littermates showed only Nrgn signals (Supp. Fig. 5) 
and control stainings without incubating with the primary antibodies using only the 
respective secondary antibodies yielded no specific signal (Supp. Fig. 11). 
 
 
 
 
 
Fig. 14 All excitatory neuronal systems express Pfn2 
All main excitatory systems express Pfn2 at different levels. 
(A) Highest levels of Pfn2 (green) are present in glutamatergic neurons of the CA2 region of the 
hippocampus, identified by localization, size and their expression of neurogranin (Nrgn, red). Nuclei 
are stained with Draq5 (blue). (B) Color-code schematic view of Pfn2 expression in the hippocampus 
showing highest expression levels of Pfn2 in CA1-3 pyramidal neurons and medium levels in granular 
neurons of the dentate gyrus (DG), while GABAergic neurons are completely devoid of Pfn2 (see 
chapter 2.1.2 for more details). (C) Glutamatergic (Nrgn, red) cortical neurons feature intermediate 
levels of Pfn2. (D) Dopaminergic neurons of the ventral tegmental area (VTA) and (E) of the substantia 
nigra (SN) specifically labelled using an antibody against tyrosine hydroxylase (TH, red) express high 
levels of Pfn2. (F) Adrenergic neurons of the locus coeruleus (LC) in the brainstem identified by 
dopamine hydroxylase (DBH, red) express medium-high levels of Pfn2. (G) Serotonergic neurons of 
the Raphe nuclei, specifically expressing tryptophan hydroxylase (TPH, red) contain high amounts of 
Pfn2. (H) Cholinergic neurons of the pedunculopontine tegmental nucleus (ppt) labelled by the choline 
transporter (ChT, red) show low expression of Pfn2. (I) Large cholinergic interneurons of the striatum 
identified by the enzyme choline acetyltransferase (ChAT, red, arrowheads) show high enrichment of 
Pfn2. 
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2.1.1.2 Dopaminergic neurons express very high levels of Pfn2 
 
Dopamine is mostly released upon reward mechanisms and therefore associated 
with motivational responses and addiction, but it is also involved in locomotion, 
learning and fine motor coordination. Dopamine acts in the striatum on two types of 
medium spiny neurons (MSNs): on the dopamine D1 receptor (D1R)-positive cells it 
increases MSN excitability, while on the dopamine D2 receptor  (D2R)-expressing 
cells it decreases MSN excitability due to the properties of the D2 receptor type (Tan 
et al., 2003). 
Dopaminergic neurons can be classified into several groups by their location (Supp. 
Fig. 1). The most prominent areas containing dopaminergic neurons are the 
substantia nigra (SN, group A9), the ventral tegmental area (VTA, group A10) with 
the small associated retrorubral field (RRF, group A8) and the olfactory bulb (OB, 
group A16) (Smidt and Burbach, 2007). Dopamine is released in three major 
pathways in the brain (mesolimbic, mesocortical and nigrostriatal pathways), which 
target different brain areas specifically (Supp Fig. 1). Dopaminergic neurons are 
regulated by inhibitory signaling from medium spiny neurons of the striatum targeting 
long dendritic projections originating from the dopaminergic nuclei and additional 
inhibition by local interneurons in the pars reticulata (Tan et al., 2003). 
To specifically identify dopaminergic neurons, the rate-limiting enzyme of dopamine 
synthesis, tyrosine hydroxylase (TH), was used as marker protein (Gelman et al., 
2003; Kumer et al., 1996; Lindgren et al., 2000; De Marchis et al., 2007; Thompson 
et al., 2005). Tyrosine hydroxylase is majorly involved in the transition of tyrosine to 
DOPA, which is further processed to dopamine in dopaminergic and noradrenergic 
neurons.  
Pfn2 was found highly expressed in dopaminergic neurons. The highest expression 
of Pfn2 was in the SN (Fig. 14D) and VTA (Fig. 14E). Less expression was observed 
in the RRF (data not shown) and a differential expression was found in the olfactory 
bulb (see 2.1.7). The control stainings from wildtype animals showed only TH signals 
(Supp. Fig. 5) and control stainings without incubating with the primary antibodies 
only using the respective secondary antibodies yielded no specific signal (Supp. Fig. 
11). 
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2.1.1.3 The noradrenergic system shows high Pfn2 expression 
 
A source of powerful excitation in the CNS is noradrenaline (norepinephrine) of the 
catecholamine family of neurotransmitters. Noradrenaline is mainly released upon 
states of stress, danger, it raises attention, arousal and emotional as well as memory 
functions, to increase the motivation for the respective task. 
Noradrenergic neurons (also addressed as adrenergic neurons) can be found 
exclusively in the locus coeruleus (LC) of the hindbrain (pons) adjacent to the 
cerebellar formation (Supp. Fig. 2). Only a very limited number of neurons releasing 
noradrenaline is present in the mouse brain (app. 30.000), but can still have a large 
impact in a number of brain areas and cognitive functions (Swanson and Hartman, 
1975).  
 
Noradrenaline is produced by an additional step in the dopamine synthesis pathway 
by dopamine-β-hydroxylase (DBH) mediated catalysis of dopamine. DBH is therefore 
used to exclusively label noradrenergic neurons (Jin et al., 2004; Swanson and 
Hartman, 1975).  
 
Noradrenergic neurons were found to express a quite high amount of Pfn2 (Fig. 14F). 
The low density of noradrenergic neurons in the brain complicates the analysis due to 
few brain sections actually containing LC neurons. Therefore several serial sections 
were analyzed to ensure the expression pattern of Pfn2 in the full area of the locus 
coeruleus (see also Fig. 20, compare Supp. Fig. 12). The control stainings of wildtype 
slices showed only DBH signals (Supp. Fig. 5) and control stainings using only the 
respective secondary antibodies yielded no specific signal (Supp. Fig.11). 
 
2.1.1.4 Pfn2 is expressed at quite high levels in serotonergic 
neurons 
 
The regulation of emotions, sleep, mood, sexuality, appetite and body temperature is 
strongly mediated by the serotonergic neuronal system (Svenningsson et al., 2004). 
This neuronal system innervates widely the CNS, eliciting both excitatory and 
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inhibitory responses from targeted cells, depending on their expression of the 
respective subtypes of the serotonin receptors (5-HTRs, 14 subtypes). Serotonergic 
signaling originates exclusively from the Raphe nuclei of the brainstem from where 
efferents reach nearly all brain regions with varying input intensity (Supp. Fig. 3).  
 
To address the question, if Pfn2 could have a role on signaling originated from 
neurons releasing the monoamine serotonin (5-hydroxytryptamine, 5-HT), the 
tryptophan hydroxylase (TPH) enzyme of the serotonin metabolism pathway was 
used as a marker for the identification of these neurons. The TPH enzyme mediates 
the final rate-limiting step of serotonin biosynthesis and is also a target in the 
serotonergic pathway of therapeutic anti-depressant drugs (Andrade, 2011; 
Chandana et al., 2005; Cohen et al., 1995).  
 
The expression of Pfn2 in the neurons of the Raphe nuclei was pronounced (Fig. 
14G) even if not as high as in the glutamatergic or dopaminergic systems (see Fig. 
20). Serotonergic neurons were found interspersed with glutamatergic neurons in the 
Raphe area (see Supp. Fig. 12).  
The wildtype control stainings showed only TPH signals (Supp. Fig. 5) and control 
stainings using only the respective secondary antibodies yielded no specific signal 
(Supp. Fig. 11). 
 
2.1.1.5 Most cholinergic neurons show minor expression of Pfn2 
 
Neurons releasing the monoamine neurotransmitter acetylcholine (ACh) in the brain 
are contributing to the responses of cognitive tasks such as attention, learning and 
memory, reward mechanisms, motor activity and analgesia (Sarter and Parikh, 
2005). ACh release can mediate excitatory or inhibitory responses due to the 
differential effects of the two families of acetylcholine receptors, nicotinic (ionotropic) 
and muscarinic (metabotropic) respectively, but excitatory stimulation is the prevalent 
form of signaling from cholinergic innervations. 
The major cholinergic regions in the brain are located in the medial septum ventral to 
the striatum as well as a pontomesencephalic region near the cerebellum (Supp Fig. 
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4). The medial septal group as well as the pedunculopontine tegmental nucleus (ppt) 
and laterodorsal tegmental nucleus (ldt) feature dispersed cholinergic neurons of 
medium size with output projections to virtually the entire brain and spinal cord (Supp 
Fig. 4) (Woolf, 1991). Apart from the cholinergic neurons in the CNS, cholinergic 
motor neuron innervations of the PNS also release ACh to stimulate muscle 
contraction. 
 
In order to produce the neurotransmitter acetylcholine, the enzyme choline 
acetyltranferase (ChAT) is synthesizing ACh from choline and acetyl coenzyme A 
(Kreitzer, 2009). After synaptic release, ACh is cleaved to choline and acetate by the 
enzyme acetylcholinesterase (AChE). The free choline is taken up again by the high-
affinity choline transporter (ChT) present on the pre-synaptic cholinergic neuron, 
which is the rate-limiting step in ACh synthesis (Misawa et al., 2001; Sarter and 
Parikh, 2005). Therefore, both ChAT and ChT were used to identify cholinergic 
neurons in this thesis. 
Cholinergic neurons express minor amounts of Pfn2 (Fig. 14H) compared to other 
neuronal systems (see also Fig. 20). These low-expressing neurons can be found in 
the medial septal group of the forebrain as well as in the ppt and ldt of the midbrain. 
An exception is the group of large cholinergic interneurons in the striatum, which 
feature high expression of Pfn2 (Fig. 14I). Also motor neurons of the spinal cord 
express Pfn2 (data not shown).  
The control stainings from wildtype brain sections showed only ChAT or ChT signals 
respectively (Supp. Fig. 5) and control stainings using only the respective secondary 
antibodies yielded no specific signal (Supp. Fig. 11). 
 
Summarizing the excitatory neuronal systems, glutamatergic neurons express the 
highest level of Pfn2 in the brain (see also Fig. 21, compare Supp. Fig. 12). 
Especially pyramidal neurons of the CA2 subfield as well as Mitral cells of the 
olfactory bulb show extensive Pfn2 enrichment, while other cells vary greatly in the 
expression and even subcellular distribution of Pfn2. The dopaminergic system is 
expressing nearly equally high levels of Pfn2 in the brain (compare Fig. 21). The 
noradrenergic system also features high amounts of Pfn2 (Fig. 14F, compare 
Fig. 21), similar to the serotonergic system (Fig. 14G, compare Fig. 21). Most 
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cholinergic neurons show a moderate expression of Pfn2 with the exception of the 
large cholinergic interneurons of the striatum (compare Supp. Fig. 12). Therefore, the 
cholinergic system is the only excitatory neuronal system not enriched in Pfn2. 
 
2.1.2 The GABAergic neuronal systems show a highly cell type-
specific expression pattern of Pfn2 
 
The key inhibitory neuronal system uses gamma-aminobutyric acid (GABA) as 
neurotransmitter (see 1.4.1). GABAergic neurons mediate the hyperpolarization of 
neurons, decreasing firing probability and as a result, typically, excitatory systems are 
tuned down by inhibitory GABA signaling to increase the dynamic range of signal 
transmission and further computing the underlying information. GABAergic neurons 
are therefore essentially involved in virtually all brain circuitries and hence all brain 
functions. 
These neurons are located in most brain regions featuring the highest diversity of 
neuronal subtypes. In order to identify GABAergic neurons, co-immunofluorescence 
stainings with antibodies directed against GABA or GAD67 (GAD1) were performed.  
A distinct trait in certain GABAergic cell types is the regulation of Ca2+ homeostasis, 
which is mediated by different Ca2+-buffering proteins in different cell types. 
Calmodulin (CaM) was first identified as a Ca2+-buffering protein, but is ubiquitously 
expressed, while other Ca2+-binding proteins, such as calbindin D28 (CB), calretinin 
(CR) and parvalbumin (PV) are expressed restricted to populations of specific cell 
types (Celio, 1990; Di Cristo, 2007; Faux et al., 2012; Figueredo-Cardenas et al., 
1998; Grateron et al., 2003; Hendry et al., 1989; Lawrence et al., 2010; Matamales et 
al., 2009; Rudy et al., 2011; Wang et al., 2004; Wierzba-Bobrowicz et al., 2011; 
Woodruff and Yuste, 2008; Woodruff et al., 2010). Both the Ca2+-binding proteins CB 
and PV were also used in this work to identify specific subtypes of inhibitory neurons. 
 
The expression pattern of Pfn2 in these neurons was found to be extremely diverse 
and differed among cell subtypes for each region of the brain.  
Therefore, the results of the expression pattern of Pfn2 in GABAergic cell types will 
be shown in a brain region-specific order. The cortical, hippocampal as well as 
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cerebellar GABAergic neurons will be described in chapter 2.1.2.1, while the striatum 
and the olfactory bulb will be shown in separate chapters (2.1.2.2 and 2.1.3). 
 
2.1.2.1 The expression pattern of Pfn2 is extremely restricted in 
GABAergic neurons of the cortex, hippocampus and cerebellum 
 
The highest variability of cell types not only restricted to GABAergic types, is present  
in the cerebral cortex, which is involved in nearly all brain functions including 
cognition, memory and language control (see 1.4) (Grateron et al., 2003; Graus-Porta 
et al., 2001). 
Cortical GABAergic neurons are mostly devoid of Pfn2 with few exceptions (Fig. 
15A). PV-positive basket cells are the most numerous cell type (Di Cristo, 2007; 
Hendry et al., 1989; Méndez and Bacci, 2011; Rudy et al., 2011) and devoid of Pfn2 
(Fig. 15B). Among PV-expressing cells, some rarer neurons feature Pfn2 expression, 
i.e. the Chandelier cells (Fig. 15B), identified by their position and characteristic 
morphology (Di Cristo, 2007; Hendry et al., 1989; Rudy et al., 2011; Woodruff and 
Yuste, 2008; Woodruff et al., 2010). Other cortical GABAergic neuron subtypes 
express calbindin, namely the bitufted neurons and a subset of Martinotti cells (Wang 
et al., 2004). None of the medium-sized Martinotti cells, but all of the few larger 
bitufted neurons, which are easily identified by the double dendritic bundle  
morphology of their projections (Di Cristo, 2007; Hendry et al., 1989; Rudy et al., 
2011), were observed to express Pfn2 (Fig. 15C). Two GABAergic neuronal cell 
types were found in the external layer I of the cortex, the Cajal-Retzius (or horizontal) 
cells and neurogliaform cells (also called spiderweb cells) (Chandana et al., 2005; 
Rudy et al., 2011), which both lacked Pfn2 expression (data not shown).  
In summary, cortical GABAergic neurons are mostly devoid of Pfn2 with the 
exception of two rare cell types, the fast-spiking Chandelier cells and the bitufted 
neurons (see also Fig. 17).  
 
The neuronal circuitry of the hippocampal formation is very well established in terms 
of the contribution of glutamatergic as well as GABAergic neurons (see 1.4.1.1, Fig. 
10). The GABAergic neuronal subpopulations can be distinguished by their  
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morphology (mostly differences in soma sizes), location and their differential 
expression of the Ca2+-binding proteins calbindin and parvalbumin (Celio, 1990). 
Similarly to the cortex, the most abundant inhibitory cell type are the parvalbumin-
positive basket cells, which also in the entire hippocampus is devoid of Pfn2 (Fig. 
15D, schematized in Fig. 15F). The most dorsal layer of the hippocampus were the 
stratum oriens, which is purely inhibitory, since the cell bodies of GABAergic neurons 
are concentrated in this layer (Lawrence et al., 2010). GABAergic neurons in the 
stratum oriens are basket cells (PV+), bistratified neurons (PV+), axo-axonic neurons 
(also called Chandelier cells, PV+) and stratum oriens interneurons (CB+), as well as 
the exclusively stratum oriens localized oriens-lacunosum-moleculare interneurons 
(O-LM interneurons, PV+), which all share the absence of Pfn2 expression (Fig. 15E, 
schematized in Fig. 15F). Most of these cell types can also be found in the remaining 
strata of the hippocampal formation with varying density but uniformly lack 
expression of Pfn2. Ivy cells (NPY+) found in the stratum pyramidale in between the 
array of pyramidal neurons were also devoid of Pfn2 (data not shown, schematized in 
Fig. 15F). 
 
 
 
Fig. 15 The expression of Pfn2 in GABAergic neurons is specific to few cell types in cortex, 
hippocampus and cerebellum 
The very specific expression pattern of Pfn2 in few GABAergic neuron subtypes is depicted for three 
major brain regions the cortex, the hippocampus and the cerebellum. 
(A) In the cortex of the mouse brain, only few GABAergic neurons (red) appear to express Pfn2 
(green), indicated by an arrowhead, while most GABAergic neurons are devoid of Pfn2 (arrows). (B) 
Parvalbumin-positive basket cells (red) lack Pfn2 (arrow), while large PV-positive Chandelier cells 
(axo-axonic neurons) (arrowhead) and (C) large CB-positive bitufted neurons (arrowhead) express 
Pfn2. Several types of GABAergic neurons in the hippocampus were specifically labelled for (D) 
parvalbumin (red) or (E) calbindin (red) and are completely devoid of Pfn2 (arrows). (F) Schematic 
view of the various hippocampal GABAergic neuron types, color-coded to indicate the expression 
profile of Pfn2. (G) Cerebellar stellate and basket cells (PV+, red) show the absence of Pfn2 (arrows). 
(H) Purkinje cells (CB+, red), do not express Pfn2 (arrows) while GABAergic Golgi cells, identified by 
their morphology and location among the glutamatergic granular neurons are positive for Pfn2 
(arrowhead). (I). Color-coded scheme representing the expression level of Pfn2 as described in the 
cerebellum. To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 (Biostatus) was used.  
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In summary, the entire hippocampal formation is devoid of Pfn2 in all populations of 
GABAergic subtypes (Fig. 17), in clear contrast to the highly Pfn2-positive adjacent 
neurons of the glutamatergic system (see Fig. 21). 
 
The cerebellum is a structure adjacent to the brainstem mainly involved in motor 
function but also in language, fear and pleasure responses. The whole cerebellar 
circuitry (see 1.4.3.3, Fig. 12) is utilizing only two neurotransmitter systems. While the 
glutamatergic cells show expression of Pfn2 (see 2.1.1), GABAergic neurons of the 
cerebellum show a similar expression profile of Pfn2 as the cortex, since only one 
single GABAergic cell type was found to be positive for Pfn2. 
GABAergic neurons in the cerebellum can be distinguished based on their location in 
the three layers of the cerebellar cortex, their morphology (mostly by their soma size 
and dendritic arborization) and by the differential expression of the Ca2+-binding 
proteins calbindin and parvalbumin.  
In the cerebellum, stellate and basket cells express PV whereas Purkinje cells co-
express calbindin and parvalbumin (Bosman et al., 2006; Celio, 1990; Hendry et al., 
1989; Sillitoe et al., 2008; Wierzba-Bobrowicz et al., 2011; Woodruff et al., 2010). 
Pfn2 was not found in any of the PV-expressing neurons, which comprise the 
majority of GABAergic neurons in the cerebellum with PV-positive basket, stellate 
and Purkinje cells (Fig. 15G, schematized in Fig. 15I), while among the CB-
expressing neurons only Golgi cells were positively recognized to express Pfn2 (Fig. 
15H, schematized in Fig. 15I). 
These observations are summarized in Fig. 15I, in which it appears that the 
molecular layer as well as the Purkinje cell layer are devoid of Pfn2, while the rare 
Golgi cells among the dense glutamatergic granular neurons show the expression of 
Pfn2 at a medium high level (Fig. 17). The glutamatergic projection neurons of the 
deep cerebellar nuclei show an intense signal for Pfn2 (see Fig. 21).  
 
Wildtype control stainings showed only GABA, PV or CB signals respectively (Supp. 
Fig. 6) and control stainings using only the respective secondary antibodies yielded 
no specific signal (Supp. Fig. 11). 
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2.1.2.2 Striatal GABAergic neurons express Pfn2 with a subtype- 
and area-specific pattern 
 
One of the key structures of the basal ganglia is the striatum (see 1.4.3.3, Fig. 11). 
The striatum is partially responsible for motor function, novelty and exploration as 
well as motivational behavior (Cuzon Carlson et al., 2011). 
 
The striatum is comprised of app. 98% GABAergic neurons with the vast majority 
(app. 95%) being medium spiny neurons (MSNs) and the remaining 2-3% aspiny 
interneurons. Also few (1-2%) cholinergic interneurons are dispersed throughout the 
striatum (see 2.1.1.5). It can be divided into the dorsal caudate putamen and the 
ventral nucleus accumbens. Medium spiny neurons are subdivided into dopamine D1 
receptor (D1R)-expressing and dopamine D2 receptor (D2R)-expressing neurons, 
with higher density of D1R-positive MSNs in the dorsal striatum and higher density of 
D2R-positive MSNs in the ventral striatum (Ennis et al., 2001; Matamales et al., 
2009). Since all MSNs receive strong dopaminergic input, these cells express high 
levels of DARPP32 (dopamine and cAMP-regulated phosphoprotein), while the 
striatal fast-spiking aspiny interneurons exclusively express parvalbumin (Figueredo-
Cardenas et al., 1998; Svenningsson et al., 2004; Zachariou et al., 2005).  
 
Pfn2 was found in a large subset of medium spiny neurons (MSNs) identified by their 
expression of DARPP32 (Fig. 16A). Few striatal neurons with large somata, identified 
as the aspiny interneurons, which were not labeled by DARPP32 but by PV (Fig. 
16B), as well as the rare cholinergic interneurons (see 2.1.1.5, Fig. 14I), were also 
positive for Pfn2 (schematized in Fig. 16C). To further elucidate the differences in the 
expression pattern of Pfn2 in MSNs, these cells were specifically labeled exploiting 
their differential expression of dopamine receptor subtypes D1R and D2R. All D1R-
expressing MSNs were also expressing Pfn2 in the caudate putamen (Fig. 16D, 
schematized in Fig. 16F) as well as in the nucleus accumbens (Fig. 16E, 
schematized in Fig. 16F). D2R-positive cells, on the other hand, were lacking Pfn2 in 
the caudate putamen (Fig. 16G, schematized in Fig. 16I) but expressed low levels of 
Pfn2 in the nucleus accumbens (Fig. 16H, schematized in Fig. 16I).  
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In addition, some astrocytes were positive for D2R, which are lacking Pfn2 (the very 
small cells in Fig. 16H, see 2.1.4 and Fig. 19). The control slices from wildtype 
animals showed only DARPP32, PV, D1R or D2R signals respectively (Supp. Fig. 7) 
and control stainings using only the respective secondary antibodies yielded no 
specific signal (Supp. Fig. 11).  
 
The striatum is the only brain region featuring a high density of Pfn2-positive 
GABAergic neurons with both medium spiny neurons and aspiny interneurons 
expressing Pfn2 with the very specific exception of dopamine D2 receptor-positive 
MSNs in the dorsal striatum (Fig. 17, compare Fig. 21). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16 GABAergic neurons of the striatum express Pfn2 depending on subtype and area 
(A) Pfn2 (green) is expressed in most medium spiny neurons (arrowheads), identified by the 
expression of DARPP32 (red), but seems to be missing from a certain subpopulation (arrows). Also 
few large neurons, which are not labelled by DARPP32, express Pfn2 (asterisks). (B) GABAergic 
aspiny interneurons, identified by their expression of parvalbumin (PV, red), show a high Pfn2 
expression (arrowheads). (C) Color-coded scheme depicting the expression of Pfn2 in aspiny and 
cholinergic interneurons (see 2.1.1.5, Fig. 14I). D1R+-MSNs (red) in both (D) dorsal and (E) ventral 
striatum express medium levels of Pfn2. (F) Schematic overview of the D1R-expressing MSNs of the 
striatum with color-coded expression level of Pfn2. (G) D2R+-MSNs (red) of the caudate putamen are 
negative for Pfn2 (arrows), but (H) D2R+-MSNs of the nucleus accumbens show low expression of 
Pfn2 (arrowheads). (I) Schematic representation of the color-coded distribution of Pfn2-positive and -
negative D2R+-MSNs in the striatum according to the expression level of Pfn2. To visualize the cell 
nuclei (blue), the DNA-intercalating dye Draq5 (Biostatus) was used. 
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Region Cell type Marker Localization 
Cortex Cajal-Retzius cells (GABAergic subtypes) Reelin Layer I 
  Chandelier cells (axo-axonic neurons) PV, GAT1 Layer III-V 
  Basket cells PV, Substance P   
  Bitufted neurons (Double Bouquet cells in humans) CB, CR Layer II-III (V) 
  Neurogliaform cells/ spiderweb cells NPY, Reelin, 5HT3aR Layer I 
Hippocampus Chandelier cells (axo-axonic neurons) PV Stratum oriens + pyramidale 
  Basket cells PV, Substance P Stratum oriens + pyramidale 
  Bistratified neurons PV Stratum oriens + pyramidale 
  Ivy cells NPY, GABA Stratum pyramidale 
  Oriens-lacunosum-moleculare (O-LM) interneurons PV Stratum oriens 
  Stratum oriens interneurons CB Stratum oriens 
Cerebellum Basket cells PV, (CB) Molecular layer 
  Golgi cells CB Granular layer 
  Purkinje cells PV, CB Purkinje cell layer 
  Stellate cells PV Molecular layer 
Striatum Aspiny interneurons PV   
  D1 medium spiny neurons Dopamine D1 Receptor   
  D2 medium spiny neurons Dopamine D2 Receptor Dorsal str. neg.; Ventral str. pos. 
Olfactory bulb Olfactory granular neurons GABA Granular layer 
  Periglomerular cells CB Glomerular layer 
  Short axon cells (GABA+/ TH-) GABA Glomerular layer 
  Short axon cells (GABA+/ TH+) GABA + TH Glomerular layer 
  Short axon cells (GABA-/ TH+) TH Glomerular layer 
 
Fig. 17 Overview of the different subtypes of GABAergic neurons in key regions of the mouse brain 
The expression pattern of Pfn2 in GABAergic neurons is restricted to specific cell types. Cell types are identified here by their specific marker proteins as 
well as their localization within the respective system. Some Pfn2-positive (green) GABAergic cell types were present in these systems, while the majority 
of cells were found to be Pfn2-negative (red). 
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2.1.3 Sensory systems show a specific expression profile of Pfn2  
 
Sensory systems in general mediate the transition of stimuli from the environment to 
synaptic signaling in the brain. One highly organized structure of the brain is the 
olfactory bulb (OB) (see 1.4.1.2, Fig. 10), which is relaying input from the olfactory 
receptor neurons located in the nasal epithelium, sending sensory output to the 
cortex (Cave and Baker, 2009). None of the neurons of the olfactory system are 
known to have distinctive marker proteins, but can easily be identified by their 
location in the different layers of the olfactory bulb (see 1.4.1.2, Fig. 10) as well as by 
their morphology and their differential expression of the neurotransmitters glutamate, 
dopamine and GABA. Mitral cells and external tufted cells (ETCs) have large cell 
bodies with extensive and long dendrites directed towards the glomerular layer, while 
their axons travel out of the OB. These cells are glutamatergic and especially Mitral 
cells are known to be one of the few neuron types missing the nuclear neuronal 
protein NeuN. Periglomerular neurons are purely GABAergic, while short axon cells 
(SACs) co-express dopamine together with GABA, therefore are reactive to the rate-
limiting enzyme in the dopamine synthesis machinery, tyrosine hydroxylase (TH, see 
2.1.1.2). 
 
Most neurons involved in sensory processing in the OB expressed Pfn2. Especially 
Mitral cells and external tufted cells showed extremely high levels of Pfn2, and in fact 
are, together with hippocampal CA2 pyramidal neurons, the highest Pfn2-expressing 
cells in the brain (Fig. 18A, schematized in Fig. 18B). Also GABAergic granule 
neurons expressed Pfn2, although at low levels (data not shown, schematized in Fig. 
18B). Neurons surrounding the glomeruli differed in their expression of Pfn2. Large 
external tufted cells were found also in this layer to be very enriched in Pfn2, while 
medium-sized purely GABAergic periglomerular neurons lacked the expression of 
Pfn2 (Fig. 18C, schematized in Fig. 18B). The most interesting population of neurons 
around the glomeruli are the small short axon cells.  
SACs seemed to differ in their expression level of Pfn2 depending on the different 
expression profiles of either dopamine, GABA or the co-expression of both 
neurotransmitters (Fig. 18C, D, schematized in Fig. 18B). SACs producing 
predominantly GABA showed low levels of Pfn2 (Fig. 18C, asterisks, schematized in  
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Fig. 18B), while the expression level of Pfn2 was increased upon co-expression of 
dopamine in those cells (Fig. 18D, asterisks, schematized in Fig. 18B). Finally, SACs 
predominantly expressing dopamine were strongly positive for Pfn2 (Fig. 18D, 
arrowheads, schematized in Fig. 18B).  
 
The olfactory bulb is not the only sensory system, in which Pfn2 plays a certain role. 
In the developing embryo (E13.5-E19.5) Pfn2 could be found at sensory areas of the 
whiskers (Fig. 18E), the tongue (Fig. 18F), the teeth (Fig. 18G) and the nasal cavity 
(Fig. 18H). 
The control stainings of wildtype sections showed only NeuN, GABA or TH signals 
respectively (Supp. Fig. 8) and control stainings using only the respective secondary 
antibodies yielded no specific signal (Supp. Fig. 11). 
 
 
 
 
 
 
 
 
 
Fig. 18 The expression profile of Pfn2 in the olfactory sensory systems of the mouse 
Pfn2 is very specifically expressed in the sensory system of the olfactory bulb. (A) Mitral cells (devoid 
of NeuN, red) are highly enriched for Pfn2 (green, arrowheads). (B) Schematic overview of the 
olfactory system with the color-coded expression level of Pfn2 in the various cell types. In the inset, a 
magnification of a glomerulus and the surrounding neuron types is shown. (C) GABAergic 
periglomerular neurons (red, arrows) are devoid of Pfn2, while short axon cells (SAC, red, asterisks) 
show low expression of Pfn2. (D) GABAergic SACs co-expressing dopamine (TH, red, asterisk) 
express Pfn2 at moderately higher levels than purely GABAergic SACs. SACs producing mainly 
dopamine show high levels of Pfn2 (arrowheads). To visualize the cell nuclei (blue), the DNA-
intercalating dye Draq5 (Biostatus) was used. Sensory receptor neurons in different regions of the 
developing embryo (E16.5-E19.5) also show an enrichment of Pfn2, such as (E) the whisker pads, (F) 
the tongue, (G) the incisor teeth and (H) the nasal epithelium. 
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2.1.4 Glial cells are devoid of Pfn2  
 
Glial cells are the most abundant cell types in the brain and are involved in nearly all 
higher brain functions and take part in neuronal networks (see 1.4.2, Fig. 8). The 
CNS of the mouse (and humans) comprises four major types of glial cells. A recent 
study reported a role for Pfn2 in morphology and spreading of cultured mouse 
astrocytes (Schweinhuber et al., 2015), furthermore neurological disorders often 
feature phenotypes associated with a role of glial cells, therefore the expression 
profile of Pfn2 in these cells was investigated in this thesis. 
 
Astrocytes are the most abundant type of glial cells, responsible for providing 
neurons with neurotrophic and neuroprotective factors, structural support and also 
feature neuromodulatory functions (see 1.4.2, Fig. 8) (Hol and Pekny, 2015; 
Nedergaard and Verkhratsky, 2012; Rossi and Volterra, 2009; Sofroniew and Vinters, 
2010; Zeidán-Chuliá et al., 2014). Astrocytes are also invading lesion sites during 
brain repair forming complex barriers called glial scars. 
 
 
A common astrocytic marker is glial fibrillary acidic protein (GFAP), an intermediate 
filament protein involved in cell-cell communication, mitosis and glial scarring (Hol 
and Pekny, 2015). GFAP is expressed typically in astrocyte precursor cells and in 
reactive astrocytes e.g. during invasion of a lesion site (15-20% of astrocytes in the 
healthy adult brain). To be able to localize Pfn2 in all (reactive and dormant) 
astrocytes, also the Ca²+-binding protein S100β was used as marker protein (Donato 
et al., 2013; Sofroniew and Vinters, 2010). S100β is involved in Ca2+-homeostasis, 
especially enhancing migration and proliferation while suppressing apoptosis and 
differentiation processes (Donato et al., 2013).  
Pfn2 was absent from GFAP-positive, reactive astrocytes (Fig. 19A) as well as 
S100β-positive, reactive and dormant, astrocytes (Fig. 19B) in all brain regions. A 
morphologically distinct type of astrocytes are the Bergmann glia of the cerebellar 
Purkinje cell layer, which were also observed to be devoid of Pfn2 (data not shown). 
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The brain is a fragile system and its blood supply separated from the rest of the body 
by the blood-brain-barrier, therefore it needs to be protected from infections and toxic 
material by brain specific immune cells called microglia (see 1.4.2, Fig. 8). Microglia 
are actively scanning the surrounding tissue for pathogens, cell debris and apoptotic 
neurons, which are consequently phagocytosed (Beutner et al., 2010; Salter and 
Beggs, 2014; Zhan et al., 2014).  
 
Microglia get activated upon brain lesions by infections or trauma and migrate to the 
lesion site, proliferate and remove toxic material. During brain development, these 
cells are major regulators of synaptic maturation and pruning of excessive synapses 
(Salter and Beggs, 2014; Zhan et al., 2014). To label specifically microglia, the 
marker protein Iba1 (ionized Ca2+-binding adaptor molecule 1) was used (Beutner et 
al., 2010; Zhan et al., 2014). Iba1 is an actin-binding protein upregulated during 
proliferation and migration of microglia when induced by e.g. brain lesions.  
Microglial cells lacked the expression of Pfn2 in the brain (Fig. 19C). In all brain areas 
these cells showed finely branched processes, which were devoid of Pfn2 as well. 
 
Myelination of axons provided by oligodendrocytes (see 1.4.2, Fig. 8) leads to an 
immense increase in signal propagation velocity, which is impaired in diseases like 
multiple sclerosis and schizophrenia (Chen et al., 2007; Pedraza et al., 2008; Saher 
et al., 2005; Zeidán-Chuliá et al., 2014).  
Oligodendrocytes were specifically labelled using the enzyme 2′,3′-cyclic nucleotide 
3′-phosphodiesterase (CNPase) and the myelin basic protein (MBP) as markers. The 
loss of the myelin-sheath associated protein MBP alters the myelin architecture and 
leads to axonal degeneration, while the loss of the CNPase enzyme has no effect on 
the ultrastructure of myelin-sheaths but induces axonal pathologies and 
neurodegeneration (Lappe-Siefke et al., 2003). 
 Like astrocytes, also oligodendrocytes were found throughout the brain with slightly 
varying densities for each brain region, but none of these cells could be observed to 
be expressing Pfn2 in neither the soma (Fig. 19D) nor the myelin-sheaths of their 
processes (Fig. 19E). Pfn2-positive axons could sometimes be seen at high 
magnification in close proximity to the myelin-sheath, but Pfn2 was absent from the 
oligodendrocytic processes.  
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NG2 cells are a distinct type of glial cells (also called synantocytes, polydendrocytes, 
GluR or complex cells) present in all brain regions and display an astrocyte-like 
appearance (see 1.4.2, Fig. 8). These cells are believed to be a type of 
oligodendrocyte precursor cell (OPC), especially active during re-myelination of brain 
lesions, but are also responsive for neuronal signaling (Bergles et al., 2010; 
Nishiyama et al., 2009; Zeidán-Chuliá et al., 2014).  
 
 
Fig. 19 All glial cell types are devoid of Pfn2  
(A) GFAP-positive (red, arrows), activated astrocytes as well as (B) S100β-positive (red) astrocytes 
(active and resting cells, arrows) are negative for Pfn2 (green). (C) Microglia, specifically expressing 
the Ca2+-binding protein Iba1 (red, arrows), also lack Pfn2. (D) Oligodendrocytes, exclusively 
producing the enzyme CNPase (red, arrows), lack expression of Pfn2 in both their cell bodies and (E) 
their myelin-sheath processes labelled with MBP (red, arrows). (F) NG2 cells, with their still enigmatic 
role in the brain, could be identified by the exclusive expression of the NG2 surface proteoglycan (red, 
arrows) and are negative for Pfn2. To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 
(Biostatus) was used.  
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NG2 cells were identified by their specific expression of the membrane-associated 
chondroitin sulphate proteoglycan NG2 (Bergles et al., 2010; Nishiyama et al., 2009; 
Zeidán-Chuliá et al., 2014). 
NG2 cells shared the absence of Pfn2 with the other glial cell types mentioned above 
(Fig. 19F). Numerous but relatively small cell bodies and their fine arborizations were 
observed at various densities in every brain region, nonetheless could never be 
colocalized with Pfn2 immunofluorescence.  
 
The control stainings of wildtype littermates brain sections showed only GFAP, 
S100β, Iba1, CNPase, MBP or NG2 signals respectively (Supp. Fig. 9) and control 
stainings using only the respective secondary antibodies yielded no specific signal 
(Supp. Fig. 11). 
 
In conclusion, Pfn2 was found to be absent from all types of glial cells throughout the 
entire brain structure (compare Supp. Fig. 12).  
 
2.1.5 Differentiation-dependent expression of Pfn2 in neural stem 
cells  
 
A class of cells in the embryonic and adult brain replenishing different populations of 
neurons and glial cells are the neural stem cells (see 1.4.4) (Altman, 1965). NSCs 
mostly proliferate in a state of self-renewal, but are also multipotent and therefore 
able to differentiate into progenitor cells and further into different types of neurons 
and glial cells (Sommer and Rao, 2002), after migrating to their final position in the 
neural networks.  
 
Neurogenesis in general is frequently impaired in neurodegenerative disorders like 
Alzheimer´s or Parkinson´s disease, while neurogenesis is often increased in 
consequence to epileptic seizures, trauma or strokes (Di Cristo, 2007; Faux et al., 
2012; Gage, 2000). Especially learning and memory formation might be impaired in 
consequence of gene mutations involving aNSCs (Aimone et al., 2011; Deng et al., 
2010; Guo et al., 2011). Since ASD is a neurodevelopmental disorder with complex 
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phenotypes including epileptic seizures, in consequent to which any cells undergo 
apoptosis, potential alterations in the process of neuronal development and 
neurogenesis are a field of interest for investigations of the role of Pfn2 in embryonic 
and adult neural stem cells. 
 
In order to specifically label neural stem cells in mouse embryonic tissue, selected 
transcription factors and intermediate filaments have been used as marker proteins, 
since they are present at very high concentration in this cell population compared to 
the remaining tissue. Adult neural stem cells (aNSCs) continue to express these 
transcription factors and intermediate filaments at higher levels compared to other 
cells. Certain intermediate filament proteins are expressed very specifically at high 
rates in NSCs, in particular Nestin, Vimentin and glial fibrillary acidic protein (GFAP) 
(Landgren and Curtis, 2011). Well known transcription factors are required in stem 
cells to maintain proliferation capacity and multipotency, among them especially 
Sox2, Oct4, Pax6 and Tbr2 are highly enriched in NSCs and/or in their derived 
progenitor cells (Beckervordersandforth et al., 2010; Gage, 2000; Ma et al., 2009; 
Maslov et al., 2004; Ming and Song, 2011; Sommer and Rao, 2002).  
 
The expression pattern of Pfn2 among the neural stem cell populations was not 
uniform. Pfn2 expression was, in fact, found in NSCs but was missing from progenitor 
cells, before being expressed again in differentiated neurons (see 2.1.2 and 2.1.3), 
while all types of glial cells continued to repress Pfn2 after their final differentiation 
(see 2.1.4).  
Radial glia cells (embryonic neural stem cells) expressed Pfn2 during later embryonic 
development (Fig. 20A) and adult neural stem cells (aNSCs) of the SVZ expressed 
Pfn2 (Fig. 20B, C, D). On the contrary, in consequence to their initial differentiation, 
progenitor cells changed their expression pattern and down-regulated Pfn2. 
Progenitor cells can be identified by the lack of the stem cell marker Nestin, but they 
continue to express the transcription factor Pax6 (Fig. 20C) (Beckervordersandforth 
et al., 2010; Ma et al., 2009; Ming and Song, 2011) and acquire the expression of the 
transcription factor Tbr2 (Fig. 20D). 
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The progenitor cells migrating along the RMS were also devoid of Pfn2 (Fig. 20E). 
Following their arrival at their destination, the olfactory bulb, progenitor cells undergo 
their final differentiation in order to replenish the pool of mature neurons, and at this 
step they started to re-express increasing amounts of Pfn2 (Fig. 20E, arrowheads). 
The expression of Pfn2 in aNSCs occured exclusively in the SVZ, whereas aNSCs of 
the hippocampal SGZ, distinguishable by the presence of Oct4, showed a lack of 
expression of Pfn2 (Fig. 20F).  
 
Fig. 20 Neural precursor cells express Pfn2 depending on their differentiation state 
(A) Pfn2 (green) is present in neural stem cells (NSCs, radial glia) of the embryo (Pax6, red, 
arrowheads). (B) Pfn2 is still expressed in adult NSCs of the subventricular zone (SVZ) identified by 
the high expression levels of Nestin (red, arrowheads) and (C) the transcription factor Pax6 (red, 
arrowheads). NSC-derived progenitor cells, positive for the transcription factors (C) Pax6 and (D) Tbr2 
(red), do not express Pfn2 (arrows). (E) The Pfn2-negative progenitor cells migrate along the rostral 
migratory stream (RMS, arrows) and up-regulate Pfn2 upon reaching the border of the olfactory bulb 
and differentiating into neurons (arrowheads). (F) Adult NSCs of the subgranular zone (SGZ) located 
in the hippocampal dentate gyrus, labelled by the transcription factor Oct4 (red), do not show 
expression of Pfn2 (arrows). To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 
(Biostatus) was used. 
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The control stainings of wildtype littermates showed only Nestin, Oct4 or Pax6 
signals respectively (Supp. Fig. 10) and control stainings using only the respective 
secondary antibodies yielded no specific signal (Supp. Fig. 11). 
 
In conclusion, the expression of Pfn2 in neural stem cells (NSCs) was found to be 
dependent on the developmental and differentiation state of the respective cell 
population (compare Supp. Fig. 12). Pfn2 was expressed in embryonic and adult 
neural stem cells of the SVZ, but was lacking from progenitor cells, with renewed up-
regulation in differentiated neurons (compare Fig. 21). In mature glial cells, instead, 
Pfn2 continued to be repressed. 
 
Fig. 21 Schematic overview of the relative expression levels of Pfn2 in the mouse brain  
Pfn2 is present in neurons of most regions of the brain with various levels of expression and the 
exception of progenitor cells along the RMS, Purkinje and many other GABAergic cells of the 
cerebellar molecular layer and the D2 receptor-positive cells of the caudate putamen. 
The regions with the highest expression of Pfn2 are hippocampus, substantia nigra, VTA and the 
Mitral cell layer of the olfactory bulb. Glial cells lack the expression of Pfn2, therefore they are not 
included into this schematic representation. A detailed description of each neuronal system with the 
corresponding regions can be found in the previous chapters (see 2.1.1-2.1.5). 
 
The astonishing specificity of the expression profile of Pfn2 not only across neuronal 
systems but also, within the same neuronal system, between different brain regions 
is shown in a color-code corresponding to the relative intensity of the expression level 
of Pfn2 (Fig. 20). Since glial cells were shown to be devoid of Pfn2 in the adult brain 
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(see 2.1.4, Fig. 19), only the expression pattern of Pfn2 in neuronal cells is depicted. 
Hippocampal CA2 pyramidal neurons, olfactory Mitral cells as well as dopaminergic 
neurons express the highest levels of Pfn2 in the brain (see 2.1.1.1, Fig. 14A, B, D, E 
and 2.1.3, Fig. 18A, B) and were therefore set as the maximum intensity value (Fig. 
21, relative intensity 10/10, shown in red).  
 
2.2 Analysis of the biochemical properties and the expression level 
of the P2-GFP fusion protein in the knock-in mouse model 
 
The P2-GFP knock-in mouse model besides being useful to study Pfn2 expression 
patterns, as described in the previous chapters, was designed to be able to follow 
Pfn2 dynamics and trafficking in vivo. Live-cell imaging can be employed to study P2-
GFP during in vitro neuronal development and in mature neurons following 
depolarization or neurotransmitter stimulation. In order to employ the mouse model 
for these purposes, the biochemical properties of the P2-GFP fusion protein needed 
to be verified as well as the effect of the fusion protein in the mouse itself by 
behavioral phenotyping. 
 
P2-GFP KI mice are viable in homozygosity and show mild behavioral alterations 
compared to wildtype mice. Several behavioral paradigms were applied, resulting in 
moderate impairments, such as minor hyperexcitability and increase in exploration 
and locomotion in a novel environment. In contrast to the extensively behaviorally 
impaired Pfn2 KO mouse model, showing autistic-like behavior, P2-GFP KI mice 
showed no alterations in anxiety or fear as well as unimpaired working memory 
(Özer, unpublished).  
 
At least two parameters could be the cause of these alterations: the expression level 
of the recombinant fusion protein could differ substantially from the levels of the 
endogenous protein, or the biochemical interactions of the fusion protein with its 
ligands could be impaired by the GFP-tag. These two causes of possible alterations 
in the P2-GFP KI mouse model due to the insertion of GFP were investigated in 
detail during this study. 
2. Results 
 
 
 
64 
2.2.1 The GFP-tag affects the recognition of P2-GFP by anti-Pfn2 
antibodies 
 
The first issue encountered with the P2-GFP mouse model was that the P2-GFP 
expressed in the homozygous mouse brain could not be quantified directly from 
tissue lysates using the standard polyclonal anti-Pfn2 antibody routinely employed in 
our group to study Pfn2, since the P2-GFP fusion protein was not recognized at all 
(data not shown). The possible reason might be that the GFP moiety fused to the C-
terminal of Pfn2 could be hindering (sterically) the C-terminal epitope(s) necessary 
for antibody recognition. Nevertheless, several different polyclonal and monoclonal 
anti-Pfn2 antibodies have been produced in the past in our lab, using peptides or 
truncated versions of Pfn2. Therefore the various anti-Pfn2 antibodies were tested on 
P2-GFP in order to determine their efficiency in the recognition of P2-GFP compared 
to the wt protein in Western blot assays to be able to choose the most suitable one 
for future experiments on the P2-GFP KI mouse model.  
The different anti-Pfn2 antibodies (see 5.7 and Supp Fig. 13) were validated to 
interact with P2-GFP using recombinant versions of the respective profilin isoforms. 
The cDNAs coding for Pfn2 and P2-GFP, as well as Pfn1 as a control, were inserted 
in a bacterial expression vector (pMW172-Streptag) in order to obtain the respective 
proteins fused C-terminally to a Strep-tag (see 4.1.7, 4.2.10-4.2.11, 5.6). The Strep-
tag is an eight amino acid long sequence (WSHPQFEK), originally found on biotin, 
but artificially altered to increase the specificity and affinity towards Streptavidin, a 
protein found in Streptomyces avidinii, or the improved StrepTactin protein. The 
Strep-tag is small (app. 1 kDa) and with relatively low charge compared to other 
common tags that can be fused to recombinant proteins (e.g. His-tag, HA-tag, FLAG-
tag, myc-tag, GST-tag) therefore we reasoned that it should not interfere substantially 
with Pfn2 antibody recognition. The elution of purified Strep-tagged proteins from an 
affinity matrix can be accomplished by the addition of biotin derivates (d-
desthiobiotin) without the need for denaturing agents and is therefore ideal to 
produce functional recombinant proteins.  
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Fig. 22 Antibody recognition assay and expression level of P2-GFP compared to Pfn2 
(A) Purified Pfn1-Strep, Pfn2-Strep (both app. 15 kDa) and P2-GFP-Strep (app. 42 kDa) were loaded 
on a Western blot in estimated equal amounts and probed with the StrepTactin-HRP reagent to control 
for loading errors. The same Western blots were incubated with (B) anti-Pfn2 3003 or (C) anti-Pfn2 
GD2 antibodies to compare the recognition ratios of Pfn2 and P2-GFP. The antibody signals were 
quantified and calibrated according to the StrepTactin-HRP measured amount of the respective 
purified protein. (D) Binding efficiencies of the anti-Pfn2 antibodies GD2 (53% ± 1.6) and 3003 (29% ± 
0.4) towards P2-GFP in comparison to Pfn2. (E) Brain tissue extracts from different genotypes were 
probed with the anti-Pfn2 GD2 antibody to be able to calculate (F) the expression level of P2-GFP 
compared to Pfn2 (43% ± 2.7 in heterozygous P2-GFP KI mice).  
 
Pfn2-Strep and P2-GFP-Strep (as well as Pfn1-Strep as a control) were purified as 
recombinant fusion proteins from bacterial extracts and estimated equal amounts 
were loaded onto a polyacrylamide gel for Western blotting (see 4.2.4-4.2.5) (n=3 
bacterial clones and purifications). The amount of the Strep-tagged proteins was 
calibrated using a StrepTactin-HRP conjugated reagent (Fig. 22A).  
The signal intensity originated from the StrepTactin-HRP luminescence is directly 
proportional to the amount of purified protein loaded onto the respective lane. Upon 
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further incubation with an anti-Pfn2 antibody, the resulting signals could be adjusted 
for the exact amounts of purified proteins on the membrane. 
The specificity and efficiency of binding to P2-GFP was calculated for 4 different anti-
Pfn2 antibodies. These antibodies were partially characterized for the specificity 
towards Pfn2 in contrast to Pfn1 in Western blot and immunoprecipitation (the latter 
was tested only for certain antibodies) (Gareus et al., 2006). All 4 rabbit-derived 
antibodies could be shown to recognize specifically Pfn2 in Western blot experiments 
without also significantly labelling Pfn1. 
Of these 4 antibodies produced in rabbit, one serum (anti-Pfn2 DB2)  showed high 
unspecific background signals and was not included in further analysis (data not 
shown). P2-GFP could be detected with highly various efficiencies using the other 
three antibodies. In particular, the antibody sera 3003 and GD2 recognized P2-GFP 
(Fig. 22B, C), although the anti-Pfn2 3003 antibody showed a minor nonspecific 
recognition of Pfn1 (Fig. 22B). The fourth anti-Pfn2 rabbit serum (T2) did not 
significantly bind to P2-GFP (data not shown) and was therefore not used further for 
the analysis of P2-GFP. 
The antibody binding efficiency to P2-GFP in comparison to Pfn2 was calculated for 
the rabbit antisera 3003 and GD2 (Fig. 22D). While the antiserum 3003 recognized 
P2-GFP with 29% ± 0.4% efficiency compared to Pfn2, the antiserum GD2 was the 
most efficient, recognizing P2-GFP with 53% ± 1.6% efficiency compared to Pfn2.  
 
2.2.2 The expression of P2-GFP is reduced compared to Pfn2 in 
heterozygous knock-in mice  
 
An often neglected consequence of mutations in genomic loci, such as the insertion 
of a GFP-tag in a gene, is a decrease of the expression level of the targeted gene 
product. The P2-GFP fusion protein expressing mouse model features certain mild 
behavioral abnormalities (Özer, unpublished), which could be explained by a 
decrease of the level of the GFP-tagged variant of Pfn2 or by a decreased 
functionality of the fusion protein. Based on the estimated antibody binding efficiency 
values (see 2.2.1), the anti-Pfn2 antiserum GD2 was chosen to probe brain tissue 
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lysates from several heterozygous P2-GFP KI mice by Western blot analysis in order 
to estimate the relative expression levels of Pfn2 and P2-GFP.  
The anti-Pfn2 antibody GD2, as expected, was able to detect Pfn2 as well as P2-
GFP on the Western blots (Fig. 22E). The signal intensities of three independent 
Western blots with different tissue lysates were quantified (Fig. 22F) and calibrated 
for the anti-Pfn2 GD2 recognition efficiency of P2-GFP. The expression level of P2-
GFP was 2.4 times lower (43% ± 2.7%) than that of Pfn2 in heterozygous mice (G/+). 
 
These results implicated a potential reason for the mild behavioral phenotype of 
homozygous P2-GFP KI mice, based on the reduced expression of the profilin 2 
isoform in these mice. 
While a reduced expression of the GFP fusion-protein is not ideal for the analysis of 
this mouse model, it is still highly enriched in nervous tissue. This expression level is 
higher than could have been expected based on previous experiences with KI mouse 
models using similar genetic targeting strategies. The P2-GFP KI mouse model can 
therefore be used further to study the role of Pfn2 in all its various facets.  
 
 
2.2.3 P2-GFP shows slightly reduced binding affinity to poly-L-
proline-stretches and G-actin 
 
The binding properties of Pfn2 are well-defined (see 1.3) and were analyzed for the 
P2-GFP fusion protein to verify its functionality for future applications. The fusion of 
the GFP moiety to Pfn2 could potentially alter the binding properties of the P2-GFP 
fusion protein towards one or more of Pfn2 ligand types. The GFP-tag could interfere 
with the functionality of P2-GFP due to steric hindrance – the GFP-tag itself is bigger 
(27 kDa) than the target protein Pfn2 (14 kDa) – or due to the introduction of charged 
residues into the fusion protein.  
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Fig. 23 The binding efficiency of P2-GFP fusion protein to poly-proline stretches but not to G-
actin is reduced compared to Pfn2 
(A) Pfn2 and P2-GFP were efficiently pulled down by PLP-beads from extracts prepared from brains of 
the respective animal lines, as shown by Western blot analysis (genotype indication on top). The Pfn2 
KO control yielded no signals. Profilin-bound G-actin could be equally co-purified with Pfn2 and P2-
GFP, but was only barely visible bound to Pfn1 in the Pfn2 KO control. GAPDH signals were used to 
calibrate the input and unbound fractions on the Western blot. (B) Quantification of the binding 
efficiency of P2-GFP in comparison to Pfn2 to poly-L-proline stretches, obtained by calculating the 
ratio of unbound/input signals (n=4 for wt, n=5 for G/G, n=3 for Pfn2 KO control) and normalizing it to 
the Pfn2 ratio. P2-GFP could bind to PLP-beads with an efficiency of 74.56% ± 0.08% compared to 
Pfn2. (C) Quantification of the G-actin binding efficiency calculated accordingly as before (n=6 for wt, 
n=4 for G/G, n=3 for Pfn2 KO control). The reduced amount of bound P2-GFP to the PLP beads (see 
in B) was taken into consideration in the calculation of the G-actin binding efficiency. G-actin binding 
was unimpaired (97.81% ± 0.0022%) by the P2-GFP fusion protein.  
IN = input fraction, B = bound fraction, UN= unbound fraction. Error bars represent S.E.M. 
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To quantify the binding properties of P2-GFP in comparison to Pfn2, a pull-down 
assay using stretches (≥300 residues) of poly-L-proline (PLP) immobilized on 
sepharose beads (see 4.2.12) was performed on brain lysates of different mouse 
lines (wt, G/G and Pfn2 KO). This assay is known to precipitate quantitative amounts 
of Pfn1 and Pfn2 (Janmey, 1991) together with profilin-bound G-actin (see 4.2.13). 
The brain extracts (input fractions) were incubated with the PLP-beads and both 
bound and unbound fractions were separated. The purified fractions were analyzed 
by Western blot to determine the respective ratio of unbound vs. input Pfn2 and P2-
GFP to see the depletion efficiency of the respective profilin isoform using the PLP 
pull-down approach.  
The binding efficiency is defined as the unbound/input ratio of the two profilin2 
isoforms to PLP. Several independent mouse brain lysates were prepared for each 
genotype (n=4 for wt, n=5 for G/G and n=3 for Pfn2 KO as a control) and the mean 
binding efficiency ratios of Pfn2 and P2-GFP to PLP were compared using specific 
antibodies (anti-Pfn2 GD2). 
Pfn2 as well as P2-GFP could be enriched in the PLP pull-down, but with slightly 
different efficiencies (app. 70% of Pfn2 could be depleted from the input, while the 
depletion of P2-GFP was 25% less efficient), while the control extracts from Pfn2 KO 
mice, as expected, yielded no profilin signals (Fig. 23A). The pull-down efficiency of 
P2-GFP with PLP-stretches was 75% (74.56% ± 0.08%) of Pfn2 (Fig. 23B). The 
binding capacity of P2-GFP to poly-L-proline stretches in vitro is therefore diminished 
to a certain degree.  
Also profilin-bound G-actin was purified with this approach. The amount of G-actin 
bound to Pfn1, which can be observed in the Pfn2 KO control (Fig. 23A), can be 
neglected compared to the amount of G-actin bound to the much higher expressed 
Pfn2 and P2-GFP. The binding efficiency of G-actin to P2-GFP compared to Pfn2 
was calculated similarly using a specific antibody (anti-actin, clone C4, Merck 
Millipore). In contrast to the reduced binding efficiency of P2-GFP to poly-L-proline 
stretches, co-purified G-actin was found to be equally enriched in P2-GFP complexes 
compared to Pfn2 complexes (n=6 for wt, n=4 for G/G and n=3 for Pfn2 KO as a 
control) (Fig. 23A). Comparing the mean unbound/input ratios of G-actin for wt and 
P2-GFP KI mouse extracts and taking into account the reduced affinity of P2-GFP to  
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the poly-L-proline beads, a binding efficiency of 98% (97.81% ± 0.0022%) of P2-GFP 
to G-actin was observed (Fig. 23C).  
In order to control for the amount of proteins in the input and unbound fractions, the 
signals for the “housekeeping” gene GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase) were used to calibrate the corresponding signals of the input and 
unbound fractions (Fig. 23A). The presence of Pfn1 and endophilin 1 in the bound 
fractions of the PLP pull-down was also observed, as expected, verifying the validity 
of the pull-down approach (data not shown).  
 
Both the expression level (see 2.2.2) and the binding capacity of the P2-GFP fusion 
protein towards poly-L-proline stretches are reduced. But the interference of the 
GFP-tag is relatively mild in comparison to other GFP fusion proteins that often 
completely lack binding capabilities. On the other hand, the GFP-tag is not interfering 
with the actin-binding capability of P2-GFP. The P2-GFP fusion protein can therefore 
be used with minor limitations in future in vivo studies. 
 
2.2.4 Binding of proline-rich ligands by P2-GFP is not significantly 
impaired compared to Pfn2 
 
The reduced affinity of P2-GFP for poly-L-proline stretches (see 2.2.3, Fig. 23) could 
imply a loss of interaction with specific ligands in vivo, since Pfn2 is known to bind to 
a large variety of different proteins involved in a vast array of cellular functions and 
pathways (Gareus et al., 2006; Witke, 2004; Witke et al., 1998). A loss of binding 
affinity to specific ligands due to the integration of the GFP moiety in Pfn2 could 
cause a potential impairment of certain molecular mechanisms in the cells. To 
unravel the potential impact of the P2-GFP fusion protein on specific Pfn2 functions, 
the ligand-binding properties of P2-GFP compared to Pfn2 were investigated by an 
immunoprecipitation (IP) assay (see 4.2.14) on brain tissue extracts. 
 
A common method for the analysis of the composition of protein complexes under 
physiological conditions is the enrichment of specific ligands of a protein of interest 
by immunoprecipitation. The co-immunoprecipitated binding partners and their 
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interaction with either the endogenous Pfn2 or the P2-GFP fusion protein were 
investigated by Western blot analysis. Specific antibodies against Pfn2 (anti-Pfn2 
2T), P2-GFP (anti-GFP-coupled beads; GFP-Trap A, Chromotek) or against both 
isoforms (anti-Pfn2 GD2; anti-Pfn2 5A7 monoclonal, see also Supp. Fig. 13) were 
incubated with brain tissue lysates from wildtype and homozygous P2-GFP KI (G/G) 
animals as well as lysates from Pfn2 KO mice as negative control. Bound protein 
complexes were precipitated using proteinA- or proteinG-coupled sepharose beads 
depending on the respective type of immunoglobulin from the host species (see 
4.2.14). Each IP that was performed with the same antibodies yielded very similar 
and comparable results, therefore different IPs for each of the respective genotype 
are shown compiled together in Fig. 24. Control lysates from Pfn2 KO animals were 
used to verify the specificity of the antibody as well as the proteinA/G-beads.  
Pfn2 is best known for its interaction with G-actin (Carlsson et al., 1977), the 
components of the WAVE complex (Witke, 2004; Witke et al., 1998), proteins of the 
formin family (Evangelista et al., 1997; Faix and Grosse, 2006; Imamura et al., 1997) 
and several proteins involving synaptic function (Gareus et al., 2006; Mammoto et al., 
1998; Murk et al., 2012; Witke et al., 1998). Therefore, a selection of these protein 
ligands of Pfn2 was analyzed by Western blot analyses (Fig. 24).  
 
Pfn2 and P2-GFP could be successfully immunoprecipitated, although with different 
efficiencies. The P2-GFP IP using the GFP-Trap beads was particularly efficient and 
yielded highly enriched fractions of P2-GFP complexes (Fig. 24A). Control IPs from 
Pfn2 KO extracts yielded no unspecific signals, confirming the high specificity of the 
respective IPs. Both Pfn2 as well as P2-GFP were found to be able to interact with 
the expected groups of protein ligands with variable affinities.  
The most well-known ligand of Pfn2 is G-actin (see 1.3), which could be found 
enriched in Pfn2 as well as P2-GFP complexes (Fig. 24B). As expected based on the 
previous observations using PLP-beads in a pull-down assay (see 2.2.3), actin 
monomers were found in similar amounts in Pfn2- and P2-GFP-bound fractions, 
relatively to the amount of immunoprecipitated Pfn2 or P2-GFP.  
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A regulator of actin polymerization through its role as a nucleation promoting factor 
(NPF), acting on the Arp2/3 complex, is the WAVE complex, which is also a well-
documented ligand of Pfn2 (see 1.2.1)  
(Chen et al., 2014, 2010; Stradal and Scita, 2006; Witke, 2004; Witke et al., 1998). 
Every analyzed component of the heteropentameric WAVE complex could be found 
associated with both Pfn2 as well as P2-GFP (Fig. 24C).  
While all three isoforms of WAVE (WAVE 1-3) were present in complexes bound to 
P2-GFP, the corresponding Pfn2 bound fractions appeared less enriched in WAVE 
proteins, but this is likely due to the lower efficiency of the Pfn2 IP compared to the 
GFP-Trap IP. Pfn2, in fact, was detected in the corresponding bound fractions of 
reciprocal IPs of each of the three WAVE isoforms 1-3 (data not shown). Each WAVE 
protein co-immunoprecipitated Pfn2, whereas a particularly high amount of Pfn2 
could be found in WAVE3 complexes. 
The interaction of CyFIP1+2 could be shown as well, very efficient with both Pfn2 and 
P2-GFP (Fig. 24C). CyFIPs (in particular CyFIP1) are believed to feature also actin-
independent functions, i.e. in translational regulation for spine development and 
stabilization associated with the hereditary mental retardation Fragile-X-syndrome 
(FXS) (Napoli et al., 2008; Pathania et al., 2014). A reciprocal IP of CyFIP1+2 also 
yielded Pfn2 in the bound fraction both by Western blot analysis and in mass 
spectrometry (MS) measurements of the co-immunoprecipitated proteins (data not 
shown). 
 
Fig. 24 Pfn2 ligands bind normally to P2-GFP with few exceptions 
(A) Pfn2 as well as P2-GFP were successfully immunoprecipitated in wildtype or homozygous P2-GFP 
KI mice, respectively, without unspecific signals in the Pfn2 KO control. The P2-GFP IP using GFP-
Trap beads was more efficient than the Pfn2 IP using the anti-Pfn2 T2 antibody. (B) Actin was equally 
co-precipitated by Pfn2 and P2-GFP. (C) The components of the WAVE-complex were present in Pfn2 
and P2-GFP complexes with slight variations in binding efficiency. Only the Abi isoforms showed a 
preference towards Pfn2. (D) The actin nucleators investigated here were equally enriched in the Pfn2 
and P2-GFP immunoprecipitated fractions, except for mDia1, which was significantly reduced in the 
P2-GFP bound fraction. Cortactin was identified as a novel interaction partner of Pfn2 and P2-GFP. 
(E) Synaptic proteins were found to interact with Pfn2 as well as P2-GFP. But the binding efficiency of 
P2-GFP to dynamin1, endophilin1 and huntingtin was reduced.  
IN = input fraction, B = bound fraction, UN= unbound fraction 
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Tightly associated with CyFIP, also the WAVE complex constituent Nap1 could be 
found in the immunoprecipitated fractions of Pfn2 and P2-GFP, although it was 
additionally present in the negative control fractions at a comparable rate (Fig. 24C). 
The two isoforms of Abi (Abi 1 and 2), were co-precipitated by Pfn2 with enhanced 
binding affinity compared to P2-GFP (Fig. 24C). Abi isoforms play a role in promoting 
actin polymerization through the effect of the WAVE complex and are additionally 
involved in spine maturation and learning and memory processes through other 
complexes (Grove et al., 2004; Innocenti et al., 2004, 2005; Kunda et al., 2003). 
 
Another family of proteins, majorly involved in the remodeling of the actin 
cytoskeleton, in particular in filopodia and lamellipodia, are formins. The formin 
mDia1 (mammalian Diaphanous 1) is able to drive actin polymerization in vitro at very 
fast rates in the presence of Pfn2, implying an efficient interaction, which was indeed 
observed in Pfn2-associated complexes as a noteworthy enrichment (Fig. 24D).  
P2-GFP, on the other hand, could only marginally enrich mDia1, possibly due to a 
negative influence of the GFP moiety to the specific complex formation of Pfn2 and 
mDia1. mDia2, in contrast to mDia1, seemed to be equally co-precipitated by Pfn2 
and P2-GFP (Fig. 24D), suggesting divergent modes of binding of the two mDia 
isoforms to Pfn2. 
 
Also the Ena/VASP family of actin nucleators is involved in regulating actin 
protrusions (see 1.2). A member of this protein family expressed in nervous tissue is 
Mena (mammalian Ena), which promotes actin polymerization e.g. in specialized 
cellular protrusions like lamellipodia, filopodia or axonal projections (Gertler et al., 
1996; Lanier et al., 1999). The two splice variants of Mena were bound to Pfn2 and 
P2-GFP. The GFP-tag did therefore not affect the binding capability. 
A novel Pfn2 ligand, the actin nucleation promoting factor cortactin (Cttn), was 
discovered as well in this study (Fig. 24D). Cortactin interacts with F-actin and the 
Arp2/3 complex, regulating actin polymerization, branching and stabilization. Cttn has 
been implicated in spinogenesis as well as activity-dependent morphological 
changes of spines (Ueda et al., 2013). In both Pfn2 and P2-GFP IPs, cortactin could 
be enriched, but appears stronger in the more efficient P2-GFP IP. 
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Pfn2 has been shown to have different synaptic functions during both synaptic 
vesicle exocytosis and endocytosis, and interacting with a variety of pre- and post-
synaptic proteins. Synapsins have a role in synaptogenesis and in synaptic 
transmission, while the loss of these proteins (Syn1 KO, Syn2 KO, Syn1/Syn2 double 
KO mouse models) lead to behavioral abnormalities consistent with traits of ASD and 
epileptiform activity (Greco et al., 2013; Murk et al., 2012). The synapsin family, as 
expected, was found to interact proportionally with Pfn2 and P2-GFP (Fig. 24E).  
A direct interaction of Pfn2 with dynamin 1 (Dyn1) has previously been shown and an 
inhibitory role of Pfn2 in Dyn1-mediated membrane endocytosis was observed 
(Gareus et al., 2006; Witke et al., 1998). Dynamin 1 was enriched in Pfn2 IPs, but 
less markedly in P2-GFP IPs, possibly due to the hindrance of the GFP moiety (Fig. 
24E). A similar distribution in Pfn2- and P2-GFP-bound fractions could be detected 
for endophilin 1 (Enph1) (although also small amounts were visible in the Pfn2 KO 
control) (Fig. 24E). Enph1 is involved in the membrane fission process during 
endocytosis (Gareus et al., 2006; Schmidt et al., 1999; Sung et al., 2008). 
Huntington´s disease, a fatal neurodegenerative movement disorder, is caused by 
mutations in the huntingtin gene (HTT) (Chakraborty et al., 2014b; Zuccato et al., 
2010). Huntingtin is interacting with a vast number of proteins, including Pfn2 (Burnett 
et al., 2008; Witke et al., 1998). Indeed, Htt could be co-precipitated together with 
Pfn2 but was lost in P2-GFP complexes, indicating a relevant effect of the GFP 
moiety specifically on this interaction (Fig. 24E). 
 
The analysis of Pfn2- and P2-GFP-complexes indicates a substantially unimpaired 
ligand-binding ability of P2-GFP to the majority of proteins. Although P2-GFP binds 
less efficiently to PLP in vitro (see 2.2.3), the interaction with proline-rich ligands in 
vivo under physiological conditions does not seem considerably affected. The binding 
efficiency of P2-GFP towards its ligands is decreased for Abi1, Abi2, mDia1, 
dynamin1, endophilin1 and huntingtin, which are associated with diverse cellular 
functions, i.e. actin dynamics and synaptic activity. 
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2.3 Pfn2 is a regulator of neuronal development in vitro 
 
To elucidate the functions of Pfn2 in neurons, primary murine hippocampal neurons 
were prepared from isolated embryonic hippocampi (embryonic day 17.5 (E17.5), see 
4.4.2) of different genotypes (wt, P2-GFP KI and Pfn2 KO). The localization of Pfn2 in 
cultured neurons was analyzed and morphological changes during neuronal 
development due to the deletion of Pfn2 as well as Pfn2 trafficking in mature neurons 
after various chemical stimulations was studied. 
The stages of neuronal development in vitro are well-documented for defined culture 
conditions that ensure the presence of fully functional, mature neuronal networks 
(Bradke and Dotti, 1999; Dotti et al., 1988; Kaech and Banker, 2006). A monolayer of 
astrocytes in an adjacent co-culture provides the neurons with nutrients and growth 
factors, which they release into the medium and therefore condition it to support 
optimal neuronal development and physiology (see 4.4.3). The positive effect of the 
astrocyte co-cultures can be acknowledged by markedly increased cell survival rates 
of the cultured neurons (Bradke and Dotti, 2000; Dotti et al., 1988; Kaech and 
Banker, 2006). 
Neuronal cultures are also a useful system to study the role of specific 
neurotransmitters without the network framing the neuron in vivo. Presumptive 
changes can therefore be observed directly related to the respective substance used 
for stimulation without the complex and possibly compromising feed-forward or feed-
back mechanisms that would otherwise give rise to secondary effects in vivo. In 
particular, primary hippocampal neurons are used, as these neurons are nearly 
exclusively glutamatergic and can be considered a single cell type compared to 
highly mixed populations of cortical or striatal neurons that are also used as neuronal 
model systems. 
 
Adult Pfn2 KO mice show a strong pre-synaptic phenotype (see 1.3.4), but Pfn2 was 
shown to be expressed already during embryonic development (see 2.1.5, Fig. 20 
and additional data not shown) although it is not essential for neuronal survival. In 
order to understand the complex role of Pfn2 during the different developmental 
stages, cultured neurons were used as a model system closely related to neurons in 
vivo.  
2. Results 
 
 
 
77 
Therefore, possible alterations during neuronal development due to Pfn2 deficiency 
at key developmental stages, such as neuritogenesis, neuronal polarization and 
synaptogenesis were examined. The complexity of Pfn2 KO neurons in comparison 
to wildtype neurons was analyzed by Sholl analysis (see 2.3.1). Cultures from P2-
GFP homozygous KI (G/G) neurons were also included in this analysis to further 
validate the fusion protein mouse model as a tool to understand Pfn2 function in vivo. 
Furthermore, neurons derived from P2-GFP KI mice were used as a validated tool 
(see 2.2 and 2.3.1) to study the localization of Pfn2 in the major subcellular structures 
of cultured neurons and astrocytes (see 2.3.2). The localization of Pfn2 in these 
neuronal compartments indicated a potential role in these structures that was further 
analyzed by stimulating mature cultured neurons. 
Finally, the trafficking of Pfn2 into the aforementioned neuronal substructures upon 
exposure to stimulatory agents was investigated in cultured neurons derived from P2-
GFP KI animals by high-resolution confocal immunofluorescence imaging (see 2.3.3). 
A function of Pfn2 in a certain neuronal compartment can be assumed with high 
confidence, if Pfn2 is enriched following a certain stimulation protocol. 
 
2.3.1 Pfn2 KO neurons show accelerated neuronal development 
 
Neurons in culture show very similar maturation stages as neurons during embryonic 
development in vivo. Dissociated neurons in culture form lamellipodia around the cell 
bodies after the first few hours (stage 1). Then, the cells extend several neurites 
(stage 2) from the soma before the neurons after app. 24-48h (DIV1-2 (days in vitro) 
polarize and one neurite starts to rapidly elongate (the future axon, stage 3). The 
minor neurites (future dendrites) also start to elongate (stage 4) at DIV3-4 to 
subsequently form elaborate networks (stage 5). Dendritic spines can be observed 
starting app. 2 weeks after plating (DIV14) but undergo further plastic changes until 
stable synapses and networks are formed at app. DIV21. Eventually the neurons 
start to gradually undergo apoptosis after 4 weeks in culture (Dotti et al., 1988; Kaech 
and Banker, 2006). 
 
In order to investigate potential abnormalities of Pfn2 KO neurons during neuronal 
development, primary hippocampal neurons were cultured (see 4.4.2) and their 
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complexity was examined at different developmental stages by Sholl analysis (Binley 
et al., 2014; Longair et al., 2011; Sholl, 1953) (see 4.4.5, Fig. 25). The Sholl analysis 
is a method to measure the complexity of neuronal extensions in silico by applying 
concentric circles with a defined interval around the neuronal somata (Fig. 25). The 
number of intersections of the neuronal tree through these circles is then plotted 
against the distance from the soma in µm. The Sholl analysis therefore requires the 
labelling of neuronal processes, which was carried out by fluorescently staining 
MAP2 (microtubule-associated protein 2), a commonly used marker protein localized 
to neurites and dendritic processes (Bradke and Dotti, 1997, 1999, 2000; Dotti et al., 
1988; Kaech and Banker, 2006; da Silva and Dotti, 2002; Witte and Bradke, 2008; 
Witte et al., 2008). The complexity of neuronal arborizations was measured and 
analyzed in this way to be able to identify potential alterations in both P2-GFP KI and 
Pfn2 KO neurons even in specific segments of the intricate dendritic tree throughout 
neuronal development. 
 
 
Fig. 25 Sholl analysis of cultured mature hippocampal neurons 
(A) Representative image of a mature (DIV21) hippocampal neuron in culture. Fluorescent staining of 
MAP2 is used to visualize the dendritic tree. (B) The dendrites of over 100 for less mature stages 
(DIV1-7) and app. 30 neurons at the mature stages (DIV14-21) are traced manually (pink lines) using 
the Fiji ImageJ plugin Simple Neurite Tracer (Longair et al., 2011) for each genotype (wt, P2-GFP KI, 
Pfn2 KO) and each culture (n=3 independent cultures). (C) Concentric circles (yellow) of a defined 
interval (10 µm) are applied in silico (shown here are only circles with an interval of 100 µm) extending 
radially around the soma of the neurons. The intersections of the neurites through these circles are 
consequently plotted against the distance from the soma (see Fig. 26). 
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Sholl analyses were carried out averaging between 24 and over 100 neurons 
(depending on the developmental stage, see Fig.25 and Fig. 26 legend) from three 
independent cultures of wt, homozygous P2-GFP KI and Pfn2 KO neurons. 
Pfn2 KO neurons developed in accordance to the known developmental stages, but 
they showed an accelerated development (Fig. 26). The number of initial neurites at 
DIV 1 was higher for Pfn2 KO neurons in comparison to wt neurons (Fig. 26A), but 
the neurons still formed one major process (the future axon) similarly to the wt 
neurons. P2-GFP KI neurons developed normally and were indistinguishable from wt 
neurons at this stage (Fig. 26A). 
After 48h of development (DIV 2), Pfn2 KO neurons showed a higher complexity than 
wt neurons and the major process was growing out longer (app. 50 µm = 25% longer) 
(Fig. 26B). P2-GFP KI neurons started to show an intermediate phenotype between 
wt and Pfn2 KO cells. They appeared to have a slightly increased complexity with the 
leading neurite extending also further than that of wt neurons (Fig. 26B). 
At DIV 3 Pfn2 KO neurons started to establish a high degree of neurite branches 
especially proximal to the soma and still extended the leading process further than wt 
neurons (app. 70 µm = 25% longer) (Fig. 26C). P2-GFP KI neurons showed an 
intermediate development with a very slight tendency towards increased proximal 
branching and an elongated leading process (app. 60 µm = 21% longer) (Fig. 26C). 
At DIV 7, neurite extension length was normalized between all genotypes, but the 
more complex proximal branching in Pfn2 KO neurons was further increased, 
especially in the first 150 µm adjacent to the soma (Fig. 26D). The intermediate 
phenotype of P2-GFP KI neurons could still be acknowledged by the low increase in 
proximal neurite complexity (Fig. 26D). 
Over the course of the second week in culture, Pfn2 KO neurons extremely amplified 
their higher complexity nearly over the full extent of the dendritic tree with only the 
most distal part at a level comparable to the wt (Fig. 26E). Also P2-GFP KI neurons 
showed an increased complexity especially in the first 300 µm proximal to the soma 
(Fig. 26E). Completely developed Pfn2 KO neurons at DIV 21 were similarly complex 
compared to wt neurons (Fig. 26F). They even started to gradually reduce their 
dendritic branching at the most distal segments of the neuronal tree (app. the last 
250 µm, Fig. 26F). 
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Pfn2 KO neuronal projections were still slightly more branched in the intermediate 
range of app. 250-400 µm from the soma. P2-GFP KI neurons were not able to 
completely develop at DIV 21, but instead shortened most of their dendritic tree (Fig. 
26F). 
 
 
Fig. 26 Sholl analysis revealed a role of Pfn2 in neuronal development 
 (A) Neurons derived from wt, P2-GFP KI and Pfn2 KO animals were analyzed 24h after plating (DIV 
1). Pfn2 KO neurons show enhanced initial neurite sprouting, while P2-GFP neurons develop 
comparably to wt cells. DIV1 wt:KO p= 0.0387, wt:G/G p= 0.08356, G/G:KO p= 0.2143 by Mann-
Whitney test, n=67/3 for wt, n=102/3 for G/G and n=64/3 for Pfn2 KO. (B) Following 48h in culture 
(DIV 2), Pfn2 KO and P2-GFP KI neurons show higher complexity than wt neurons and increased 
neurite elongation. DIV2 wt:KO p= 0.0333, wt:G/G p= 0.843, G/G:KO p= 0.0065 by Mann-Whitney 
test, n=73/3 for wt, n=90/3 for G/G and n=37/2 for Pfn2 KO. (C) Pfn2 KO neurons at DIV 3 increase 
their proximal complexity in comparison to wt neurons. Both Pfn2 KO and P2-GFP KI neurons develop 
longer extensions than wt cells. DIV3 full range wt:KO p= 0.4935, wt:G/G p= 0.4636, G/G:KO p= 
0.8794, proximal neurites (20-80 µm from soma) wt:KO p= 0.0409 by Mann-Whitney test, n=66/3 for 
wt, n=73/3 for G/G and n=37/2 for Pfn2 KO. (D) The neurite length is similar at DIV 7 between all three 
genotypes, but the proximal branching of Pfn2 KO neurons remains highly increased. P2-GFP KI 
neurons show an intermediate phenotype, similar to DIV3. DIV7 full range wt:KO p= 0.001, wt:G/G p= 
0.0211, G/G:KO p= 0.4462, proximal neurites (20-150 µm) wt:KO p= 0.0009, wt:G/G p= 0.0047, 
G/G:KO p= 0.2411 by Mann-Whitney test, n=63/3 for wt, n=53/3 for G/G and n=38/3 for Pfn2 KO. (E) 
After two weeks in culture (DIV14), all genotypes are increasingly complex, but P2-GFP KI and 
particularly Pfn2 KO neurons show an extreme level of (especially proximal, but at this stage also 
distal) dendritic complexity. DIV14 full range wt:KO p= 0.00001, wt:G/G p= 0.0345, G/G:KO p= 
0.00001, proximal neurites (10-200 µm) wt:KO p= 0.00001, wt:G/G p= 0.0143, G/G:KO p= 0.00001, 
distal neurites (200-890 µm) wt:KO p= 0.00001, wt:G/G p= 0.0891 by Mann-Whitney test, n=39/3 for 
wt, n=47/3 for G/G and n=40/3 for Pfn2 KO. (F) Wt neurons show a similar complexity to Pfn2 KO 
neurons at the fully mature stage (DIV21) with the Pfn2 KO neurons starting to gradually reduce their 
complexity in the distal part of the dendritic tree. P2-GFP KI neurons were not able to reach the 
completely developed stage. DIV21 full range wt:KO p= 0.5253, wt:G/G p= 0.9261, G/G:KO p= 0.222, 
proximal neurites (10-200 µm) wt:KO p= 0.0385, wt:G/G p= 0.001 , G/G:KO p= 0.0021, intermediate 
neurites (250-400 µm)  wt:KO p= 0.0011, wt:G/G p= 0.3179, i G/G:KO p= 0.005, distal neurites (600-
830 µm) wt:KO p= 0.00001 by Mann-Whitney test, n=24/3 for wt, n=35/3 for G/G and n=36/3 for Pfn2 
KO. (G) Representative example image of mature (DIV21) neurons in culture. Scale bar 10 µm. 
Minitab17 software was used for statistical analysis employing the Mann-Whitney test: p ≥ 0.05 = n.s., 
p ≤ 0.05 = *, p ≤ 0.01 = **, p ≤ 0.001 = ***, p ≤ 0.0001 = **** Error bars represent S.E.M. 
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In conclusion, comparing wt and Pfn2 KO neurons, the latter appeared to develop a 
longer leading neurite and to maintain increased arborization complexity. The Pfn2 
KO cells therefore developed at a higher velocity, reaching the next developmental 
stage at an accelerated rate compared to wt neurons. P2-GFP neurons showed an 
intermediate phenotype between wt and Pfn2 KO cells.  
 
 
2.3.2 Pfn2 is localized to key structures in neuronal development 
 
Pfn2 KO neurons showed alterations in neuronal development pointing to an 
accelerated development (see 2.3.1, Fig. 26). Especially specific segments of the 
dendritic tree were affected by the loss of Pfn2 (proximal branching starting from 
early stages of development and additionally distal branching at more mature 
stages). Consequently, a role of Pfn2 in the regulation of dendrite formation and 
branching (maturation) could be hypothesized. In order to identify the distinct roles of 
Pfn2 in key structures of neuronal development as well as pre- and post-synaptic 
compartments, the subcellular localization of Pfn2 was investigated in detail by 
fluorescent imaging in cultured neurons derived from homozygous P2-GFP KI (G/G) 
mice.  
Several studies used different approaches (mostly based on transfection assays) to 
visualize Pfn2 in nervous tissue and cultured neurons so far. Nonetheless, the 
distribution of endogenously expressed Pfn2 in neuronal cells has not been 
conclusively reported. 
 
Neuronal subcellular compartments were specifically labelled employing common 
marker proteins for neurites and dendritic shafts (Map2, see 2.3.1), dendritic spines 
(PSD95) (Chen et al., 2007a; Craig et al., 2006), axonal shafts (Tau1) (Bradke and 
Dotti, 2000; Kaech and Banker, 2006; Witte et al., 2008) and axonal boutons 
(VAMP2 (synaptobrevin 2)) (Okawa et al., 2014; Rossi and Volterra, 2009). 
Fluorescently labelled Phalloidin was used to stain the actin cytoskeleton and 
cultured astrocytes were identified as GFAP-positive cells (see 2.1.4). 
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Fig. 27 Localization of Pfn2 in subcellular compartments of cultured neurons and astrocytes 
(A) Cultured neurons (DIV 2) show Pfn2 (green) enriched in the cell body and neurites (Map2, red, 
yellow in the merged image). More specifically, Pfn2 is found in future dendrites (shorter processes) as 
well as in the future axon (longer proces). Actin-rich growth cones (Phalloidin, blue) were enriched in 
Pfn2 as well (cyan in the merged images, arrowheads). (B) Zoomed image of a mature neuron (DIV 
21), which localized Pfn2 to dendrites and less markedly to axons (Tau1, red). Pre-synaptic terminals 
(VAMP2, blue) are, in contrast to the axonal shafts, highly enriched in Pfn2 (cyan in the merged 
images, arrowheads). (C) Post-synaptic spines (PSD95, red) on dendrites of mature neurons (DIV 21) 
are positive for Pfn2 (yellow in the merged images, arrowheads). (D) Cultured astrocytes (GFAP, red) 
express Pfn2 in vitro. 
 
Pfn2 appeared ubiquitously localized in cultured hippocampal neurons (Fig. 27). The 
initial stages of neuronal development are characterized by neurite extension, growth 
cone formation and neuron polarization (see 2.3.1). Pfn2 was localized in neurites 
(Fig. 27A) and more specifically in polarized neurites becoming either the future 
dendrites (Fig. 27A, shorter processes) or the future axon (Fig. 27A, single longer 
process). Also growth cones that are essential for neurite outgrowth were strongly 
enriched in Pfn2 (Fig. 27A, arrowheads). In mature neurons, Pfn2 was mostly 
localized in dendritic shafts and less to axonal projections (Fig. 27B). Nevertheless, 
pre-synaptic boutons on axonal projections were prominently labelled by Pfn2 (Fig. 
27B, arrowheads). Similarly post-synaptic spines were enriched in Pfn2 (Fig. 27C, 
arrowheads). The different types of spines, which can be clearly distinguished by 
their morphology (see 1.4.1), were analyzed as well and showed an equal distribution 
of Pfn2 among thin/filopodial, stubby and mushroom-shaped spines. Spine necks as 
well as the PSD-containing tip showed signals for Pfn2, comparable to the known 
localization of the actin cytoskeleton (data not shown). 
In contrast to the observations in the adult brain described previously (see 2.1.4, Fig. 
19), Pfn2 was found in cultured astrocytes (Fig. 27D). But these cells were derived 
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from embryonic GFAP-positive radial glia cells (embryonic stem cells), which were 
shown to express Pfn2 (see 2.1.6, Fig. 20) and therefore most likely continue to 
express Pfn2 also under in vitro culture conditions. 
 
In summary, Pfn2 is enriched in neurites during neuronal development and localizes 
to synaptic compartments during maturation. The localization of Pfn2 in cultured 
neurons emphasizes the importance of this particular profilin isoform for specific 
processes that need fast and tightly regulated actin dynamics, such as growth cone 
motility, neurite outgrowth and pre- and post-synaptic compartment physiology. 
 
2.3.3 Stimulation-induced trafficking of Pfn2 into pre- and post-
synaptic compartments  
 
A potentially specific function of Pfn2 in neuronal compartments, as mentioned above 
(see 2.3.2, Fig. 27), was analyzed by differentially stimulating cultured hippocampal 
neurons and investigating the corresponding trafficking of P2-GFP in response to the 
stimulus (see 4.4.6). Cultured hippocampal neurons were therefore isolated from P2-
GFP KI animals (n=2 independent cultures) and stimulated at developmental maturity 
(DIV21) (see 4.4.6). 
 
Neurons respond to various neurotransmitters and to changes in specific ion 
concentrations in the environment (see 1.4.1, Fig. 6 and 7). The application of 
glutamate activates ionotropic (AMPA and kainate receptors) as well as metabotropic 
(mGluRs) receptors, which cause sodium influx and depolarization of the cell. A 
strong depolarization of the membrane potential consequently leads to firing of an 
action potential. Glutamate binds to NMDA receptors as well, but the co-agonist 
glycine (or D-serine) is necessary in order to activate the channel. NMDA receptors 
not only mediate the influx of sodium and efflux of potassium ions, but also induce a 
high degree of calcium ion entry. Consequently, calcium ions can act as second 
messenger molecules, activating downstream Ca2+-dependent signaling pathways 
that include long-term changes in synaptic plasticity (Zito and Scheuss, 2009). The 
opening of the channel is also voltage-dependent, since a blockage by a magnesium 
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ion prevents its activation, which can be released by depolarization, e.g. by AMPA or 
kainate receptor activity. The response of NMDA receptors is therefore not as 
immediate compared to the AMPA or kainate receptors and has a larger impact on 
changes in synaptic plasticity. The application of NMDA itself will only open NMDA 
receptors lacking an effect on the other receptors. 
Applying an excess of extracellular potassium leads to a reversal of the membrane 
potential, allowing potassium entry and the depolarization of the cell. A strong 
depolarizing effect leads to an increase in the probability of the formation of an action 
potential.  
Changing the ratio of calcium to magnesium ions in the medium to 7:1 has a less 
strong effect, since extracellular calcium is not able to freely diffuse into the cell, but 
the probability of synaptic transmission is increased.  
 
GABA stimulation, on the other hand, has the opposing effect of hyperpolarizing the 
cell, as chloride ion influx is induced by activating GABA receptors, further lowering 
the membrane potential and decreasing the excitability of the cell.  
Finally, LTD is a powerful means to induce synaptic plasticity including decreased 
synaptic transmission, spine shrinkage, loss of F-actin in spines, protein degradation 
and decreased local translation (see 1.4.1) (Bellot et al., 2014; Bosch et al., 2014; 
Chen et al., 2007a; Cingolani and Goda, 2008; Huang et al., 2014; Lee et al., 1998; 
Li et al., 2007; Oberman and Pascual-Leone, 2013; Shehata et al., 2012). To obtain 
LTD in cultured neurons, a chemical model of LTD can be applied using a brief 
application of NMDA at high concentrations (3 min., 25 µm NMDA, see 4.4.6) that is 
nearly indistinguishable from electrically stimulated LTD in the brain or brain slices 
(Huang et al., 2014; Lee et al., 1998; Li et al., 2007; Shehata et al., 2012).  
The neurons were investigated directly after the stimulations and in addition after 
washing out the stimulus and incubating the cells in stimulant-free medium for a 
certain period of time, which allowed the cells to recover from the induced de- or 
hyper-polarization. 
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Fig. 28 Pfn2 trafficking into neuronal compartments induced by depolarizing stimulation 
Primary hippocampal neurons were stimulated with various depolarizing treatments (indicated at the 
top) and the trafficking of Pfn2 (P2-GFP, green) in neuronal compartments at specific time points is 
shown. Fluorescent puncta corresponding in size, shape, density and distribution to either pre-synaptic 
boutons (identified by labelling VAMP2, blue) or post-synaptic spines (identified by labelling PSD95, 
red) are visible. Axons are stained using Tau1 (red) as a marker protein. 
(A) Under normal conditions Pfn2 (green) is present in moderate amounts in pre-synaptic boutons 
(VAMP2, blue, arrowheads), (B) axonal shafts (Tau1, red, arrows) and (C) spines (PSD95, red, 
arrowheads). (D) An excess of potassium in the medium (10 min. of exposure) leads to enrichment of 
Pfn2 in boutons (cyan merge), (E) moderately in axons (yellow merge) and (F) more pronounced in 
spines (yellow merge). (G) Increasing the Ca2+/Mg2+ ratio to 7:1 has similar effects (10-30 min. of 
exposure) triggering Pfn2 re-localization to boutons, (H) slightly to axons and (I) to spines. (J) Applying 
NMDA to the cells has a stronger impact. Pfn2 is enriched in pre-synaptic terminals after 5-10 min. of 
exposure, (K) but in axonal shafts most efficiently after 30 min. to 1 h of incubation after washing away 
NMDA in the medium. (L) The application of NMDA induced Pfn2 enrichment into a subset of dendritic 
spines. (M) The strongest effect is observed using glutamate as a stimulatory agent. Pfn2 is re-
localized to pre-synaptic boutons after 5 min. of exposure, (N) but into axons after 1 h of incubation 
after removal of glutamate. (O) Glutamate stimulation induced Pfn2 re-localization also into post-
synaptic spines.  
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In resting (control) neurons Pfn2 was moderately localized to pre-synaptic boutons, to 
a minor amount in axonal shafts and also moderately in post-synaptic spines (Fig. 28 
and Fig. 29A-C). But Pfn2 showed dynamic responses to the stimulating conditions. 
  
All excitatory stimulation agents (K+, Ca2+, glutamate (together with glycine) and 
NMDA) induced similar trafficking of Pfn2 into both pre- and post-synaptic terminals 
as well as axonal shafts, while enhancing the overall expression level of Pfn2.  
Strong depolarization of the cell induced by an excess of potassium in the medium 
caused a re-localization of Pfn2 into synaptic boutons (Fig. 28D), axonal shafts (Fig. 
28E) and dendritic spines (Fig. 28F). The effect of an excess of potassium (KCl, 60 
mM, see 4.4.6) in the medium was most pronounced after 5-10 min. of exposure. The 
re-localization of Pfn2 into pre-synaptic boutons was obvious after 5 min., while an 
enrichment of Pfn2 in axonal shafts was noticeable after 10 min. of exposure. 
Dendritic spines showed both an increase in F-actin and Pfn2 after 10 min.  
Similarly, but less efficiently, an increased ratio of calcium to magnesium ions in the 
medium (Ca2+/Mg2+ ratio 7:1, see 4.4.6) triggered moderate Pfn2 trafficking to 
synaptic boutons (Fig. 28G) after 10 min. of exposure, while an enrichment in axons 
(Fig. 28H) could be observed after 15 min. and dendritic spines (Fig. 28I) were 
affected after 30 min. The increase in Pfn2, VAMP2 and F-actin levels was also not 
as obvious as induced by the KCl treatment. 
Targeting specifically NMDA receptors (NMDA, 10 µM, see 4.4.6) efficiently induced 
enrichment of Pfn2 in pre-synaptic terminals (Fig. 28J) and axonal shafts (Fig. 28K), 
but only a subset of dendritic spines were enriched in Pfn2 (Fig. 28L). The effects 
were still visible after washing and 30 min. till up to 2h of incubation time after the 
application of the agonist (data not shown). 
The most efficient stimulation was achieved by exposure to glutamate with or without 
the addition of glycine (glutamate 10 µM, glycine 10 µM, 10 min., see 4.4.6). 
Activating all types of glutamate receptors induced a prominent enrichment of Pfn2 
mostly in pre-synaptic boutons (Fig. 28M), but also in axonal shafts (Fig. 28N) and 
dendritic spines (Fig. 28O). The changes persisted for 30 min. to at least 2h 
subsequently to washing the cells. 
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Fig 29 Pfn2 trafficking into 
neuronal compartments 
induced by hyperpolarizing 
stimulation 
Primary hippocampal neurons 
stimulated with hyperpolarizing 
treatments (indicated at the top) 
and stained as mentioned above 
(see Fig. 28) are shown. The 
trafficking of Pfn2 (P2-GFP, 
green) into neuronal 
compartments is shown. 
Fluorescent puncta 
corresponding in size, shape, 
density and distribution to either 
pre-synaptic boutons (identified 
by labelling VAMP2, blue) or 
post-synaptic spines (identified 
by labelling PSD95, red) are 
visible. Axons are stained using Tau1 (red) as a marker protein. 
(A-C) The subcellular localization of Pfn2 at resting conditions is shown for specific neuronal 
compartments (compare Fig. 27). (D) The treatment of neurons with GABA (3 h of exposure), on the 
other hand, has no obvious effect on pre-synaptic boutons, (E) but triggers an enrichment of Pfn2 in 
axons and (F) moderately in spines. (G) Chemically inducing long term depression using a brief 
application (3 min.) of a high dosage of NMDA (chem. LTD) also triggers an enrichment of Pfn2 in pre-
synaptic terminals, while (H) axonal shafts are nearly devoid of Pfn2. (I) Post-synaptic spines are 
moderately enriched in Pfn2 following chemically induced LTD. 
 
 
An opposite effect on Pfn2 trafficking was observed by hyperpolarization of the cell 
by GABA treatment and after chemical LTD (Fig. 29). The application of GABA 
(GABA, 50 µM, see 4.4.6) and a brief, highly concentrated pulse of NMDA as a 
chemical model of LTD (NMDA, 25 µM, see 4.4.6) and yielded an overall reduction of 
the fluorescent signals of Pfn2 and VAMP2, but no change in F-actin levels (data not 
shown, the fluorescent signals were digitally intensified during the acquisition in order 
to visualize Pfn2 in neuronal compartments). 
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Even though Pfn2 levels were decreased, GABA-mediated hyperpolarization of the 
neurons lead to no obvious trafficking of Pfn2 into boutons (Fig. 29D) but interestingly 
into axons (Fig. 29E) and Pfn2 was found slightly increased in dendritic spines (Fig. 
29F). 
The chemical LTD protocol still induced an enrichment of Pfn2 in pre-synaptic 
boutons (Fig. 29G), but was mostly absent from axons (Fig. 29H). The reduction of 
Pfn2 in axons was only transient, as Pfn2 was present in axons at baseline levels 
after 1 h of recovery after washing away the NMDA. A slight increase of Pfn2 in post-
synaptic spines was also detectable (Fig. 29I). 
 
Pfn2 showed distinctive trafficking following each stimulatory treatment, indicating a 
role and function in the processes induced by the specific stimulation. Due to the fact 
that Pfn2 was responding mostly to excitatory stimulation, Pfn2 predominantly 
responds to depolarization rather than to hyperpolarization of the cell. During and 
consequent to depolarization, Pfn2 appeared to be needed in both pre- and post-
synaptic terminals as well as axonal shafts. In dendrites Pfn2 was stably expressed 
at high levels. 
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3.1 Neuronal systems potentially involved in autism spectrum 
disorder 
 
Autism spectrum disorder is a neurodevelopmental disease of genetic origin 
becoming more and more relevant, now with a prevalence of app. 13/10,000 children 
(Kogan et al., 2009). The key observation in autistic patients is an imbalance in the 
excitation/ inhibition ratio in the central nervous system. Nevertheless, it is still 
debated, which neuronal systems are involved or contribute to this imbalance in ASD. 
The Pfn2 KO mouse model shows autistic-like phenotypes, such as hyperexcitability, 
social and communication deficits, coordination impairments and epileptic seizures. 
In order to understand the possible contribution of Pfn2 to these complex 
phenotypes, its expression profile in the different neuronal systems has been 
investigated in detail in this thesis taking advantage of a P2-GFP fusion protein 
knock-in mouse model, by co-localizing the P2-GFP fusion protein with a range of 
specific markers for neuronal sub-populations. 
 
3.1.1 Excitatory neuronal systems are all potentially involved in 
ASD and seizures phenotypes of Pfn2 KO mice 
 
Autistic patients show an excess of glutamate in the brain (Hussman, 2001) and 
many brain functions are modulated by pathways involving glutamatergic signaling, 
such a majority of behavioral functions, including social behavior, emotion, learning 
and memory as well as motor functions. Therefore glutamatergic neurons are under 
growing investigation in autism research (see 1.4.2) (Abrahams and Geschwind, 
2008; Alarcón et al., 2008; Bellot et al., 2014; Di Cristo, 2007; Jacob et al., 2011; 
Peñagarikano et al., 2011; Szatmari et al., 2007).   
Previous studies have shown a function of Pfn2 in glutamatergic neurons, in which 
pre-synaptic vesicle release was increased due to impairments in fast actin-dynamics 
in pre-synaptic terminals (Pilo Boyl et al., 2007). In this study, Pfn2 was found 
expressed in all excitatory neuronal systems with varying levels (see 2.1.1). More 
specifically, glutamatergic neurons express the highest levels, dopaminergic, 
noradrenergic as well as serotonergic neurons express high levels of Pfn2, while 
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cholinergic neurons are the exception among excitatory systems producing only low 
levels of Pfn2 (see 2.1.1.2-2.1.1.5, Fig. 14, Fig. 21, Supp. Fig. 12).  
 
3.1.1.1 The potential role of Pfn2 in increased sensitivity of sensory 
neurons in ASD 
 
Pfn2 could play a relevant role in the neuronal regulation of sensory information 
propagation. This work shows a strong expression of Pfn2 in the olfactory system of 
the mouse, as an example of the various sensory systems (see 2.1.3, Fig. 18, Fig. 
21, Supp. Fig. 12). The highest expression level of Pfn2 was indeed observed among 
all glutamatergic neurons, but in particular in pyramidal neurons of the hippocampal 
CA2 region and in olfactory Mitral and external tufted cells (see 2.1.1.1, 2.1.3, Fig. 
14, 18, 21 and Supp. Fig. 12). 
 
Glutamatergic Mitral cells and external tufted cells (ETCs), which mediate the sole 
output from the olfactory bulb (De Saint Jan et al., 2009) would become 
hyperexcitable in the absence of Pfn2. Short axon cells (SACs), on the other hand, 
are the primary active cells around glomeruli that filter sensory information reaching 
the glomeruli structures from sensory neurons in the nasal epithelium. These cells 
can directly modulate Mitral cell and ETC signaling but primarily target neighboring 
SACs and GABAergic periglomerular neurons, which in turn inhibit Mitral cell and 
ETC signaling (Cave and Baker, 2009; Ennis et al., 2001; McQuiston and Katz, 2001; 
Murphy et al., 2005). SACs show increased expression of Pfn2 upon expression of 
dopamine and is present in minor levels in cells co-expressing GABA and dopamine 
(see 2.1.3, Fig. 18, Fig. 21, Supp. Fig. 12). 
The complexity of this network makes it difficult to decipher the role of Pfn2 in each of 
these neurons in the olfactory circuitry, but it is conceivable to hypothesize that the 
hyperactivation of Mitral cells and ETCs is enough to lead to a strong excitatory 
output transmission from the olfactory bulb in response to environmental stimuli. The 
excess of excitation could be further potentiated in Pfn2 KO mice, since sensory 
information might not be filtered as efficiently by feed-back mechanisms in the 
glomerular network, since also modulatory short axon cells, partially lacking Pfn2, 
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could be dysregulated as well. This hyperexcitable state of the olfactory circuit leads 
to a higher probability of sensory information being transferred to the rest of the brain, 
inducing a hypersensitivity towards sensory stimulation, a trait that is also often 
observed in autistic patients. 
 
On the same line, although not specifically addressed yet, an increased sensitivity to 
pain has also been observed in Pfn2 KO mice (Pilo Boyl, unpublished observation). 
On embryonic tissue, also other sensory compartments, such as the whiskers, teeth 
and the tongue showed the expression of Pfn2 (see 2.1.3, Fig. 18) and in a previous 
study, expression of Pfn2 in the retina has been observed (Perlas, unpublished 
observation). It can therefore be assumed that other, if not all, sensory systems might 
show similar abnormalities due to the deletion of Pfn2. Thus a dysregulation of the 
sensory systems could be an initial cause of the shift in the excitation/inhibition 
balance in the brain that is a key feature in ASD.  
 
Often associated with ASD are epileptic seizures, which most often result from 
hyperactivity of the hippocampal formation (Gant et al., 2009). Excitatory 
glutamatergic signaling was already shown to be increased in Pfn2 KO mice (Pilo 
Boyl et al., 2007). Therefore, the highest Pfn2 levels in glutamatergic hippocampal 
neurons reported in this study (see 2.1.1.1, Fig. 14 and 21), point to their causative 
role for the spontaneous epileptic seizures observed in Pfn2 KO mice. Hippocampal 
GABAergic neurons, on the other hand, were shown to be generally devoid of Pfn2 in 
the hippocampus and are therefore not directly affected by the deletion of Pfn2 (see 
2.1.2.1, Fig. 15, 17 and 21). Hence, even feed-back mechanisms in the hippocampal 
circuitry that normally regulate excessive signaling might be hyperactivated in Pfn2 
KO mice, leading to a potentiation of the excitability that ultimately leads to the 
observed epileptic seizures.  
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3.1.1.2 The possible contribution of Pfn2 in other excitatory 
systems to ASD-related symptoms  
 
Autistic traits such as novelty-dependent hyperactivity and motor coordination deficits 
could be associated with dysregulation of the dopaminergic system, which also 
features very high levels of Pfn2 (see 2.1.1.2, Fig. 14, Fig. 21, Supp. Fig. 12). 
Dopamine is released to medium spiny neurons in the striatum, where it can induce 
differential behavioral patterns that could be affected by the deletion of Pfn2 (see 
3.1.3, Supp. Fig. 1). Stimulating VTA fibers in the Pfn2 KO background yielded an 
approximately 2-fold increased dopamine release compared to wildtype mice, which 
leads to elevated dopamine levels in striata of Pfn2 KO mice (Pilo Boyl, unpublished). 
Especially the deletion of the dopamine transporter (DAT) was shown to lead to 
excessive dopamine in the striatum due to a lack of neurotransmitter reuptake and 
behavioral (motor) abnormalities (Giros et al., 1996) similar to the Pfn2 KO mouse 
phenotype. Pfn2 expression was found in the major dopaminergic regions of the SN 
and the VTA at high levels, a dysregulation of dopaminergic signaling might therefore 
contribute to motor abnormalities, such as the novelty-dependent hyperactivity and 
hyperlocomotion phenotypes of Pfn2 KO mice. The dopaminergic system in humans 
is affected in neurodegenerative diseases, such as Parkinson´s disease, causing 
severe phenotypes mostly concomitant with motor deficits (Björklund and Dunnett, 
2007; Cave and Baker, 2009; Durieux et al., 2011; Kreitzer, 2009; Miller et al., 2013; 
Missale et al., 1998; Nakatani et al., 2007; Oades et al., 2005; Santos et al., 2010; 
Smidt and Burbach, 2007; Svenningsson et al., 2004; Tan et al., 2003). 
 
The noradrenergic signaling from the locus coeruleus is impaired in a number of 
neurological disorders including Rett syndrome, a closely related variant of autism 
spectrum disorders, where adrenergic neurons were found to be hyperexcitable 
(Santos et al., 2010). This hyperexcitability phenotype could also be present in 
adrenergic neurons of Pfn2 mutant mice, since these neurons are highly Pfn2-
positive (see 2.1.1.3, Fig. 14, Fig. 21, Supp. Fig. 12). A potential hyperexcitability of 
adrenergic neurons in Pfn2 KO mice could contribute to a subset of the autistic traits 
observed in the mouse model.  
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Noradrenergic neurons fire minimally in resting conditions and answer by strongly 
increasing their firing upon relevant stimuli (danger, threat, novelty) to induce the 
“fight-or-flight” response (Cannon, 1929), not only innervating certain brain areas but 
also the entire body through receptors at organs and especially neuromuscular 
junctions (NMJs). Behavioral abnormalities like panic (Pilo Boyl, unpublished), low 
aggressivity (Di Nardo, unpublished) and increased novelty seeking behavior (Pilo 
Boyl et al., 2007) of Pfn2 KO mice could in part originate from dysregulation of 
stimulus-induced activity of adrenergic neuronal signaling due to the lack of Pfn2. 
Further detailed studies on the activity of adrenergic neurons in Pfn2 KO mice would 
therefore be important. 
 
The serotonergic system is often associated with ASD and its symptoms both at the 
genetic and physiological level. Thus a high expression level of Pfn2 in serotonergic 
neurons (see 2.1.1.4, Fig. 14, Fig. 21, Supp. Fig. 12) could be in line with the autism-
like phenotype of Pfn2 KO mice. In fact, early studies on autistic patients already 
reported elevated serotonin levels in whole blood as well as platelet samples 
(Anderson et al., 1990; Chandana et al., 2005; Chugani et al., 1997, 1999; Cohen et 
al., 2003, 1995; Crawley, 2004; Dufour-Rainfray et al., 2010; Makkonen et al., 2008; 
Schain and Freedman, 1961) and elevated serotonin levels were found in the 
striatum (especially the nucleus accumbens) in association with neurological 
disorders like schizophrenia, depression and addiction (Brocco et al., 2002; 
Svenningsson et al., 2004) as well as with traits of ASD like hyperlocomotion and 
social interaction impairments. Elevated serotonin levels were also found in 
hippocampi of Pfn2 KO mice (Pilo Boyl, unpublished) and the high expression level of 
Pfn2 in serotonergic neurons could support the hypothesis that hyperactivation of the 
serotonergic system as a consequence to the loss of Pfn2 could participate to the 
autistic phenotype to some degree. Furthermore serotonin metabolism alterations 
were evident in some cases of autism linked to mutations in the genes coding for the 
tryptophan 2,3-oxigenase and monoamine oxidase-A (MAO-A) enzymes required for 
serotonin synthesis (Chandana et al., 2005; Cohen et al., 2003; Jones et al., 2004; 
Nabi et al., 2004). Alterations in serotonin synthesis can lead to developmental delay, 
which is a trait often associated with ASD. Children normally produce high serotonin 
levels (app. double than adults) until reaching 5 years of age when the levels 
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gradually decrease to adult levels, while autistic children produce serotonin 
increasingly more starting from approximately 2 years till 15 years of age with finally 
app. 1.5 times the average adult levels (Chandana et al., 2005). This phase of high 
serotonin levels during early childhood is critical for normal brain development and 
might be affected in ASD patients, furthermore accounting for increased anxiety 
(leading to learning deficits), obsessive-compulsive disorder symptoms and repetitive 
behavior. These changes have not been investigated in mouse models of ASD, but 
Pfn2 is already expressed in nervous tissue during embryonic development (earliest 
stage investigated was E13.5, see 2.1.5). The absence of Pfn2 could therefore be 
responsible for sustained serotonergic activation during embryonic and early 
postnatal development and consequently for developmental alterations similar to 
human ASD patients. Serotonin reuptake inhibitors are among the few 
pharmacological treatments, applied to ASD patients, which contribute to alleviate 
certain symptoms (Kim, 2015). Interestingly, systemic injection of the SSRI fluoxetine 
(Prozac) completely rescued the novelty-dependent hyperlocomotion phenotype in 
adult Pfn2 KO mice (Pilo Boyl, unpublished). Further investigations of the 
serotonergic system in Pfn2 mutant mice during embryonic development and under 
pharmacological stimulation could shed light on the impact of Pfn2 to the ASD-
associated phenotypes. 
 
The ASD-related Rett syndrome is also associated with the loss of (acetyl-) 
cholinergic neurons (see 1.3.4) and a reduced ChAT activity in the brain (Nag and 
Berger-Sweeney, 2007; Zimmerman, 2008). The impact of this system in the Pfn2 
KO model for autism spectrum disorders could be interesting, as cholinergic 
innervations have a widespread and powerful influence throughout the CNS (Supp. 
Fig. 4). Interestingly, Pfn2 is expressed at low levels in the acetylcholinergic system, 
which is an exception within the excitatory neuronal systems (see 2.1.1.5, Fig. 14, 
Fig. 21, Supp. Fig. 12). Alterations in the cortical cholinergic input can lead to 
cognitive impairments often found in Alzheimer´s dementia and schizophrenia 
patients, shown in human and rodent studies by performing attention tasks and in 
mouse models with lesions in the cholinergic brain regions (Sarter and Parikh, 2005). 
The large impact of cholinergic neurons on cognitive functions has been 
acknowledged as a result of the specific loss of cholinergic neurons at the initial 
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stages of Alzheimer´s disease. A known trait of Alzheimer´s disease is in fact 
cholinergic hypofunction early in the disease propagation (Dineley et al., 2015), 
leading to the most common Alzheimer treatment of increasing the acetylcholine 
levels in the brain by pharmacologically inhibiting the enzyme acetylcholinesterase, 
which inactivates ACh under normal conditions. In autistic patients lower binding of 
ACh to certain acetylcholine receptors as well as a reduction of their expression level 
was observed (Dineley et al., 2015; Perry et al., 2001), but further studies are 
necessary to achieve better insight in the role of ACh in ASD in general and the result 
of the possibly increased ACh signaling due to the loss of Pfn2.   
The expression of Pfn2 could be especially important for fine adjustments of synaptic 
transmission, since rare cholinergic interneurons of the striatum show higher levels of 
Pfn2. Cholinergic interneurons are tonically active and stop firing only briefly and 
upon reward-related dopaminergic input. Pfn2 could be needed to fast and precisely 
control synaptic vesicle release in these neurons. 
 
Excitatory synaptic circuits are enriched in Pfn2 and upon its removal could therefore 
all be potentially involved in various ASD-related phenotypes. In order to understand 
the specific roles of Pfn2 in these systems, a conditional deletion of Pfn2 in individual 
types of neurons would be necessary to be able to grasp the specific impact of each 
of these systems to the complex autistic symptoms. 
 
3.1.2 The possible role of Pfn2 in the fine-tuning of cortical and 
cerebellar circuit activity 
 
The implications of the GABAergic system in ASD are various and highly dependent 
on the respective neuronal circuitry and the impact of the cell type to the network 
activity. The best described physiological alteration in ASD is the imbalance of the 
excitation/inhibition ratio in the brain, which is most often shifted towards a 
hyperexcitable state. Hyperexcitation could be an effect of increased excitatory 
activity or a loss of inhibitory signaling. It is conceivable that alterations in either 
excitatory or inhibitory systems or even the summation of several systems working 
consecutively could lead to the hyperexcitable state most of the times associated with 
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ASD and other common neurological disorders (Chao et al., 2010; Hussman, 2001; 
Lawrence et al., 2010). Alterations in GABAergic signaling could contribute to the 
autism-like behavior of Pfn2 KO mice especially in certain pathways, since the 
expression pattern of Pfn2 in the GABAergic system is restricted to very specific 
neurons (see 2.1.2, Fig. 15-18, Fig. 21, Supp. Fig. 12).  
Pfn2 is present in only two rare types of GABAergic cortical neurons, namely 
Chandelier cells and bitufted neurons (see 2.1.2.1, Fig. 15, Fig. 17). Chandelier cells 
(axo-axonic neurons) are large, fast-spiking neurons, important for feed-forward 
inhibition in cortical circuits including sensory information processing (Rudy et al., 
2011). These cells are active upon high network activity to spatiotemporally fine-tune 
cortical circuits (Molnár et al., 2008; Szabadics et al., 2006; Woodruff and Yuste, 
2008; Woodruff et al., 2010). Pfn2 in Chandelier cells might be necessary to provide 
a regulation of fast and precise pre-synaptic actin-dynamics and therefore control 
cortical network activity. GABAergic bitufted neurons (Double-Bouquet cells in 
humans) form reciprocal connections with pyramidal neurons (Zilberter et al., 1999) 
but target also other GABAergic neurons in a dense array of hundreds of synapses 
formed by a single bitufted neuron (Ballesteros Yáñez et al., 2005; Pesold et al., 
1999; Sills et al., 2012; Staiger et al., 2009). Therefore bitufted cells are able to 
locally and comprehensively regulate cortical neuronal firing, a process which in turn 
Pfn2 could have a role for precisely regulating synaptic signaling.  
In contrast to Chandelier and bitufted neurons, GABAergic basket cells, which are 
responsible mostly for the synchrony of network activity (Méndez and Bacci, 2011), 
are generally devoid of Pfn2 (see 2.1.2.1, Fig. 15, Fig. 17). 
Similarly to the cortex, the only cerebellar GABAergic neuron type that expresses 
Pfn2 are Golgi cells, which are rare cells located among the granular neurons in 
charge of additional modulation of mossy and parallel fiber signaling (Sillitoe et al., 
2008). Pfn2 therefore could again have a role for fine-tuning of the cerebellar 
circuitry. 
The excitation/inhibition ratio in the brain is shifted towards an excess of excitation in 
Pfn2 KO mice. Synaptic signaling of most GABAergic neurons is not directly affected 
by the loss of Pfn2, but Pfn2 is present specifically in the rare GABAergic neurons 
that are important for fine-tuning of the respective brain circuitry, which could be 
altered in consequence to the deficiency of Pfn2. If these rare GABAergic neurons 
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would also be hyperexcitable in Pfn2 deficient mice, their increased local inhibition 
probably does not significantly alter the global excess of excitation. Therefore these 
cells cannot counterbalance the ASD-associated imbalance in the 
excitation/inhibition ratio. The exact function of Pfn2 in GABAergic cells might also be 
different from excitatory neurons. Further studies using a conditional knock-out 
mouse model for Pfn2 in GABAergic neurons will be necessary to examine the 
specific role of Pfn2 in the rare cortical and cerebellar GABAergic neuron types that 
endogenously express Pfn2. 
 
3.1.3 The potential role of Pfn2 in motor coordination 
 
Pfn2 was shown to be upregulated specifically in striatal medium spiny neurons of a 
3-nitropropionic acid (3NP)-induced neurodegeneration model of Huntington´s 
disease in the rat (Chakraborty et al., 2014b). Striatal neurons show an interesting 
expression pattern of Pfn2 (see 2.1.2.2, Fig. 16) that could suggest a direct 
involvement of Pfn2 in MSN-mediated motor functions. MSNs are divided into two 
groups, expressing either D1 receptors, denser in the caudate putamen (dorsal 
striatum, CPu) than in the nucleus accumbens (ventral striatum, NAc), or D2 
receptors, denser in the NAc than in the CPu. Only the D2R+ MSNs of the CPu are 
devoid of Pfn2. 
The loss of Pfn2 could lead to hyperactivity of MSNs, either due to alterations of 
intrinsic synaptic properties or due to the increase of dopaminergic input into the 
striatum. Among MSNs, the balance of D1R+- and D2R+- neuronal activity mediates 
the regulation of motor functions through the direct and indirect pathways (Kreitzer, 
2009; Sano et al., 2003). Striatal efferents of the direct pathway coordinate motor 
functions via disinhibition of the motor cortex – involving a direct signaling through the 
internal globus pallidus and the thalamus to the cortex –, while the indirect pathway 
act via a feed-back loop between the external globus pallidus and the subthalamic 
nucleus back to the internal globus pallidus, the substantia nigra and the thalamus to 
inhibit cortical motor circuits. Therefore, immediate motor responses are activated by 
the direct pathway, such as anxiety, fear and flight responses, while the indirect 
pathway is mostly involved in tasks like motor learning and activity planning (Ena et 
al., 2011). As a result of the specific expression pattern of Pfn2 in MSNs, the motor 
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alterations of Pfn2 KO mice could be linked to the specific pathway, in which the 
Pfn2-expressing cells are involved. Since Pfn2 is found predominantly in D1R+-
MSNs, motor dysfunctions in Pfn2 KO mice are more likely to involve the direct 
pathway. Hence, the dysfunction of the direct pathway could be partially responsible 
for behavioral abnormalities of Pfn2 KO mice, such as hyperlocomotion, increased 
response to novel stimuli and panic behavior. 
The association of MSNs with motor functions can also be acknowledged by the 
various mouse models involving the different dopamine receptors. D1R KO mice 
show deficits in spatial learning, movement initiation and response to stimuli (Drago 
et al., 1998a). The targeted ablation of D1R+-MSNs causes severe abnormalities with 
bradykinesia, dystonia and myoclonic jerks (Drago et al., 1998b). On the contrary, the 
ablation of D2R+-MSNs in mice induces a hyperactivity phenotype and a reduced 
sensitivity to dopaminergic stimulation (Sano et al., 2003). Possibly, the deletion of 
Pfn2 leads to hyperactivity in these MSNs that are normally Pfn2-positive, inducing 
an opposing effect to the KO of dopamine receptors or ablation of MSNs in mice, 
resulting in the behavioral phenotypes of Pfn2 KO mice mentioned above. 
 
A type of rare interneuron located throughout the whole striatum is the GABAergic 
aspiny interneuron, which is fast-spiking and aids to regulate the proper function of 
MSNs by local inhibition. The loss of Pfn2 in these cells could therefore also lead to a 
more pronounced dysregulation of the signal propagation in MSNs. 
 
3.1.4 Glial cells are not directly responsible for ASD-associated 
phenotypes due to the loss of Pfn2  
 
The population of glial cells in general is also a target of autism research, since 
several behavioral endophenotypes of ASD could be contributed by the various types 
of glial cells. A role of Pfn2 in glial cells is not directly responsible for with this 
phenotype, since Pfn2 was found to be completely absent from these cells (see 
2.1.4, Fig. 19, Supp. Fig. 12). 
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Astrocytes are the glial cells responsible for neurotransmitter clearance at the 
synaptic cleft and part of the so-called tripartite synapse (pre- and post-synaptic sites 
together with an astrocytic process). A dysfunction of potassium clearance from the 
extracellular space by astrocytes leads to a rise of extracellular potassium 
concentrations that can cause epileptic seizures by impairing neuronal repolarization 
efficiency (Rossi and Volterra, 2009; Schousboe, 2003). Similarly an excess of 
glutamate resulting from disturbed clearance of the extracellular space by astrocytes 
can cause excitotoxicity or epileptic seizures. Seizures, in turn, are known to induce 
astrogliosis (Sofroniew and Vinters, 2010; Zeidán-Chuliá et al., 2014), which was 
absent in Pfn2 KO mice (data not shown).  
Even though a function of Pfn2 was proposed in cultured astrocytes (Schweinhuber 
et al., 2015), a direct role of Pfn2 in mature astrocytes could be ruled out in vivo, 
since these cells are devoid of Pfn2. Cultured astrocytes are isolated from embryonic 
brain tissue, in which mature astrocytes that can be found in adult tissue have not 
developed, yet. Embryonic brains contain radial glia, embryonic stem and precursor 
cells, which give rise to the astrocytic cultures. Cultured astrocytes are therefore still 
radial glia-like, which is probably why they express Pfn2 (see 2.3.2, Fig. 26), while 
mature astrocytes in vivo lack its expression (see 2.1.4, Fig. 19). 
Synaptic transmission is influenced by many parameters, including maturation of 
synapses also mediated by microglial pruning (Rossi and Volterra, 2009; Salter and 
Beggs, 2014; Zeidán-Chuliá et al., 2014; Zhan et al., 2014) and by a mechanism 
involving myelination provided by oligodendrocytes. Indeed, excessive myelination of 
a particular brain region (left and right medial frontal cortex) and a loss of myelination 
of another region (left temporo-parietal junction) was also observed in children 
diagnosed with autism spectrum disorder (Zeidán-Chuliá et al., 2014). Even NG2 cell 
differentiation to oligodendrocytes, which re-myelinate neurons at the lesion site, 
could be important for certain aspects of ASD symptoms, since an increase in NG2 
cell number was observed in a mouse model for ASD (Bergles et al., 2010; 
McFarlane et al., 2008; Nishiyama et al., 2009; Pedraza et al., 2008; Zeidán-Chuliá et 
al., 2014). But Pfn2 is absent from all these cell types, therefore glial cells have no 
direct influence on the autistic-like phenotype that arises in consequence of a 
deficiency of Pfn2. Nevertheless glial cells in other mouse models or in human 
patients could still feature certain Pfn2-independent roles in ASD-related symptoms.  
3. Discussion 
 
 
 
102 
3.1.6 Neural stem cells as a novel field of research for ASD  
 
An interesting observation was the expression of Pfn2 in neural stem cells both in 
embryonic (radial glia) and adult (aNSCs) tissue (see 2.1.5, Fig. 20, 21, Supp. Fig. 
12). Detailed studies revealed a differentiation state-dependent expression of Pfn2, 
which is present at moderate levels in NSCs, absent from NSC-derived progenitor 
cells and upregulated again upon the final differentiation to neurons. 
Pfn2 does not necessarily have a decisive role during neuronal or glial cell 
differentiation, as all major cell types were present in Pfn2 KO mice (data not shown). 
Pfn2 could be important for the maintenance of the highly proliferative state and/or 
the differentiation of neural stem cells. An interesting observation was the 
upregulation of two transcription factors important for multipotency (Sox2 and Oct4) 
in NSCs of Pfn2 KO mice (see 2.1.5, data not shown). 
The loss of Pfn2 in NSCs could have several possible consequences. Pfn2 is 
normally upregulated upon progenitor differentiation to post-mitotic neurons (see 
2.1.5, Fig. 20), possibly in consequence to differentiation-associated cytoskeletal 
remodeling. Therefore, the KO of Pfn2 could lead to cytoskeletal changes in NSCs 
accompanied by diminished differentiation, which can be observed by the increase in 
transcription factors in NSCs necessary for the maintenance of pluripotency. A 
possible consequence could be a decreased asymmetric cell division (differentiation) 
of NSCs and therefore the loss of newly generated progenitor cells and neurons.  
On the other hand, the upregulation of transcription factors important for the 
stemness (potential to differentiate into all types of progenitor cells) that was 
observed in NSCs of Pfn2 KO mice is generally associated with a high proliferation of 
NSCs. The pool of NSCs at the SVZ could therefore be enlarged in Pfn2 KO mice.  
These possible outcomes of Pfn2 deletion should be investigated further in more 
detail.  
 
During the migration phase, progenitor cells travel along the RMS at a speed of up to 
0.5-1 mm per day (22.8 µm/h), so that proliferation is nearly absent (Luskin and 
Boone, 1994). Pfn2 is suppressed during the migration of progenitors, which is in 
agreement with the proposed inhibitory role of Pfn2 in migration processes involving 
the invasiveness of epithelial tumor formations (Mouneimne et al., 2012). Migration 
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processes seem to require Pfn1 rather than Pfn2, as could be shown by neuronal 
migration deficits in mutant mouse lines of Pfn1 (Pfn1+/- and Pfn1flx/flx;Nes-Cre mice) 
(Kullmann et al., 2011, 2012; Pilo Boyl et al., 2007). 
At their final destination, progenitor cells upregulate Pfn2 upon differentiating to post-
mitotic neurons, indicating a role of Pfn2 in developmental processes like axonal vs. 
dendritic polarization or synaptogenesis. Pfn2 KO neurons do not show gross 
morphological abnormalities (2.3.1, data not shown), but Pfn1 could compensate to a 
certain degree for the loss of Pfn2. In fact, Pfn2-/-/ Pfn1flx/flx;Nes-Cre double KO mice are 
embryonic lethal (Pilo Boyl, unpublished observation), which suggests at least a 
compensatory role of Pfn2 in developmental processes. 
 
A potential contribution of Pfn2 in the development of neuronal circuits is in 
agreement with autism etiology, which is commonly believed to be of 
neurodevelopmental origin with dysregulation and imbalance of neuronal network 
activities. Also epileptic seizures often originate from impairments in neuronal 
network integrity due to developmental alterations, in which neural stem cells are 
majorly involved (Ma et al., 2009; Ming and Song, 2011).  
In conclusion, a novel involvement of NSCs in ASD could be hypothesized with a 
potential role of Pfn2 in embryonic and adult neurogenesis.  
 
3.2 The P2-GFP fusion protein is a validated tool for further studies 
on the roles and functions of Pfn2  
 
A part of the thesis project was the characterization of the biochemical properties of 
the P2-GFP fusion protein. The P2-GFP fusion protein knock-in mouse model was 
generated mainly in order to visualize Pfn2 either in vitro or in vivo (see 1.5, Fig. 13), 
but the fusion of the GFP-tag to the protein of interest often affects the expression 
level and/or the function of the targeted protein as well as its interaction with potential 
binding partners due to steric or ionic interference of the GFP moiety. Indeed, 
homozygous P2-GFP KI mice show mild behavioral abnormalities, in particular a low 
degree of hyperexcitability and transiently increased exploratory behavior, but no 
changes in anxiety, fear or working memory (Özer, unpublished). These are only 
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moderate behavioral alterations in comparison to Pfn2 KO mice that show complex 
ASD-related phenotypes, pointing to a substantial expression and functionality of the 
P2-GFP fusion protein. Nevertheless, in order to study Pfn2 using the P2-GFP KI 
model as a tool, the expression and functionality of the P2-GFP fusion protein was 
accurately verified (see 2.2, Fig. 22-24). 
 
3.2.1 Sufficient expression levels of the P2-GFP fusion protein 
 
The first problem encountered studying the P2-GFP fusion protein was the limited 
capability of the anti-Pfn2 antibodies currently used in the lab to recognize it in 
Western blotting. Therefore, several anti-Pfn2 antibodies were analyzed for their 
recognition efficiency of P2-GFP in comparison to Pfn2. While most antibodies failed 
to bind to P2-GFP, two polyclonal antibodies (anti-Pfn2 3003 and anti-Pfn2 GD2) 
were able to sufficiently recognize P2-GFP, although less efficiently than the wt 
isoform (see 2.2.1, Fig. 22). The GFP moiety (27 kDa) is fused to the C-terminus of 
Pfn2 (14 kDa) creating the P2-GFP fusion protein, therefore especially C-terminal 
antibody-binding epitopes could be shielded and only anti-Pfn2 antibodies targeting 
farther located epitopes could possibly efficiently bind to P2-GFP. 
This phenomenon is not unique for Pfn2. A similar problem was encountered while 
generating a GFP-actin fusion protein mouse model (Gurniak and Witke, 2007), 
where some anti-actin antibodies were not able to recognize the fusion protein on 
Western blots. 
Secondly, the expression level of P2-GFP in comparison to Pfn2 was calculated 
using brain tissue extracts from heterozygous P2-GFP KI mice probed with the 
antibodies directed against Pfn2 that were previously verified to bind most efficiently 
also to P2-GFP (see 2.2.1-2.2.2, Fig. 22). The results are very promising, since the 
GFP moiety is not interfering substantially with the expression of the P2-GFP fusion 
protein. Heterozygous P2-GFP KI animals still express 43% (± 2.7%) of P2-GFP 
compared to Pfn2. This level of expression can be considered quite high compared to 
other GFP fusion protein KI mouse models (Chan et al., 2004; Gurniak and Witke, 
2007). Pfn2 was estimated to be present in most cells at very high concentrations (2-
10 µM) (Mogilner and Edelstein-Keshet, 2002; Pollard et al., 2000), which means that 
the P2-GFP mutant mice would still express P2-GFP in quite high amounts that are 
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sufficient  to study its cellular functions. There are indications that homozygous P2-
GFP KI mice express P2-GFP at even higher levels than heterozygous P2-GFP KI 
mice, as homozygous KI mice are only able to produce the fusion protein without 
possible compensatory expression of Pfn2 (data not shown). 
 
3.2.2 P2-GFP binding to Poly-L-Proline stretches is only slightly 
impaired 
 
Even though the expression level of P2-GFP is adequate in comparison to Pfn2, the 
main effect of the GFP moiety (27 kDa) on a smaller protein, such as Pfn2 (14 kDa), 
could easily be an impairment of its functionality by interfering with interaction 
partners. One of the best characterized binding domains of profilins is their poly-L-
proline interaction site that can be exploited for in vitro Pfn2 pull-down experiments 
using poly-L-proline stretches immobilized on beads. The results shown in this thesis 
demonstrate that binding efficiency of the fusion protein to poly-L-proline is up to 75% 
of that of Pfn2 (see 2.2.3, Fig. 23). The poly-L-proline binding domain of Pfn2 is 
composed of both a C- and an N-terminal helix (see 1.3). Since the GFP-tag is fused 
to the C-terminus of Pfn2 in the P2-GFP fusion protein, at least three hypotheses are 
possible to explain the slight reduction of binding efficiency: either the formation of 
the PLP-binding groove is disturbed or the GFP moiety could sterically hinder the 
access of the PLP stretches to the domain, or finally, since long proline-rich stretches 
can accommodate several adjacent profilins in very close proximity, the GFP moiety 
could increase the spacing between them, thus reducing the pull-down efficiency. 
From the binding efficiency of P2-GFP to its ligands in vivo, as determined by 
immunoprecipitation (see 2.2.4, Fig. 24) and discussed below, the latter two 
hypotheses appear more plausible. 
The interaction with G-actin, on the other hand, is unimpaired. PLP-beads are known 
to be able to pull down the profilactin complex with profilin and actin in a 1:1 ratio 
(Janmey, 1991). Based on this fact, the observed reduction of the signal for actin in 
the P2-GFP-bound fraction to 73% of the signal of Pfn2-bound actin is due to the 
decrease in PLP-binding efficiency of P2-GFP rather than actin binding itself. When 
corrected for the PLP-binding efficiency of P2-GFP, actin binding to P2-GFP shows 
nearly 100% efficiency. The GFP moiety is therefore not interfering with the actin 
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binding efficiency of the P2-GFP fusion protein. This outcome was expected, as the 
actin binding domain on Pfn2 is located on the opposite side of the PLP-binding 
domain and is therefore not inhibited by the GFP-moiety that is located on the C-
Terminus near the PLP-binding site. 
The P2-GFP fusion protein is therefore mainly functional in vitro and only slightly 
reduced in its ability to bind to poly-L-proline stretches. 
 
3.2.3 P2-GFP binds only specific proline-rich ligands with reduced 
affinity  
 
In order to finally characterize P2-GFP properties in more physiological conditions, an 
immunoprecipitation assay was performed, verifying the binding of P2-GFP to a 
variety of known interaction partners of Pfn2. P2-GFP is able to bind to various 
known ligands of Pfn2, but with varying efficiency (see 2.2.4, Fig. 24). In particular, 
interaction partners with a high molecular weight are the most affected (i.e. 
huntingtin, mDia1 and dynamin1). The non-proline residues in proximity of the 
proline-rich domains of the ligands are known to mediate the specificity and binding 
efficiency to the proline-binding domain of Pfn2 (Kursula et al., 2008, Massimi, 
unpublished). These interactions could influence the binding strength of P2-GFP with 
certain ligands to a greater extent than with others, since the GFP-tag could sterically 
interfere (e.g. on proteins like mDia1, which can accommodate an array of up to 13 
Pfn2 proteins in close proximity (Kursula et al., 2008), but also add repulsive charges 
in the vicinity of the binding domain. 
 
Confirming the results from the pull-down assays (see 2.2.3, Fig. 23), actin interacts 
equally well with Pfn2 and P2-GFP. The actin-binding domain of P2-GFP is therefore 
functional in the cell, as expected from its location opposite of the PLP-binding 
domain and the GFP moiety. 
P2-GFP can also co-precipitate all investigated components of the WAVE- complex. 
It is not yet understood, how Pfn2 is binding to the WAVE- complex. The WAVE and 
Abi subunits are not accessible to profilins when incorporated in the WAVE-complex 
(Innocenti et al., 2004), but there are indications by pull-downs using Pfn2-beads that 
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the interaction occurs either with the CyFIP or the Nap1 subunits. Interestingly, 
specifically the interaction of Abi1 with P2-GFP was inhibited by the GFP-tag. If the 
incorporation of Abi1 into the WAVE- complex would be hindered, the proper function 
of the WAVE- complex in promoting actin polymerization through the Arp2/3- 
complex could be impaired, resulting in dysfunctional actin dynamics. More likely, the 
interaction of P2-GFP with free Abi1, that was not incorporated in the WAVE-
complex, is diminished, since the remaining components of the WAVE- complex were 
all unaffected. The potential outcome of the loss of this specific interaction should be 
investigated in more detail in the future. 
An interesting observation was the high loss of mDia1 in the P2-GFP-bound fraction. 
The formin mDia1 contains an array of 13 proline-rich binding domains for Pfn2 
(Kursula et al., 2008), which means, since mDia1 is mostly present in vivo in a 
dimerized form, that 26 Pfn2 molecules could possibly interact with a single mDia1 
dimer. The closely localized proline-rich domains of mDia1 imply a steric hindrance of 
the GFP moiety that decreases the binding efficiency of P2-GFP. On the other hand, 
the interaction with mDia2 or Mena was undisturbed by the GFP moiety, possibly due 
to a wider spacing between the proline-rich regions. 
During this thesis work, a novel interaction partner of Pfn2 was discovered. The F-
actin and Arp2/3- complex interacting protein cortactin was enriched in P2-GFP 
complexes. 
As a consequence of the largely uninhibited interaction of protein ligands involved in 
actin dynamics with P2-GFP, only minor alterations in cytoskeletal functions would be 
expected in this fusion protein knock-in mouse model. 
 
The mild behavioral hyperexcitability phenotype of P2-GFP KI mice raises the 
question if P2-GFP is able to interact with synaptic proteins in a similar way as Pfn2. 
Especially certain synaptic proteins (dynamin1, endophilin1 and huntingtin) were 
found to be binding less efficiently to P2-GFP than to Pfn2. This weaker interaction 
could therefore account for synaptic dysfunctions leading to the minor increase in 
novelty-induced excitability and locomotion of (homozygous) P2-GFP KI mice. Based 
on this hypothesis, the complete loss of these interactions could contribute to the 
stronger behavioral phenotype of Pfn2 KO mice. Nevertheless, an indication of the 
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functionality of the P2-GFP fusion protein in vivo is the unimpaired binding of the 
synapsin isoforms Syn1 and Syn2a.  
Since it has been shown that the GFP-tag of P2-GFP has only a minor effect on the 
ligand binding properties of the fusion protein, the P2-GFP KI mice can be 
considered a validated tool for any further investigations regarding Pfn2 trafficking 
and dynamics in vivo. Furthermore, the GFP moiety can be exploited as a target for 
pull-down or immunoprecipitation experiments. For the analysis of protein complexes 
associated with Pfn2 this approach could be very beneficial, since no ligand loss 
would occur due to binding to an epitope by an antibody and it seems that only few 
and specific ligands are affected by the GFP-tag, while the efficiency of the GFP-Trap 
IP system is very high. 
 
3.3 Diverging roles of Pfn2 throughout neuronal development 
 
Pfn2 is highly expressed in neuroectodermal embryonic tissue and later in neural 
stem cells and post-mitotic neurons. A role of Pfn2 in developmental processes could 
therefore be assumed. Neuronal development can be studied in great detail in 
primary hippocampal neurons in culture, which during the developmental stages 
undergo changes considered to be very similar to neurons in vivo. These cells are 
able to reach mature stages including synaptogenesis and form complex neural 
networks, which makes them a valuable model for the investigation of the different 
roles that Pfn2 could have throughout the different stages of neuronal development 
as well as in maturity. 
 
3.3.1 The loss of Pfn2 induces accelerated neuronal development  
 
The loss of Pfn2 causes an accelerated developmental phenotype in cultured 
neurons, since Pfn2 KO neurons appeared to develop the characteristic features of 
the respective developmental stages in a shorter time period than wt neurons. Pfn2 
KO cells were forming more initial neurites that extended at a higher velocity and 
showed more complex branching compared to wt neurons during each investigated 
developmental stage (see 2.3.1, Fig. 26).  
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The observed increase in initial neurite number upon deletion of Pfn2 is in agreement 
with previous findings (Pilo Boyl et al., 2007). Neurite sprouting and initial elongation 
(DIV 1-3) are processes well-known to be dependent on cytoskeletal dynamics 
(Bellot et al., 2014; Bradke and Dotti, 1999, 2000; Cingolani and Goda, 2008; Coles 
and Bradke, 2015; Ertürk et al., 2007, 2012; Hellal et al., 2011; Pilo Boyl and Witke, 
2014; Schubert and Dotti, 2007; Schubert et al., 2006; da Silva and Dotti, 2002; Witte 
and Bradke, 2008; Witte et al., 2008). In consequence to the loss of Pfn2, it has been 
proposed that filamentous actin networks become less stable (Da Silva et al., 2003), 
possibly facilitating the growth of microtubuli that are the main cytoskeletal 
component necessary for neurite formation and elongation, resulting in more and 
longer processes (app. 20-25%, see 2.3.1). In fact, Pfn2 is enriched in the growth 
cone of wt neurons (see 2.3.2, Fig. 27), therefore the loss of Pfn2 could lead to 
disturbed growth cone dynamics due to local actin instability and effectively enhance 
tubulin filament outgrowth. 
After one week in culture (DIV 7), the Pfn2 KO cells resemble wt cells that have been 
cultured for close to two weeks. Pfn2 KO neurites elongate to a maximal distance 
similar to wt neurites (app. 700 µm), but already form extensive branching, mostly 
proximal to the soma. The developmental program is therefore undisturbed in Pfn2 
KO neurons, but the stages appear to be reached at advanced time points in 
comparison to wt cells.  
Similarly, after two weeks in culture (DIV 14), the Pfn2 KO cells remind of nearly fully 
mature neurons with complex arborizations over the full range of the dendritic tree, 
which is characteristic of the third week in culture (DIV 21) in wt neurons. The cells 
are also able to start synaptogenesis, since synaptic protrusions appear on the 
projections (data not shown). 
Finally after three weeks in culture, Pfn2 KO cells become nearly indistinguishable 
from fully mature wt neurons, except for the most distal part of the dendrite network. 
Therefore, Pfn2 KO cells do not extend their dendritic network beyond the usual 
average range of mature wt neurons, and develop extensions with similar length and 
complexity as wt neurons. The loss of the most distal branches in Pfn2 KO neurons 
could originate either from a gradual degradation of their processes beginning at the 
most distal part, reminding of wt neurons that are past the fourth week in culture, or 
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from problems establishing complex branches at the most distal dendritic segments 
(app. the last 250 µm) possibly due to impairments in actin-dynamics. 
In this study, the loss of Pfn2 therefore leads to a different phenotype than reported 
in a previous study, where the knock-down (KD) of Pfn2 in hippocampal CA1 neurons 
in organotypic slice cultures (to app. 70% of baseline level due to silencing using 
plasmid for shRNAs delivered by the gene gun approach) induced a mild reduction of 
dendritic complexity (app. 30%) and spine number (app. 20%) (Michaelsen et al., 
2010). The hippocampal slices cultures were prepared at postnatal day 6 (P6) and 
transfected after 5 more days inducing the KD of Pfn2, when the neuronal projections 
are mostly developed. Therefore, hippocampal neurons in culture could lead to 
different results, since Pfn2 is completely deleted already at the beginning of the 
development and the cells have to newly establish their neurites while Pfn2 is absent.  
In contrast to partial loss of Pfn2 in organotypic brain slices (Michaelsen et al., 2010), 
the complete loss of Pfn2 in mice induced no changes in the number of synaptic 
terminals (Pilo Boyl et al., 2007).  
Considering the expression of Pfn2 during development in vivo (see 2.1.5, 3.1.6, Fig. 
20-21), the loss of Pfn2 could induce an accelerated neuronal development during 
embryonic development as well. Synaptogenesis could also be affected by the 
absence of Pfn2, since local actin-polymerization at synaptic terminals, in which Pfn2 
is normally enriched (see 2.3.2, Fig. 27), could be dysregulated. It would be 
interesting to analyze synaptogenesis in detail (i.e. the time point of synapse 
formation and the number of synaptic protrusions). An earlier onset of 
synaptogenesis in vivo could lead to the observed excess of synaptic activity and 
hyperexcitability of Pfn2 KO neurons (Pilo Boyl et al., 2007), ultimately resulting in 
autistic-like behavior in adulthood. 
P2-GFP KI neurons were analyzed as well to verify the proper development of the KI 
mouse model. The cells displayed an intermediate phenotype between wt and Pfn2 
KO neurons. They did not develop a higher number of initial neurites, but showed a 
similar increase in neurite elongation as Pfn2 KO cells. A moderate increase in 
proximal neurite complexity was visible in P2-GFP KI neurons until the second week 
in culture. The cells started to degenerate during the third week in culture, possibly 
due to a technical bias in the culture conditions. The P2-GFP fusion protein is likely to 
cause impairments in actin-polymerization only to a moderate degree, which is 
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enough to trigger enhanced neurite elongation and proximal branching, but not 
severe enough to induce the accelerated development and extensive branching of 
Pfn2 KO neurons. 
 
3.3.2 Enrichment of Pfn2 in neuronal substructures is mostly 
dependent on excitatory stimuli and depolarization 
 
Taking advantage of the validation of the P2-GFP KI mouse at the biochemical (see 
2.2, 3.2), developmental (2.3, 3.3.1) and behavioral (Özer, unpublished) level, the 
trafficking of P2-GFP was visualized in mature primary hippocampal neurons 
following different stimulations. 
 
Under normal culture conditions of primary hippocampal neurons Pfn2 is found 
mostly in dendritic projections, but also in moderate amounts in pre- and post-
synaptic specializations, while axonal shafts show only minor levels of Pfn2 (see 
2.3.2-2.3.3, Fig. 27-29). Pfn2 therefore is localized majorly on the post-synaptic 
compartments of neurons. All the more striking is therefore the quick and efficient 
trafficking of Pfn2 into axonal shafts and pre-synaptic boutons upon exposure to 
specific stimulatory agents (see 2.3.3, Fig. 28-29).  
Stimulating neurons with glutamate or NMDA causes excitatory post-synaptic 
potentials (EPSPs), which can lead to action potentials, if the stimulation is provided 
for an appropriate duration. Action potentials in turn require the activity of axons and 
pre-synaptic boutons. Prolonged post-synaptic stimulation can therefore have an 
effect on pre-synaptic compartments as well. The enrichment of Pfn2 not only in post-
synaptic sites but also in axons and pre-synaptic terminals can therefore be induced 
also by post-synaptic stimulation. 
 
A different effectiveness of different excitatory stimulatory agents on neuronal activity 
can be observed on Pfn2 as well. Post-synaptic stimulation by the application of 
glutamate (with or without glycine) induced the strongest trafficking of Pfn2 to pre-
synaptic boutons, followed by direct pre-synaptic stimulation by increasing the 
extracellular potassium concentration. Moderately effective results were obtained 
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from the addition of NMDA and increasing the Ca/Mg ratio to 7:1 in the medium. The 
differences in the effects of these excitatory stimulations are due to the activation of 
different pathways in the neurons. 
High levels of extracellular potassium lead to inward flow of potassium inducing a 
strong depolarization and synaptic vesicle release probably by opening pre-synaptic 
voltage-gated Ca2+- channels (Oltedal et al., 2008). Glutamate activates several 
kinds of post-synaptic receptors (NMDAR, AMPAR, kainate receptors and 
metabotropic glutamate receptors (mGluRs)) (see 1.4.1), which mediate a strong 
depolarization (EPSPs) of the cells, ultimately increasing action potential firing rates 
and raising F-actin levels (Bellot et al., 2014; Schubert and Dotti, 2007). NMDA is 
specifically activating NMDARs but not the remaining glutamate receptors. Specific 
activation of NMDARs induces re-localization of AMPARs, actin polymerization and 
cytoskeletal reorganization associated with synaptic plasticity changes (Bosch et al., 
2014; Zhou et al., 2009). Therefore the strong trafficking of Pfn2 into neuronal 
compartments induced by glutamate stimulation and the observed moderate effect of 
NMDA on the trafficking of Pfn2 leads to the conclusion that NMDARs definitely have 
an influence on Pfn2 trafficking, but is not the only pathway that is contributing to 
Pfn2 re-localization. The activity of other glutamate receptors is therefore likely to 
contribute to Pfn2 trafficking as well. Neuronal stimulation of AMPA receptors alone 
has already been shown to have no significant effect on Pfn2 trafficking (Ackermann 
and Matus, 2003). It can be hypothesized that a combination of not only the activity 
of NMDARs, but also the activity of kainate receptors and/or mGluRs are able to 
efficiently induce Pfn2 re-localization into neuronal substructures. 
Increasing the Ca2+/Mg2+ ratio to 7:1 in the extracellular space probably induces the 
removal of the Mg2+ blockade of NMDA receptors, leading to a higher excitability of 
the neurons. 
 
It is noteworthy that Pfn2 is more rapidly enriched in synaptic boutons and spines 
than in axons by excitatory stimuli, as can be seen e.g. by an excess of Ca2+ in the 
medium, which triggered re-localization of Pfn2 to boutons and spines after 10 min. of 
the exposure, while axonal shafts could be seen enriched in Pfn2 after a minimum of 
30 min. after stopping the stimulation exposure by medium exchange (see 2.3.3, Fig. 
28). Even glutamate that triggered the strongest enrichment of Pfn2 in pre-synaptic 
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sites already after 5 min. of exposure was able to induce the trafficking and/or 
expression of Pfn2 in axons only after 1 h subsequently to the end of glutamate 
application by the exchange of the medium. Similar results were obtained by NMDA 
stimulation that induced enrichment of Pfn2 in axonal shafts after an incubation of 30 
min. to 1 h after removal of the stimulus. With increasingly elapsed time, Pfn2 might 
therefore be transported to axonal shafts either as a reserve for fast trafficking into 
boutons upon high activity, or to stabilize the axonal projections in consequence to 
prolonged agonist exposure and increased neuronal activity. The presence of Pfn2 
mRNA in axonal shafts of developing neurons has been reported (Wang et al., 2014). 
Pfn2 mRNA is still present in mature neurons, the necessary Pfn2 could also be 
locally expressed from the mRNA upon stimulation-induced increased neuronal 
activity. 
In excitatory post-synaptic spines, an enrichment of Pfn2 was observed induced by 
either de- or hyperpolarization of the cells (see 2.3.3, Fig. 28-29). This enrichment of 
Pfn2 was most pronounced by application of glutamate or an excess of potassium 
and can still be seen even 1-2 h after the exposure to the stimuli (i.e. glutamate and 
NMDA). A role of Pfn2 in spines is expected for actin-dependent synaptic plasticity. 
Pfn2 could either be necessary during the stabilization of the spine structure by 
enhancing actin polymerization, or Pfn2 could be important for the formation and/or 
maintenance of spine structure, where it is known to interact with a variety of proteins 
involved in cytoskeletal dynamics, such as ROCK (Schubert et al., 2006; da Silva and 
Dotti, 2002), the Arp2/3-complex and formins (Witke, 2004). Also an overexpressed, 
GFP-tagged version of Pfn2 could be induced in a previous work to localize to 
dendritic spines by KCl or NMDA treatment as well as by electric LTP and LTD 
protocols (Ackermann and Matus, 2003). More recently, profilin (isoform not specified 
as Pfn1 and/or Pfn2) was also re-localized to dendritic spines in an activity-
dependent manner (NMDA treatment) (Michaelsen et al., 2010). 
 
In post-synaptic sites it is well established, and was observed following neuronal 
stimulation in the experiments presented here (2.3.3, Fig. 28-29), that F-actin levels 
increase in an activity-dependent manner (Bellot et al., 2014; Bosch et al., 2014; 
Cingolani and Goda, 2008; Pilo Boyl and Witke, 2014; Schubert et al., 2006). 
Similarly, pre-synaptic terminals are believed to contain an actin meshwork, which is 
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essential to maintain the separation of the large reserve pool of synaptic vesicles 
from the smaller readily releasable pool of docked/primed vesicles at the pre-synaptic 
membrane as well as the tightly regulated flow of synaptic vesicles between these 
pools and the vesicle reuptake process (see 1.4.1). Consequently following excitatory 
stimuli, Pfn2 enrichment in spines and in axons and pre-synaptic terminals might be 
needed in order to contribute to the regulation of actin dynamics following stimulation-
induced enhanced neuronal activity. Murk et al. reported a similar re-localization of 
Pfn2 to pre-synaptic terminals following KCl treatment (Murk et al., 2012), which is 
compliant with the results of the present study. In pre-synaptic boutons it could be 
hypothesized that Pfn2 is needed for the regulation of synaptic activity by stabilizing 
and enhancing the rapid formation of a pre-synaptic actin network between the two 
synaptic vesicles pools in order to limit excessive vesicle release that would 
otherwise be triggered by the stimulation. In line with this hypothesis, the loss of Pfn2 
in vivo showed a complex phenotype of enhanced synaptic vesicle release and lack 
of F-actin formation upon stimulation of synaptosomes (Pilo Boyl et al., 2007), while 
loss of Pfn1 had no effect on excitatory synapse morphology and physiology (Görlich 
et al., 2012). Pfn2 therefore has an inhibitory role on synaptic vesicle exocytosis 
possibly by enhancing the formation of actin filaments and thereby strengthening the 
actin network in pre-synaptic terminals. In Pfn2 KO animals the pre-synaptic actin 
network could be disturbed leading to the observed excessive synaptic vesicle 
release, which is the cause of the hyperexcitability and autistic-like behavior of the 
Pfn2 KO mice. 
 
Pre-synaptic vesicle release can be triggered in the millisecond range (Südhof, 
2013), while already within 2 min. 85% of post-synaptic actin is exchanged at 
dendritic spines (Cingolani and Goda, 2008). Therefore these enormously dynamic 
processes need to be regulated precisely. The proposed role of Pfn2 in the regulation 
of fast actin dynamics and remodeling (see 3.1.2-3.1.4) could be further emphasized 
by the observed enrichment of Pfn2 upon stimulated neuronal activity in synaptic 
terminals, where the regulation of actin dynamics is necessary.  
 
Consequently to the chemical induction of LTD, Pfn2 levels are also increased in pre-
synaptic boutons but reduced in axons (see 2.3.3, Fig., 29). Pfn2 could play a role in 
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the inhibition of vesicle release, as proposed above, by enhancing the restraining 
actin network in pre-synaptic boutons also in consequence to LTD. In axons, on the 
other hand, LTD might induce less dynamic changes in actin filament turnover and 
Pfn2 is not essential at this point. On the post-synaptic site a moderate enrichment of 
Pfn2 could be observed.  Pfn2 could contribute to the cytoskeletal reorganization 
necessary for LTD-induced shrinkage of post-synaptic spines. Over extended 
durations, LTD causes a shift of the G/F-actin ratio towards G-actin in spines 
(Cingolani and Goda, 2008) that needs to be sequestered and recharged by an ADP-
ATP exchange, at which point the contribution of Pfn2 could be essential. For 
example, Pfn2 could also have a possible function in the process of unsilencing of 
synapses after the immediate effects of LTD. 
Neurons also do not show any excitotoxic effects prior to 18 h after the induction of 
chemical LTD, but protein degradation, the inhibition of local translation and a 
decrease in synaptic plasticity are immediate consequences of LTD (Shehata et al., 
2012). Hence, Pfn2 could also be degraded in neurons, which could be observed by 
reduced overall levels of Pfn2 (see 2.3.3).  
An impairment in LTD in dendritic spines can also cause hyperexcitability (Sano et 
al., 2003), but the loss of Pfn2 is known to have no effect on LTP or LTD (Pilo Boyl et 
al., 2007). Hence, the contribution of Pfn2 in pre- rather than post-synaptic sites is 
mostly responsible for the hyperexcitability phenotype in Pfn2 KO mice. 
 
The application of GABA to neuronal cultures leads to a reduced excitability of the 
cells and coincided with a diminished expression of Pfn2. The hyperpolarization 
(IPSP) of the neurons caused by a treatment with GABA had no effect in boutons, but 
Pfn2 was potently enriched in axons and moderately in post-synaptic terminals (see 
2.3.3, Fig. 29). The enrichment of Pfn2 in axons following GABA treatment could be 
due to a reorganization of actin filaments, but more detailed studies are necessary to 
understand the specific pathway. Pfn2 could be needed to form new filopodial 
protrusions that are needed to sample the environment for active neuronal 
projections and to establish new active synaptic contacts, as existing synaptic 
connections were silenced by the GABA-induced hyperpolarization. 
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In conclusion, trafficking of Pfn2 into both pre- and post-synaptic compartments as 
well as axonal shafts can be observed mostly following excitatory stimuli (both pre- 
and post-synaptic stimulation) but also to a minor extent using inhibitory stimulation. 
Therefore, Pfn2 is responsive to neuronal activity. 
 
3.4 Outlook on the future research directions to further understand 
the various roles of Pfn2 in neuronal circuits and its implication in 
ASD 
 
Several approaches would shed additional light on the role and function of Pfn2 also 
with respect to autism and epilepsy. Removal of Pfn2 does not have an evident effect 
on neuronal survival, since the different neuronal populations investigated in this 
study are still present in Pfn2 KO mice, but certain neuronal subtypes could still be 
affected. Either their cell number could be reduced, e.g. in consequence to the 
excess of excitation and the resulting excitotoxicity or by the effects of epileptic 
seizures, or the connections of certain pathways are altered. Especially the number 
and distribution of NSCs should be examined further in Pfn2 KO mice, since this work 
also yielded indications that NSC number and the level of certain transcription factors 
(Oct4 and Sox2) might be altered in the KO mouse model. A higher number of NSCs 
could be expected, if the stem cells are driven to a hyperproliferative state by the loss 
of Pfn2. If the deletion of Pfn2 has negative effects on differentiation, e.g. due to 
impaired actin remodeling during asymmetric cell division, the number of progenitor 
cells in the RMS would be reduced in Pfn2 KO mice. 
 
The Pfn2 KO mouse model is a conventional KO, with deletion of Pfn2 in all cells that 
express Pfn2 at any time point throughout development. A conditional KO mouse 
model could be very useful to induce Pfn2 deficiency in specific cell types, 
populations or brain regions. The resulting changes would affect only certain 
neuronal circuits that might give rise to only a subset of symptoms. The impact of a 
specific neuronal system to ASD- or epilepsy-related phenotypes could therefore be 
unraveled and further studied in greater detail. 
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Different sensory systems could be investigated in more detail in Pfn2 KO mice as 
well, e.g. using behavioral tests for pain sensitivity (tail flick or hot plate tests). More 
specific approaches, such as the buried food test (Greco et al., 2013), could also 
reveal a potential hypersensitivity of the olfactory system in Pfn2 KO mice. This 
proposed hypersensitivity phenotype could contribute to autistic behavior, since 
sensory stimuli could be received differentially (e.g. more intense) or their output 
signaling from the olfactory bulb could be increased in autistic brains. 
In order to address behavioral phenotypes, pharmaceutical therapies could be 
applied to Pfn2 KO mice targeting the neuronal systems that were investigated in this 
study. Indeed, dopamine antagonists are among the drugs that are commonly used 
to treat autistic patients. Haldol is so far the most effective treatment in reducing 
autistic symptoms by counterbalancing elevated dopamine levels, but it has severe 
side effects (McDougle and Posey, 2002).  
 
Pfn2 has a function in neuronal development as shown in axonal and dendritic 
projections (see 2.3.1-2.3.3, 3.3.1-3.3.2, Fig. 25-28). In line with the accelerated 
developmental phenotype of Pfn2 KO neurons in vitro, the loss of Pfn2 could lead to 
impairments in connectivity or synaptogenesis in vivo, where a regulation of the 
cytoskeletal reorganization is crucial. Histological analyses of dendritic branching and 
synaptic connections at high resolution (i.e. Golgi-staining or super-resolution 
fluorescent microscopy) in Pfn2 KO mice would be valuable to investigate these 
processes. Electrophysiological measurements would reveal differences in the 
excitability, firing rates and related parameters could be performed on different 
neuronal populations or pathways connecting different brain areas.  
 
Taking advantage of the validation of the P2-GFP mouse model presented in this 
work, Pfn2 dynamics could be investigated and visualized in live cells either in vitro or 
in vivo (for the latter e.g. using two-photon microscopy). Furthermore, the GFP-tag 
could be exploited for efficient immunoprecipitation experiments using anti-GFP 
antibodies that do not interfere with the binding of Pfn2 to its ligands. The interaction 
of Pfn2 with pre- or post-synaptic proteins could be verified and in addition 
stimulating conditions could be applied to analyze quantitative changes of ligand 
binding. 
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One of the tools developed during this thesis could also be used in a potentially 
highly beneficial approach to pull down native complexes (e.g. Arp2/3- or the different 
WAVE- complexes) using Strep-tagged versions of Pfn2 (see 2.2.1), since a mild 
elution protocol (biotin for competitive binding) can be used that would leave entire 
complexes intact. Therefore e.g. the composition of the different WAVE- complexes 
interacting with Pfn2 in certain brain areas, cell types or stimulation conditions could 
be unraveled, which would help to understand the role of the different complexes and 
Pfn2 during the initiation of actin polymerization. 
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4.1 Molecular Biology  
 
4.1.1 Genomic DNA extraction from mouse tails  
 
To extract genomic DNA from mouse tail tips, 200 µl of DNA extraction buffer (see 
5.1.1) containing 0.5 mg/ml proteinase K were added to tail biopsies (app. 3-4 mm) 
and the proteins of the tissues were digested o.n. at 55°C. 
After the digestion the solution was mixed briefly and shaken vigorously for 1 min. 
with ½ Vol. of saturated NaCl solution before spinning it down at 14,000 rpm for 
15 min at room temperature (RT). 2.5 Vol. of absolute ethanol were added to 200 µl 
of the supernatant and the resulting flocculum of genomic DNA was precipitated by 
spinning down at 14,000 rpm for 3 min. The supernatant was aspirated using a pulled 
Pasteur pipet and air dried (or at 37°C for 5 min.). The DNA was resuspended in 200 
µl of Milli-Q water (aqua bidest.) on a shaker at RT (or at 37°C) for app. 30 min 
before storing the DNA at 4°C. For a genotyping PCR (see 4.1.2.1), 1 µl of this 
solution was used.  
 
4.1.2 Polymerase Chain Reaction 
 
Nearly any DNA sequence can be amplified by a PCR (polymerase chain reaction) 
(Mullis and Faloona, 1987). For this purpose the DNA template (e.g. genomic DNA, 
see 4.1.1) is first denatured at 94-98°C for 30 sec.-2 min. This treatment separates 
the leading and lagging strand of the DNA, so that they are both able to function as 
templates for DNA replication. To these ssDNA (single-stranded DNA) templates can 
anneal specific oligonucleotides, so called “primers”, at a temperature of app. 55-
65°C for 15-90 sec. The primers are chosen in pairs, with one in the 5´-3´ direction 
(sense or forward primer) and the other in the 3´-5´ direction (antisense or reverse 
primer) of the DNA template and are 18-25 nt long oligonucleotide sequences. Other 
features of the primers that help to increase the performance of the reaction should 
be a relatively high content of GC base pairs (40-60%) and at least two cytosines (C) 
or guanines (G) at the 3´-terminal of the primer. This yields a strong DNA-primer 
interaction, which is needed for the binding of an enzyme called the Taq-polymerase 
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(see 5.2.1) to the DNA-primer interaction site. The Taq-polymerase is a thermostable 
enzyme from the archaea bacterium Thermus aquaticus. At a temperature of 68-
72°C (temperature optimum for the activity of the Taq-polymerase) the polymerase 
catalyzes the incorporation of free deoxynucleotides (dNTPs) (see 5.2.1) at the 3´-
OH of the primer, complementary to the template strand of DNA. The enzyme needs 
divalent ions for its catalytic function, which are supplemented to the reaction in form 
of magnesium chloride (MgCl2) (see 5.2.1) to work efficiently. This whole process of 
denaturing, annealing and elongation of the desired DNA template is repeated in 25-
35 cycles in which the DNA is amplified exponentially. The reaction finishes with final 
elongation period of 5 min. to ensure the full length of the newly synthesized DNA. 
 
4.1.2.1 Genotyping PCRs 
 
Determination of mouse genotypes was done by PCR, screening for mutated 
allele(s). 
Genomic DNA from tail biopsies (see 4.1.1) was used as DNA template. 
 
P2-GFP knock-in mice genotyping PCR 
To determine the genotype of the P2-GFP knock-in (KI) mice, the corresponding 
PCR was performed with a primer pair (see 5.5) amplifying a sequence with a length 
of 273 bp from the Pfn2 wt allele and a primer pair, amplifying a 404 bp fragment of 
the P2-GFP knock-in allele (Tab. 1). The sense primer was the same in both primer 
pairs. The resulting DNA samples were loaded on a 1.5% agarose gel (see 4.1.3, 
5.1.1). 
 
Tab. 1 P2-GFP genotyping PCR reaction conditions 
Degrees Time 
98°C 2 min.  
96°C 
55°C 
72°C 
30 sec. 
1 min. 15 sec. 
30 sec. 
 
35 cycles 
72°C 5 min.  
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Reagent Concentration Amount [µl]
H2O  11.2
Go-Taq Flexi Buffer 5x 4.0
MgCl2 25 mM 1.2
dNTPs 10 mM 0.4
Primer pair  
Pfn2-for/ Pfn2-rev 
20 µM 1.0
Primer pair 
Pfn2-for/ PGFP-1 
20 µM 1.0
Go-Taq-polymerase 
(Promega) 
5 u/µl 0.2
   
Subtotal  19 µl
Genomic DNA  1 µl
   
Total  20 µl
 
 
Pfn2-lacZ (Pfn2 KO) mice genotyping PCR 
The genotype of the Pfn2-lacZ (Pfn2 KO) mice was determined by a PCR with a 
primer pair amplifying a sequence with a length of 273 bp of the Pfn2 wt allele and a 
primer pair (see 5.5) amplifying a DNA fragment of app. 200 bp of the Pfn2-lacZ 
allele (Tab. 2). The sense primer was the same in both primer pairs. The resulting 
DNA samples were loaded on a 2% agarose gel (see 4.1.3, 5.1.1). 
 
 
 
Tab. 2 Pfn2-lacZ (Pfn2 KO) genotyping PCR reaction conditions 
Degrees Time 
98°C 2 min.  
96°C 
55°C 
72°C 
30 sec. 
1 min. 15 sec. 
30 sec. 
 
35 cycles 
72°C 5 min.  
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Reagent Concentration Amount [µl] 
H2O  11.2
Go-Taq Flexi Buffer 5x 4.0
MgCl2 25 mM 1.2
dNTPs 10 mM 0.4
Primer pair  
Pfn2-for/ Pfn2-rev 
20 µM 1.0
Primer pair 
Pfn2-for/ nestLacZ-rev 
20 µM 1.0
Go-Taq-polymerase 
(Promega) 
5 u/µl 0.2
   
Subtotal  19 µl
Genomic DNA  1 µl
   
Total  20 µl
 
4.1.3 Gel Electrophoresis 
 
Visualization of nucleic acid samples was performed by loading them on agarose 
gels (1.5-2% agarose in 1x TAE buffer, see 5.1.1) supplemented with ethidium 
bromide (app. 7-9 µl from stock (10 mg/ml) in 100 ml agarose in TAE). Nucleic acids 
are negatively charged due to the phosphate residues of their backbone structure. 
This feature can be exploited in electrophoresis, since nucleic acids run through the 
agarose gel towards the cathode (plus pole), when an electric potential difference is 
applied. The detection of the loaded samples was accomplished by imaging the 
ethidium bromide incorporated in the nucleic acid, when excited by UV radiation.  
 
4.1.4 Engineering of plasmids for the expression of Streptag-fusion 
proteins 
 
A plasmid vector for the production of Streptag-fusion proteins (pMW172-Strepag, 
produced by Julia Hecker) was used to insert the cDNA sequences of mouse Pfn1, 
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Pfn2 and P2-GFP respectively in order to produce recombinant Streptag-fusion 
proteins of these profilin isoforms (see 5.6).  
The cDNA sequences of Pfn1, Pfn2 and P2-GFP were obtained by PCR amplification 
(see 4.1.2) from previously engineered plasmids (produced by Pietro Pilo Boyl and 
Walter Witke). The primer pairs were designed to include unique restriction sites for 
endonucleases suitable to insert these sequences into the Streptag plasmid vector 
(see . The PCR was performed using the Phusion polymerase instead of the Taq-
polymerase (see 4.1.2), a proof-reading polymerase that minimizes the occurrence of 
sequence errors. 
 
Tab. 3 Restriction digestion 
Reagent  Concentration PCR digestion Vector digestion 
DNA (PCR product)  pellet  
pMW172-Streptag 1 µg/ µl  2 µl 
Endonuclease I (NdeI) 10 U 1 µl 1 µl 
Endonuclease II (SacI) 10 U 1 µl 1 µl 
Restriction buffer (Buffer 4, 
NEB) 
10x 5 µl 5 µl 
H2O  43 µl 11 µl 
    
Total  50 µl 20 µl 
 
The PCR products were verified on agarose gels and afterwards diluted to 100 µl 
with H2O and 1/10 vol. 3 M Na-acetate and precipitated by the 2.5 vol. of absolute 
EtOH by incubating at -80°C for a few hours. The precipitate was spun down at 
14,000 rpm for 5 min. and the pellet was resuspended in the buffer required for the 
restriction digestion (see Tab.3). The restriction digestion was carried out for 1 h at 
37°C. The digested DNA was loaded onto a preparative agarose gel (1.2%) and a 
current of 120 V was applied. After the electrophoresis, the desired band of the PCR 
product was cut out of the gel and the DNA was eluted with help of the Fermentas gel 
extraction kit. Briefly, the agarose was solubilized and the DNA bound to silica- 
membranes in microspin columns before the DNA was washed and recovered with 
10 mM Tris-HCl pH 8.0 (35 µl). The amount of the eluted DNA was verified by 
loading it on an agarose gel. 
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The pMW172-Streptag vector (4 µg) was digested with the same restriction enzymes 
as the inserts (see Tab. 3), producing the same base pair overhangs. The digested, 
linearized vector was treated with a phosphatase (Antartic phosphatase, 1 µl) for 
app. 1 h to cleave off the 5´-phosphate-group left on the vector by the restriction 
digestion in order to prevent relegation of residual single-digested plasmids. The 
enzyme was inactivated by incubation at 75°C for 10 min. The concentration of the 
linearized, dephosphorylated vector (2 µl = ~200 ng) was verified on an agarose gel 
together with 200 ng of the undigested, circular vector as a control. The linear 
plasmid DNA was precipitated as described above and app. 200 ng were added to a 
ligation reaction with the respective insert DNA sequence.  
The insert and vector sequences were ligated (see Tab. 4) as well as a control 
reaction exclusively ligating the vector to account for the dephosphorylation 
efficiency. The connection of the juxtaposed 3´-OH and 5´-phosphate groups was 
mediated by a T4 DNA ligase catalyzed reaction of the DNAs of the Streptag vector 
and the insert sequences of the respective profilin isoform (Pfn1, Pfn2, P2-GFP). The 
reaction was carried out o.n. at 16°C in a water bath. 
The ligated vector can be transformed into bacteria as described in 4.1.6.  
 
Tab. 4 Ligation of vector and insert sequences 
Substance Concentration Pfn1 
ligation 
Pfn2 
ligation 
P2-GFP 
ligation 
Empty vector 
ligation 
Vector DNA 100 ng/µl 2 µl 2 µl 2 µl 2 µl 
Pfn1 cDNA (426 bp) 50 ng/µl 1 µl    
Pfn2 cDNA (426 bp) 50 ng/µl  1 µl   
P2-GFP cDNA (1246 bp) 30 ng/µl   5 µl  
T4 Ligase 2000 U/ µl 1 µl 1 µl 1 µl 1 µl 
Ligase buffer 10x (NEB) 1.5 µl 1.5 µl 1.5 µl 1.5 µl 
H2O  9.5 µl 9.5 µl 5.5 µl 10.5 µl 
      
Total  15 µl 15 µl 15 µl 15 µl 
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4.1.5 Alkaline lysis miniprep of bacterial plasmids 
 
Miniprep inoculi were prepared picking single colonies from LBAmp agar plates and 
transferring them into 2 ml of LBAmp medium. Inoculi were grown o.n. at 37°C in a 
shaker. The inoculi (1.5 ml) were spun down at 14,000 rpm for 30 sec. and the 
supernatant was discarded. The bacteria were resuspended in 50 mM glucose/20 
mM EDTA/25 mM Tris-HCl pH 7.4 (miniprep solution 1, 100 µl) before adding 0.2 N 
NaOH/1% SDS (miniprep alkaline solution, 200 µl) to lyse the cells. The alkaline 
solution was mixed with the bacterial suspension by inversion of the Eppendorf tube 
and incubated on ice for 3-5 min. for an efficient lysis of the cells. Precipitation of 
membranes, genomic DNA and other debris was achieved by adding 3 M K-acetate 
pH 5.2 (miniprep solution 2, 150 µl) and mixing by inversion of the Eppendorf tube. 
The suspension was kept on ice for 10 min. before it was centrifuged at 14,000 rpm 
for 15 min. at 4°C. The supernatant (400 µl) was transferred in absolute EtOH (1 ml), 
mixed and incubated at RT for 5 min to precipitate the plasmid DNA. After spinning 
down the solution at 14,000 rpm for 10 min. at RT, the supernatant was discarded 
and the pellet was air dried. The dry pellet was resuspended in 10 mM Tris-HCl pH 
7.4 (40 µl) and the RNA was digested with RNAseA (200 ng/µl) for 15 min. at 37°C. 
The plasmid DNA was stored at -20°C. Positive clones were identified by restriction 
digestion with the cloning enzymes (NdeI/ SacI, see Tab. 3). 
 
4.1.6 Chemical transformation of competent bacteria 
 
Chemically competent bacteria (100 µl) treated with CaCl2 to achieve the capacity to 
uptake plasmids were thawed on ice and gently mixed with 5 µl of a ligation reaction 
for each transformation. The bacteria were incubated on ice for 20 min. with 
occasional mixing before inducing plasmid uptake with a heatshock of 45 sec. at 
42°C. The bacteria were afterwards incubated for 5 min. at RT and transferred to 900 
µl of LB0- medium in glass tubes. The glass tubes were incubated shaking for 30 min. 
(minimum) at 37°C in a shaker before plating them on LB- agar plates supplemented 
with the required antibiotics (100 µg/ml ampicillin). The plates were then incubated 
o.n. at 37°C. 
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4.1.7 Production of Profilin-Streptag expression glycerol stocks 
 
Competent bacteria from the strain BL21 (DE3) RP were transformed with the 
respective profilin-Streptag plasmids and plated on LB-agar plates supplemented 
with ampicillin (100 µg/ml) and chloramphenicol (25 µg/ml). A single colony was 
picked with a sterile toothpick and inoculated in LBAmp/Cam-medium (25 ml). The 
culture was incubated o.n. at 37°C before addition of 20% glycerol (6 ml) to the 
culture. The cell suspension was mixed and aliquoted in Eppendorf tubes (1 ml). 
Each aliquot shock frozen in liquid nitrogen (N2(l)). The glycerol stocks were stored in 
at -80°C. Expression of recombinant proteins was obtained starting from the glycerol 
stocks (see 4.2.10). 
 
4.2 Biochemistry 
 
4.2.1 Total protein lysates from mouse tissues 
 
Mouse tissues were dissected on ice, washed briefly in cold PBS- (see 5.1.3) to 
remove the blood and either stored after shock freezing in liquid nitrogen (N2(l)) at -
80°C or used directly for a protein lysate. 
To obtain a total protein lysate, the dissected mouse tissue (fresh or frozen) was 
homogenized in 2x SDS loading buffer (see 5.1.2) with an electric homogenizer sat at 
600 rpm in a glass/Teflon douncer. The solution was transferred to an Eppendorf 
tube and boiled at 99°C for 10 min. vortexing for 15-30 sec. every 2 min. (in total 4-5 
times). The lysates were stored at -20°C. 
 
4.2.2 Cytoplasmic protein lysates 
 
Cytoplasmic protein lysates were obtained by homogenizing a mouse tissue (fresh or 
frozen) in cold TritonX-100 lysis buffer (TLB, see 5.1.2) with a homogenizer set at 
600 rpm in a glass/Teflon douncer on ice. The homogenate was incubated for 10 
min. on ice to completely solubilize the cell membranes, transferred into Eppendorf 
tubes and centrifuged for 15 min. at 14,000 rpm at 4°C to remove the nuclei and cell 
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debris (including the actin cytoskeleton). The supernatant was recovered and, 
depending on the type of further analysis, ultracentrifuged for 30 min. at 60,000 rpm 
and 4°C or transferred to a new Eppendorf tube. After a quantification of the protein 
concentration by Bradford assay (see 4.2.3), the lysate was either denatured by 
boiling at 99°C for 10 min. 1x SDS loading buffer or the lysate was shock frozen in 
liquid nitrogen and stored at -80°C. 
 
4.2.3 Protein quantification 
 
Quantification of the protein content in protein lysate samples was carried out by 
Bradford assays. 
The Bradford assay is based on the shift of the absorbance wavelength of the dye 
Coomassie Brilliant Blue G-250 from 465 nm in an unbound condition to 595 nm, 
when the dye is in a complex with the proteins in the lysate (Bradford, 1976).  
This excitation and emission detection are obtained using a spectrophotometer, 
which has to be calibrated to the absorption of a serial dilution of a protein solution 
with defined concentration (usually BSA) and blanked with lysis buffer before the 
protein sample can be measured.  A fraction (4 µl) of the native protein lysate was 
boiled with 1 µl of 5x SDS-loading buffer in an Eppendorf tube for 2-3 min. at 99°C, 
cooled on ice and briefly spun down diluting it to 50 µl with H2O. The same amount of 
lysis buffer was treated in the same way as a control (blank) sample. 
For total protein lysates an aliquot of 5 µl was transferred into an Eppendorf tube and 
diluted to 50 µl with H2O. 5 µl of 1x SDS loading buffer were used as a blank. 
12.5 µl (cytoplasmic protein lysate) or 10 µl (total protein lysate), corresponding to 1 
µl of the original lysate, were then added to 1 ml of a 1:5 dilution of Bradford reagent 
in a quartz photometer cuvette, mixed and measured after 3 min..  
The measured absorbance (A) value was divided by the slope of the calibration curve 
of defined concentrations of BSA (here 0.048) to calculate the protein concentration 
of the sample in µg/µl. 
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4.2.4 Discontinuous SDS-polyacrylamide gel electrophoresis 
 
The SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) is a 
common method to separate proteins based on their apparent molecular weight.  
To achieve a continuous separation, the proteins are denatured by the hydrophobic 
interaction with sodium dodecylsulfate (SDS), the reducing reagent β-
mercaptoethanol and high temperatures. The denatured proteins remain coated by 
the negative charge of the sulfate group from the SDS according to their molecular 
weight, so that their native charge by their amino acid sequences is negligible.  
Polyacrylamide gels used for SDS-PAGE consist of two solid phases. The upper 
phase, called “stacking gel”, contains 4% acrylamide, is app. 2 cm in length and 
allocates wells to load the protein samples (see 5.1.2). The pH of the stacking gel is 
slightly acidic at 6.8. The pH of the stacking gel should ensure the concentration of 
the protein samples to a thin layer. The bottom phase, also referred to as the 
“resolving gel”, consists of a more variable percentage of acrylamide in the range 
from 6%-20% with a basic pH of 8.8 for optimal migration towards the anode. The 
different percentages of acrylamide are chosen to achieve an optimal separation of 
the protein of interest. In the case of Pfn2, which has a MW of 14 kDa, a 
polyacrylamide gel with a dense pore size (15%) is optimal to achieve a good 
separation of the proteins from low molecular weight proteins. The polyacrylamide 
gels were casted using a homemade casting chamber. To run protein samples 
through the gels, they were mounted in running chambers, containing running buffer 
and a current was applied. Electrodes placed on the top and at the bottom of the gels 
create a current passing through the gel, so that the negatively charged proteins 
migrate towards the anode (positive pole). A voltage of 80 V was applied to the 
polyacrylamide gel while the proteins ran through the stacking gel (30 min.). A 
voltage of 120-150 V was applied to the resolving gel depending on the percentage 
of acrylamide used. 
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4.2.5 Western Blotting 
 
Western blot assays are used to transfer proteins from a polyacrylamide gel onto a 
polyvinylidene difluoride (PVDF) or nitrocellulose membrane (see 5.3.3)  (Towbin et 
al., 1979). This transfer onto membranes is convenient to label proteins with specific 
antibodies and detect them using an enzymatic reaction that produces a colored or 
luminous signal. 
 
4.2.5.1 Submerged transfer 
 
The transfer of proteins onto a membrane is most efficient, when the applied current 
is moderate over a longer period of time. A submerged transfer (wet blot) relies on 
these features, so especially proteins with a molecular weight over app. 90 kDa, that 
are sometimes less efficiently transferred using other methods, can be quantitatively 
fixed onto a membrane.  
After a SDS-PAGE has been run, the gel is mounted on two sheets of Whatman 
paper laid on a sponge pad and covered by a Methanol-activated PVDF membrane, 
two more sheets of Whatman paper and another sponge pad. This stack is mounted 
in a chamber filled with Towbin transfer buffer (see 5.1.2) and a current is applied. 
The voltage applied to the blotting chamber was 110 V for 1h with a cooling ice piece 
at RT or at 20 V o.n. at 4°C. 
 
4.2.5.2 Semi-dry transfer 
 
The semi-dry transfer method (semi-dry blot) was used as a fast transfer method, 
especially for proteins below the a molecular weight of app. 90 kDa. 
The treatment of the components and the assembly of the blot stack were similar to 
the description in 4.2.5.1 for the submerged transfer except for the sponge pads that 
are not needed. 
The components of the blotting stack were put directly between the electrodes of a 
semi-dry blotting chamber and a fixed amperage of 280 mA per 6x9 cm stack was 
applied for 30-35 min. 
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4.2.6 Antibody signal detection via enhanced chemiluminescence  
 
After the transfer, the membranes were washed quickly in 1x NCP (see 5.1.2) and 
nonspecific binding sites were blocked using 5% nonfat milk/1xNCP for 30 min. at 
RT. 
Then the membranes were incubated with appropriately diluted primary antibodies in 
5% nonfat milk/1xNCP (blocking solution) for 2h at RT or o.n. at 4°C depending on 
the antibody (the latter was normally preferred). Membranes were washed 3 times for 
15 min. each with 1x NCP to remove unbound primary antibody. Secondary 
antibodies, corresponding to the host species of the primary antibody, conjugated to 
the enzyme horseradish peroxidase (HRP), were diluted 1:5000 in blocking solution 
and applied to the membranes for 1h at RT. The membranes were washed again 3 
times for 10 min. each with 1x NCP at RT and afterwards developed using enhanced 
chemiluminescence (ECL) reagents as substrates for the HRP. 
The ECL reagents were mixed from two stock solutions, which contained luminol 
(Solution A) and hydrogen peroxide (Solution B) (see 5.1.2), before the incubation on 
the membranes. The HRP enzyme catalyzes the chemiluminescent reaction, in which 
the luminol emits light upon its oxidation. 
The light signal was captured by exposing x-ray films for a definite time period or 
digitally using an imager with a CCD-camera (LAS4000 Mini, GE Healthcare). 
 
4.2.7 Western blot quantification 
 
The light emitted by a protein band is proportional to the amount of primary antibody 
on the membrane, so the light intensity was used to quantify the relative amounts of 
proteins between the lanes on the same membrane or different membranes using 
one or more stably expressed marker proteins (housekeeping genes) as controls. 
Using the software Multi Gauge V3.0 from Fujifilm Life Science the intensity of 
detected antibody signals was quantified. The ratios between lanes within the same 
blot were calculated using Microsoft Office Excel. 
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4.2.8 Coomassie staining 
 
Visualization of proteins on polyacrylamide gels is often accomplished by a 
Coomassie Brilliant Blue staining. This staining is widely used to estimate protein 
concentration and to verify the blotting efficiency after a Western blot transfer. The 
method can detect proteins starting from a minimal amount of app. 50 ng. 
Subsequent to the SDS-PAGE the proteins were fixed in the gel twice for 15 min. 
each at RT with a fixation solution (40% MeOH/10% AcOH, see 5.1.2) (not necessary 
for gels after a Western blot, as the proteins were fixed by the methanol of the 
blotting buffer and the heat produced during the blotting process). The gel was 
stained with a 0.1% Coomassie Brilliant Blue solution for 30 min. at RT before 
washing 1-2x for 15 min. with the fixation solution and afterwards 2 times 30 min. 
each with a washing solution (20% MeOH/10% AcOH, see 5.1.2), to completely 
remove unbound Coomassie. The gels were scanned and stored in water. 
 
4.2.9 Silver staining 
 
The silver staining technique also helps to visualize proteins by incorporating 
elementary silver to proteins in polyacrylamide gels. It is about 10x more sensitive 
then Coomassie staining and is therefore preferred, when low protein concentrations 
are analyzed on a gel (e.g. IP or pull-down fractions). 
After the polyacrylamide gels the proteins were fixed to the gel by a fixation solution 
of 50% MeOH/12% AcOH/0.5 ml 37% HCOH/l /H2O (see 5.1.2) and incubated for 2 h 
to o.n. at RT. Subsequent to the fixation, the gels were washed 3 times with 50% 
EtOH/H2O for 10 min. each. The gels were incubated next with a sodium thiosulfate 
solution (0.2 g/l Na2S2O3/H2O, see 5.1.2) for 1 min., rinsed with tap water 3 times for 
20 sec. each and afterwards incubated with a silver nitrate solution (2 g/l AgNO3/0.75 
ml 37% HCOH/l  H2O, see 5.1.2) for 20 min. Rinsing of the gels with tap water 2 
times for 20 sec. each was followed by a silver precipitation step using a reducing 
sodium carbonate/ sodium thiosulfate solution (60 g/l NaCO3/0.5 ml 37% HCOH/l /4 
mg/l Na2S2O3/H2O) for 5-10min. When the development of the silver staining yielded 
sufficiently prominent signals, the precipitation of elementary silver was interrupted by 
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rinsing away the reducing solution with tap water twice and stopping the reaction by 
adding a solution of 10% EtOH/10% AcOH (see 5.1.2). The stained gels were 
scanned and stored in water in the dark at 4°C. 
 
4.2.10 Protein expression in bacterial cells 
 
The E. coli BL21 (DE3) RP, T7 polymerase expressing, bacterial strain was 
transformed with the plasmids encoding for the three tagged profilin isoforms (see 
4.1.5). After the transformation, they were plated on LB-agar plates supplemented 
with chloramphenicol (25 µg/ml) and ampicillin (100 µg/ml) and incubated o.n. at 
37°C. One colony was picked, inoculated in LB-medium (30 ml) supplemented with 
the same antibiotics and grown o.n. at RT on a shaker. One aliquot directly from the 
fresh culture (25 ml) or one frozen aliquot of the bacterial glycerol stocks (see 4.1.7) 
were inoculated in 2 l of LB-medium supplemented with chloramphenicol (25 µg/ml) 
and carbenicillin (200 µg/ml) and grown at RT to an OD600 of 0.5-0.7. An aliquot of 
the culture was pelleted and frozen (non-induced sample) and the remaining 
bacterial culture was induced to produce the desired recombinant protein by addition 
of 1 mM IPTG for 4h at 37°C or o.n. at 22°C.  
In order to purify the protein, the culture was incubated on ice for 15 min. and 
pelleted at 8,000 rpm for 5 min. at 4°C. The supernatant was discarded and the 
bacterial pellet was resuspended in 50 ml Streptag-lysis-buffer containing 5 mM 
EDTA, 0.5% TritonX-100, 10% sucrose, 1x “Complete” protease inhibitor in PBS (see 
5.1.2). The lysis-solution was further incubated on ice and treated with ultrasonication 
4x 1 min. with 30 sec. intervals at a tip energy of 8 AU. The lysate was homogenized 
using a tight-fitting glass douncer and afterwards cleared by ultracentrifugation for 30 
min. at 35,000g at 4°C. The supernatant was recovered and the soluble proteins 
were purified as described in 4.2.11.  
  
4.2.11 Protein isolation by Streptag purification 
 
The recombinant Streptag fusion proteins (see 4.2.10) were isolated using an affinity 
column purification approach. 
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The column was filled slowly with 2 ml of Streptavidin-coupled sepharose beads 1:1 
slurry (GE Healthcare) at 4°C. The beads were washed according to the 
manufacturer´s specifications and equilibrated with 5 Vol. of Streptag lysis buffer (see 
5.1.2).  
The cleared bacterial lysate (see 4.2.10) was passed on the Streptavidin-coupled 
sepharose beads column three times before the unbound sample (flow through 
fraction, FT) was collected. The column was washed with 16 Vol. of Streptag washing 
buffer containing 100 mM Tris-HCl pH 8/150 mM NaCl/1 mM EDTA (see 5.1.2) until 
no further proteins were detected in the washing fraction, which was verified by 
Bradford assay. The Streptag fusion proteins bound to the beads were eluted using 
0.5 Vol. of Streptag elution buffer containing 100 mM Tris-HCl pH 8/150 mM NaCl/1 
mM EDTA/2.5 mM D-desthiobiotin (see 5.1.2) by incubating it with the beads on the 
capped column for 1 min. before collecting the eluate. The eluate was supplemented 
with 2x SDS loading buffer for Western blot analysis (see 4.2.5) or stored at -80°C. 
The beads were regenerated using 15 Vol. of Streptag regeneration buffer containing 
100 mM Tris-HCl pH 10.5/150 mM NaCl/1 mM EDTA/1 mM HABA (see 5.1.2) and 
washed again after the regeneration process with 15 Vol. of Streptag washing buffer. 
The beads were stored in the capped column with Streptag washing buffer at 4°C for 
further use.  
 
4.2.12 Coupling of Poly-L-Proline to CNBr-activated sepharose 
beads 
 
Poly-L-proline (PLP, 500 mg, Sigma) was dissolved in cold 1x coupling buffer for 2 
days at 4°C on a rotating wheel. CNBr (cyanobromide)- activated sepharose beads 4 
Fast Flow™ (10 g, GE Healthcare) were resuspended in 200 ml of cold 1 mM HCl 
and afterwards washed 5 times for 3 min. each with 200 ml cold 1 mM HCl. After a 
centrifugation at 2000 rpm for 5 min. the supernatant was removed carefully with a 
glass Pasteur pipet. The sepharose beads were washed once with cold distilled 
water and once with cold 1x coupling buffer before adding the dissolved poly-L-
proline in coupling buffer (see 5.1.2). The coupling reaction was carried out o.n. at 
4°C on a rotating wheel. 
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The poly-L-proline-coupled beads were washed three times with 200 ml of cold 
coupling buffer before unbound PLP was removed by incubation with  
0.1 M Tris-HCl pH 8/0.5 M NaCl for 2 hours at RT. The beads were washed four 
times alternating between the washing solutions of 0.1 M sodium acetate pH 4 /0.5 M 
NaCl and Tris-HCl pH 8 /0.5 M NaCl each and were finally washed and stored at 4°C 
in 20 mM Tris-HCl pH 8/5 mM EDTA/100 mM NaCl/0.1% NaN3/20% EtOH as a 1:1 
slurry. 
 
4.2.13 Poly-L-Proline binding assay 
 
An aliquot of 50 µl of PLP beads slurry (see 4.2.12) was packed into a microspin 
column and equilibrated with TLB lysis buffer. The columns were loaded with 1 mg of 
protein lysates from wt, Pfn2 KO, homozygous and heterozygous (G/G; G/+) P2-GFP 
KI mouse cortex lysates. The lysates were incubated by flowing through the columns 
3 times to optimize binding efficiency before collecting the unbound (or flow through 
fraction, FT). 
The beads in the columns were washed 3-4 times with TLB (without “Complete” 
protease inhibitor) and removed from the columns by adding 50 µl of 2x SDS-loading 
buffer twice and transferring the beads into new Eppendorf tubes to ascertain that the 
maximal amounts of beads were collected. 
The beads were boiled in the SDS loading buffer for 10 min. at 99°C to elute the 
bound proteins from the beads. After cooling the tubes quickly on ice, the beads were 
spun down at 14,000 rpm for 1 min. and supernatants (bound fraction) were 
recovered. 
The unbound fractions (FT) and an aliquot of each of the original lysates (input 
fraction) were diluted to a concentration of 0.5 µg/µl in 1x SDS loading buffer and the 
proteins were denatured by boiling at 99°C for 10 min. The fractions (input, bound, 
unbound (FT)) were stored at -20°C. For Western blot analysis equal amounts of 
input and flow through fractions from each of the different mouse genotypes were 
loaded together with 1% of the respective bound fractions. 
 
 
4. Methods 
 
 
 
136 
4.2.14 Immunoprecipitation 
 
Profilin2 and P2-GFP were immunoprecipitated with the help of the polyclonal rabbit 
antibody anti-Pfn2 T2 (Walter Witke), which is known to specifically recognize Pfn2. 1 
mg of mouse cortex lysates of wildtype and Pfn2 KO animals in TLB (see 4.2.2, 
5.1.2) were incubated with the anti-Pfn2 T2 antibody (15 µl, terminal bleed) o.n. at 
4°C on a rotating wheel. The host-species specific Fc (heavy) chain of the anti-Pfn2 
antibody was precipitated with a mixture of proteinA- and proteinG-coupled 
sepharose beads (50 µl beads slurry in a 1:1 ratio of proteinA and proteinG) by 
incubation for 4 h at 4°C on a rotating wheel. After the incubation period, the tubes 
were placed on ice to let the beads settle for 5 min. before spinning them down in a 
cooled (4°C) centrifuge at 1500 rpm for 1 min. The supernatant (unbound or flow 
through fraction, FT) was recovered and denatured with 1x SDS loading buffer for 10 
min. at 99°C. The beads were washed 4 times with 1 ml of cold TLB with intervals of 
5 min. on ice to let the beads settle down in the tube between each step, followed by 
spinning 1 min. at 1,500 rpm. Bound proteins were eluted by denaturation with 100 µl 
of 2x SDS-loading buffer at 99°C for 10 min. The samples were placed on ice for a 
few minutes before spinning them down at 14,000 rpm for 1 min. and recovering the 
supernatant (bound fraction) before Western blot analysis.  
P2-GFP complexes were immunoprecipitated using monoclonal llama antibodies 
(nanobodies) specific for GFP (green fluorescent protein) coupled to agarose beads 
(GFP-Trap®-A, Chromotek). The GFP-Trap beads were used for 
immunoprecipitation (20 µl) according to the manufacturer´s instructions. 
The input fraction (cortex lysate) and FT fraction from all IPs were boiled at 99°C in 
2x SDS loading buffer for 10 min. and adjusted to a final concentration of 0.5 µg/µl.  
 
The proteinA- and proteinG-sepharose beads were treated before the application in 
the immunoprecipitation assay to block unspecific binding and equilibrate them in the 
dilution buffer. The beads were stored in a 1:1 slurry in 20% EtOH. To remove the 
EtOH, 100 µl of beads slurry were spun down at 1,500 rpm for 1 min. at 4°C and the 
supernatant was aspirated. The beads were washed twice with 1 ml of cold PBS and 
unspecific binding capacity of the sepharose beads was blocked by incubation with 
PBS/0.1% BSA for 1 h at 4°C. The beads were spun down at 1,500 rpm for 1 min. at 
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4°C before discarding the supernatant and washing them twice with 1 ml of cold TLB, 
preparing a 1:1 slurry in cold TLB (+ Complete protease inhibitors) for the 
immunoprecipitation reaction.  
 
4.3 Histology 
 
4.3.1 Mouse tissue dissection 
 
Mice were sacrificed by cervical dislocation. Mouse tissues were dissected on ice 
and fixed in 4% PFA (see 5.1.3) for 24-48 hours at 4°C to crosslink the proteins. 
Each tissue was washed 2x with cold PBS (see 5.1.3) for at least 30 min. each at 
4°C. 
 
4.3.2 Vibratome cutting of mouse brains 
 
Mouse brains were cut sagittally or coronally to sections with a thickness of 20 µm 
using a Leica Vibratome VT 1200S. A razor blade was cleaned with 70% EtOH 
(careful not to bend the blade) and inserted into the blade holder at a slightly inclined 
angle to the object table to achieve the optimal settings. The vibration accuracy was 
measured using the Leica “VibroCheck” device and tuned to perfectly horizontal 
levels (0° alteration). 
For sagittal slices, the brains were cut with a scalpel near the midline at the height of 
app. 2/3rds of the brain before the cut surface was glued to the vibratome tray. 
In this way, the resulting slices would comprise at least one entire hemisphere. A 
piece of 2% agarose was glued next to the brain (on the opposite side of the blade) 
to stabilize it during the cutting procedure.  
For coronal slices, the cerebellum was cut off with a scalpel and the brain was glued 
to the vibratome tray on the cut surface. 
An optional step for sectioning of soft tissue (young mice) was embedding of the 
brain in using 6% low-melting agarose. The agarose was removed after cutting the 
sections, since it mediates strong autofluorescence. 
The vibratome tray was submerged in ice cold 1x PBS supplemented with 0.1% 
sodium azide (NaN3) and cooled with ice surrounding the tray. Brain slices were cut 
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at a speed of 0.16-0.26 mm/s and a vibration amplitude of 1 mm to a thickness of 20-
25 µm. The sections were collected with a smoothened glass pipet in 24-well plates 
containing cold 1x PBS/0.1% sodium azide (NaN3) and stored at 4°C wrapped in 
plastic and aluminum foil.  
 
4.3.3 Vibratome cutting of mouse spinal cords 
 
Mouse spinal cords were dissected from adult mice on ice under a binocular 
microscope. The skin was removed before the muscles were separated from along 
the spine. The vertebrae were opened dorsally to expose the spinal cord. The spinal 
roots were removed in order to lift the spinal cord.  
The spinal cord was separated in the thoracic, lumbar and sacral segments, 
embedded in 6% low-melting agarose and cut coronally with a Leica Vibratome VT 
1200S. The agarose was removed after obtaining the sections, since it is strongly 
autofluorescent. The preparation of the instrument and the cutting process was 
performed as described in 4.3.2. The cutting speed was set at 0.26 mm/s and 
sections were cut with a thickness of 80 µm. 
 
4.3.4 Vibratome cutting of mouse embryos 
 
Mouse embryos at different embryonic stages were dissected in HBSS under a 
binocular microscope. Maternal tissue was completely removed and the embryos 
were fixed 24-40h at 4°C with 4% PFA depending on the age (embryonic day) of the 
embryo. For embryos of embryonic day 16.5 (E16.5) and later, the head was 
separated from the body before the fixation to achieve maximal penetration of the 
PFA in the tissue. After fixation the embryo was washed twice with cold PBS for 30 
min. each. 
The embryos (or embryo heads) were cut sagittally with a Leica Vibratome VT 
1200S. For this procedure, the limbs and skin were removed from one side of the 
embryo and the sample was glued to the vibratome tray on the exposed surface. 
Embryos at early developmental stages (E13.5) were embedded in 6% low-melting 
agarose. The agarose was removed after obtaining the sections, since it is strongly 
autofluorescent. 
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The preparation of the instrument and the cutting process was performed as 
described in 4.3.2. The cutting speed was set at 0.20-0.26 mm/s and sections were 
cut with a thickness of 60-80 µm depending on their age. 
 
4.3.5 Immunofluorescence 
 
4.3.5.1 Immunofluorescence staining of vibratome sections 
 
Matched tissue sections from several homozygous P2-GFP KI, wildtype and Pfn2 KO 
mice as controls were chosen with the help of a stereomicroscope, depending on the 
area to be investigated. 
The sections were transferred to 24-well plates with an aluminium foil lid and 
autofluorescence was quenched by incubation with 50 mM ammonium chloride 
(NH4Cl, see 5.1.3) for 1 h at RT. The slices were washed 10 min. at RT with 1x TBS 
(see 5.1.3) to adjust the pH after the acidic ammonium chloride treatment. Afterwards 
nonspecific binding sites for the primary and secondary antibodies were blocked by 
addition of 300 µl of a blocking solution containing 1x TBS-T/2%-10% NGS and 1%-
2% DMSO (see 5.1.3) o.n. at 4°C. The composition of the blocking solution was 
antibody-, antigen- and section-dependent. Antibodies with relatively high 
background require a blocking solution with a higher amount of serum proteins (5-
10% NGS). Inaccessible target antigens (scaffolding proteins, PSD-associated 
proteins etc.) or thick sections (embryos, spinal cord) required incubation with a 
higher concentration of DMSO (2%). 
The blocking solution was removed using a glass Pasteur pipet and 200 µl of the 
respective primary antibody appropriately diluted in blocking solution were added to 
each brain slice that was incubated o.n. (or 24-48 h) at 4°C or RT. The incubation 
period and the dilution of the primary antibody (several primary antibodies can be 
applied together, in the same solution) are dependent on the affinity and the binding 
kinetics of the antibodies, which need to be tested individually. After the incubation, 
the primary antibody solution was removed and the slices were washed a minimum 
of three times with 1 ml of TBS-T (see 5.1.3) for 15 min at RT to remove unbound 
antibodies. 
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The sections were incubated with 250 µl of secondary antibodies appropriately 
diluted in blocking solution (Alexa- or ATTO-dyes 1:1000, CF-dyes 1:500) for 1-2 h at 
RT. The secondary antibody solution was removed from the sections and they were 
washed a minimum of three times with 1 ml of TBS-T for 15 min each at RT to 
remove unbound antibodies. A subsequent washing step was performed o.n. at 4°C.   
To visualize the cell nuclei, DNA-intercalating dyes were chosen with regard to their 
excitation wavelengths. To localize cell nuclei and tissue structures through the 
oculars by eye, the DNA dye DAPI was added in 300 µl of TBS-T for  
15 min. at RT at a concentration of 10 ng/ml (1:100,000 from the stock). Another 
DNA- binding dye (Draq5, Biostatus, UK), was chosen to visualize the nuclei, which 
can be excited at 640 nm and has an emission peak at 680 nm. Draq5 was incubated 
in TBS-T for 15 min. at RT at a concentration of 1 µM (1:5000 from the stock). 
Maximal efficiency is achieved by incubating with Draq5 solution before incubating 
with DAPI solution, due to DAPI´s higher affinity and the saturation of binding sites for 
Draq5. To wash away unbound DNA dyes, an incubation with 1 ml of TBS-T for 15 
min. at RT followed. A subsequent washing step with 1 ml of TBS for 10 min. at RT 
was included to remove the TritonX-100 from the sections. 
 
The staining of the Ca2+-binding proteins calbindin (CB) and parvalbumin (PV) 
required an additional step of incubation with a calcium-buffer before quenching the 
autofluorescence with the ammonium chloride solution. These proteins are 
recognized by the specific antibodies preferably in their Ca2+-bound conformation. 
 
4.3.5.2 Immunofluorescence of cultured hippocampal neurons 
 
Hippocampal neurons were stained in a humid chamber. The paraffin dots were 
removed from the coverslips and they were washed quickly with TBS by turning the 
coverslips with the cell side on drops of washing buffer (100 µl). Before lifting the 
coverslips to transfer them on a drop of the following solution, 100 µl of TBS were 
added underneath the coverslip, raising it slightly from the parafilm, so no cells were 
harmed during the transfer. The cells were permeabilized for 1 min. at RT using 
TBS/0.2% TritonX-100 (TBS-T) and autofluorescence was quenched by incubation 
with ammonium chloride (NH4Cl, 50 mM) for 10 min. at RT. The coverslips were 
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washed by dipping them thrice gently in a beaker with TBS and once with a drop of 
TBS/0.2% Tween-20 on parafilm. Unspecific binding sites were blocked by incubation 
with TBS/0.2% Tween-20/10% NGS (see 5.1.3) o.n. at 4°C. The cells were incubated 
with primary antibodies o.n. at 4°C or RT depending on the antibody in blocking 
solution. The coverslips were washed again by gently dipping them thrice in TBS and 
placing them on a drop of TBS/0.2% Tween-20. The secondary antibody was added 
in blocking solution for 2 h at RT before washing in the same way as described above 
and washing a fourth time o.n. at 4°C. The cells were incubated, if required with a 
DNA dye to stain the nuclei. Draq5 (1 µM), propidium iodide (0.5 µg/ml) or DAPI (10 
ng/ml) was therefore added in TBS for 10 min. at RT. The coverslips were washed 
quickly again in TBS/0.2% Tween-20 and quickly in H2O before mounting them on a 
glass slide with app. 10 µl of Mowiol mounting medium per 13 mm2 coverslip (see 
5.1.3). They were sealed with nail polish after drying for a few hours at RT.  
 
4.3.5.3 Mounting of vibratome sections 
 
The sections were transferred on glass slides, flattened using a fine brush and the 
slide was dried around the slices. A mounting medium was warmed (55°C) and was 
added to the slice with a cut P200 pipet tip (app. 100-120 µl/ brain section or 80 µl/ 
spinal cord section or 150 µl/ embryo section). The amount of mounting medium also 
determines the distance of the sample from the glass of the coverslip, which should 
be minimal to prevent light scattering and absorption by the mounting medium.  
To achieve maximal resolution of the resulting images, certain mounting media were 
prepared dependent on the type of analysis. A new mounting medium was invented 
with consideration of a high number of publications and articles yielding an increased 
signal-to-noise ratio (SNR) due to minimal scattering of light.  
The “glycerol mounting medium” (see 5.1.3) consists of glycerol, a Tris-based 
buffering system to keep the basic pH and three kinds of antifadent reagents to 
scavenger different species of (mostly oxygen) radicals. 
Glycerol is a viscous medium that, at a concentration of 90%, has a refractive index 
of n= ~1.46, which is close to the refractive index of immersion oil (n= 1.518) and the 
cover glass (n= ~1.5). The Tris-buffer in the medium is needed to keep the pH above 
8.5 to achieve an optimal quantum yield efficiency of the fluorophores in absorbing 
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photons of the desired wavelength and emitting maximal amounts of photons in their 
respective spectrum. Free radicals in the mounting medium are inevitably produced 
by the high power of the laser light excitation. These (mostly oxygen) radicals need to 
be hindered in reacting and therefore permanently inactivating the fluorophores. 
Different radical species can be scavenged by different antifadent substances such 
as n-propyl-gallate (NPG), 1,4-diazabicyclo[2.2.2]octane (DABCO) or 
p-phenylendiamine (PPD). These reagents are added to the medium in different 
concentrations (see 5.1.3), since especially PPD is also partially quenching the 
fluorescence emission efficiency, if it is too concentrated. PPD also produces a slight 
yellow color of the medium, which turns brown upon oxidation, which is an indicator 
for suboptimal storage. An additional step in medium preparation is to de-gas the 
solution to minimize oxygen in the mounting medium, which can be processed to free 
oxygen radicals. The antifadents are chemically very active, so, in order to keep them 
stable, high temperatures (above app. 70°C) and a long light exposure should be 
avoided. The solution is stored at -80°C to further prevent degradation and oxidation 
of the antifadents. 
The medium is therefore ideal for imaging high-resolution images, since it diminishes 
light scattering and prevents photodamage of the fluorophores. Due to the high 
concentration of glycerol, this mounting medium will not get solid, so immediate air- 
tight sealing with nail polish is required.  
The handling of a fluid mounting medium can be difficult especially for round 
coverslips commonly used in tissue culture conditions.  
Another mounting medium was prepared to achieve a better sample stability without 
diminishing the refractive index too much (see 5.1.3). This medium was Mowiol-
based – a polyvinylalcohol (PVA), which solidifies upon oxygen exposure and is 
otherwise inert in terms of reaction capabilities with the cell or tissue sample. The 
Mowiol mounting medium has a refractive index of n= 1.45 at 20% in a Tris-based 
buffering system to keep the pH above 8.5. This refractive index is slightly worse than 
that of the glycerol mounting medium, but still good enough for high-resolution 
imaging. Mowiol needed to be mixed in 40mM Tris-HCl pH 8.5 for several hours at 
~50°C to solubilize completely. The medium could be de-gassed and the same 
antifadents at the same concentrations as for the glycerol mounting medium were 
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added. The solution was stored at -80°C to further prevent degradation and oxidation 
of the antifadents. 
 
The sections were gently covered with a glass coverslip from one side, so the 
mounting medium was evenly distributed. These coverslips No. 1.5 (Marienfeld) had 
a definite thickness of 0.17 mm (+/- 0.005 µm) optimized for the refractive index of 
the immersion oil (n= 1.518) and for the correction of an oil- immersion objective lens 
to further reduce light scattering. The samples were sealed air-tight with nail polish to 
prevent oxygen from reacting with the antifadents of the mounting medium. 
 
 
4.4 Neuron culture 
 
4.4.1 Preparation of coverslips 
 
Coverslips with a thickness of 0.17 mm and a diameter of 13 mm (No. 1.5 H 
Marienfeld) were were stacked in porcelain staining racks and incubated with 
concentrated HNO3 (≥ 65%) in glass beakers under a fume hood o.n. at RT. The 
porcelain staining racks were washed 4 times with Milli-Q water and sterilized with 
dry heat for 6h with rising temperature of 100-220°C. The coverslips were transferred 
to 6 cm2 dishes with sterile forceps, so each dish would contain max. 8 coverslips. 
Paraffin was melted in a waterbath on a heating block for min. 3 h and 3 dots were 
applied on each coverslip with a glass Pasteur pipet. For enhanced adhesion of 
neuronal cells, poly-L-lysine in borate buffer (see 5.1.4) was applied to each coverslip 
two days before a hippocampal neuron culture was planned. A drop of poly-L-lysine 
was placed on each coverslip (app. 100-200 µl) and incubated for 24 h at RT in a 
humid chamber. One day before a hippocampal neuron culture was planned, the 
coverslips were washed with sterile H2O 3 times before adding MEM-HS or MEM-
FCS (see 5.1.4). The coverslips were equilibrated with the medium at 37°C in an 
incubator for min. 24 h and maximal 2 weeks before neuronal cells were plated on 
the coverslips. 
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4.4.2 Hippocampal neuron culture 
 
A pregnant mouse was sacrificed by cervical dislocation and E17.5 embryos were 
recovered. To obtain the hippocampi of the embryos, they were decapitated, a piece 
of tail was cut for genotyping and the skull was opened with a fine bend pair of 
forceps. The skin and skull bones were removed and the entire brains were dissected 
out of the skull without harming their structure. The brains were transferred to 6 cm2 
cell culture dishes filled with app. 5 ml of HBSS/HEPES (see. 5.1.4) under a 
stereomicroscope (see 5.4.1). The meninges were removed from the brains with two 
pairs of fine forceps and the hippocampi were dissected out. The hippocampi were 
transferred to an Eppendorf tube with app. 1 ml of HBSS/HEPES. The isolated 
hippocampi were transferred to a 15 ml tube in a laminar flow hood, the HBSS was 
removed. A Trypsin (0.05%) solution (see 5.1.4) was added (5 ml) and the tissues 
were incubated in a water bath at 37°C for 15 min. After the incubation, the Trypsin 
solution was removed and the hippocampi were washed thrice with HBSS/HEPES. 
The hippocampi were dissociated in 3 ml HBSS/HEPES by pipetting up and down 
using a glass Pasteur pipet, which had been presoaked with a 5% BSA solution. The 
cells were further isolated by pipetting up and down with a fire-polished Pasteur pipet 
with app. half of the normal diameter. The cell density was determined with the help 
of a hemocytometer and the cells were plated at a density of 150,000 cells/ 6 cm2 
dish containing 8x 13 mm Ø coverslips and an astrocyte co-culture with MEM-FCS 
medium (see 5.1.4). The MEM-FCS medium was exchanged for N2-medium (see 
5.1.4) 24 h after plating and the medium was further changed (2/3) once per week. 
The coverslips were treated as described in 4.3.1 and astrocytes were grown app. 
30-50% confluent in the 6 cm dishes as described in 4.4.3. 
 
4.4.3 Astrocyte culture 
 
Astrocytes were cultured as co- cultures for hippocampal neurons from E19.5 
embryos. The brains were dissected as described for culturing hippocampal neurons 
(see 4.4.2) but the cortices were recovered from the embryos instead of the 
hippocampi. The cortices were treated in the same way as the hippocampi (see 
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4.4.2) but the dissociated cell suspension was resuspended in  
10 ml of MEM-FCS and plated on 75 cm2 flasks (app. 5 brains/flask).  
The astrocytes in the flasks were grown to 100% confluency and split in 3 new flasks. 
For that the cells in the flask were washed with HBSS/HEPES and incubated with a 
Trypsin (0.05%) solution for 10 min. at 37°C before splitting the cell suspension 
equally into 3 new flasks. Astrocytes could be split maximum 3 times before problems 
with adhesion and proliferation occurred. One 75 cm2 flask with 90-100% confluent 
astrocytes could be spilt onto app. 40x 6 cm2 dishes as a co-culture for hippocampal 
neurons. The MEM-FCS medium was changed (2/3) once per week. 
 
4.4.3.1 Astrocyte freezing 
 
An astrocyte co-culture can be established from previously cultured cells, which were 
stored in a cryo-tank with liquid nitrogen. A 90-100% confluent 75 cm2 flask was 
washed with HBSS/HEPES and incubated with 3 ml of a Trypsin (0.05%) solution for 
10 min. at 37°C. The trypsinization was stopped by 5 ml of FCS and the cell 
suspension was transferred to a 15 ml tube. DMSO was added to the cell suspension 
to a final concentration of 10% (app. 1 ml) and the cells were transferred to 2 ml cryo-
tubes. The tubes were incubated first on ice for several minutes and afterwards at  
-80°C in a stryropor box for 24 h. The cell suspension in the cryo-tubes was 
permanently stored in liquid nitrogen. The cells were thawed quickly in a water bath 
at 37°C and plated on 6 cm2 dishes or 25-75 cm2 flasks with MEM-FCS. 
 
4.4.4 Cell fixation 
 
Hippocampal neurons and astrocytes were grown in 6 cm2 dishes with MEM-FCS 
(astrocytes) or N2-medium (neurons). The dishes were washed once with 
HBSS/HEPES and fixed afterwards using 4% PFA, 0.25% glutaraldehyde, 2% 
sucrose in PBS for 20 min. at 37°C (see 5.1.4). After the fixation period, a small 
amount of the fixation solution was left and the dishes were filled to 5 ml with 
HBSS/HEPES. The dishes were stored in the dark at 4°C wrapped with parafilm. 
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4.4.5 Sholl analysis 
 
Hippocampal neurons of different mouse lines were fixed (see 4.3.4) at different time 
points (days in vitro, DIV) and their complexity was compared applying Sholl analysis. 
Sholl analysis is based on the intersections of dendritic projections through circles of 
a defined diameter in silico.  
Hippocampal neurons (see 4.3.2) originating from wildtype, homozygous P2-GFP KI, 
and Pfn2 KO mice were fixed at different developmental stages (DIV 1, 2, 3, 7, 14 
and 21). The cells were immuno-stained using the early neurite/dendrite specific 
antigen Map2 (see 4.3.5.2) and imaged using a widefield fluorescence microscope 
(Keyence Biorevo BZ-9000). The images were stitched together (Adobe Photoshop), 
if necessary, due to large dendritic arborizations exceeding the field of view of the 
20x objective. The projections were semi-automatically traced (Simple Neurite Tracer 
plugin in Fiji ImageJ) and traced neurites were implemented in the Sholl analysis 
plugin in Fiji ImageJ. The intersections of neurites at rings of 10 µm intervals 
surrounding the neuronal somata were counted for each time point and genotype 
(high number of neurons were analyzed for n=3 individual neuronal cultures for each 
genotype). The mean number of intersections for each DIV and genotype was 
calculated and Sholl plots were generated to compare differences in the complexity 
of the neuronal arborizations. 
 
4.4.6 Neuron Stimulation 
 
The hippocampal neurons were cultured from homozygous P2-GFP (G/G) embryos 
(E17.5) for 21 days (DIV 21) and subsequently stimulated. The cells were washed 
with ACSF (see 5.1.5) once and equilibrated in ACSF for 15 min. at 37°C before a 
stimulating solution or drug was added. 
General pre- (and post-) synaptic stimulation was accomplished by exchanging the 
ACSF with ACSF containing 90 mM KCl (see 5.1.5) or ACSF with an increased 
Ca/Mg ratio of 7:1 (see 5.1.5) (the sodium concentration was adjusted accordingly to 
keep the osmolality stable) and incubating the cells for varying time periods (1 min., 5 
min., 10 min.).  
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Specific receptor agonists were applied directly into the ACSF (see 5.1.5). 
 Glutamate (10 µM final concentration) or a solution containing both glutamate  
(10 µM final concentration) and glycine (10 µM final concentration) were added to 
target the different types of glutamate receptors for varying time periods (5 min., 
15 min., 30 min.).  
 NMDA was supplied to the hippocampal neurons for 30 min. at a final 
concentration of 10 µM 
OR for 3 min. at a final concentration of 25 µM to chemically induce long-term 
depression (chem. LTD) of the neurons. 
 GABA (50 µM final concentration) was applied to hippocampal neurons in ACSF 
for 3 h. 
The cells were fixed (see 4.3.4) directly after stimulation or after washing away the 
respective stimulatory agent with ACSF and an incubation period of 30 min., 1 h or  
2 h in fresh ACSF medium. 
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5.1 Solutions and buffers 
5.1.1 Solutions for the analysis of nucleic acids 
 
Name Substance concentration 
DNA extraction buffer Tris-HCl pH 7.4 50 mM 
 NaCl 100 mM 
 SDS 1% 
 EDTA 5 mM 
 Proteinase K 0.5 μg/ μl 
DNA loading buffer (100 ml) Sucrose 40% 
 SDS 0.5%  
 Bromphenole blue 0.25% 
 TE buffer  to 100 ml 
Proteinase K (stock in H2O) Proteinase K 10 μg/ μl 
TAE-buffer 50x pH 8.3 Tris base 2 M (242.2 g) 
 Acetic acid (glacial) 57.1 ml 
 EDTA 0.5 M (pH 8,0) 0,05 M (100 ml) 
TE buffer Tris-HCl pH 8.0 100 mM 
 EDTA 1 mM 
 
5.1.2 Solutions for biochemical analysis 
Name Substance concentration 
Coomassie gel destain  Methanol 40% 
(fixation solution) Acetic acid 10% 
Coomassie gel staining solution Methanol 50% 
 Acetic acid 10% 
 Coomassie Brilliant Blue G-250 0.1% 
  filtrated 
Coomassie gel destain  Methanol 20% 
(washing solution) Acetic acid 10% 
Sepharose-resin Coupling  NaCO3 pH 8.3 0.1 M 
buffer NaCl 0.5 M 
ECL solution A (200 ml)  Tris-HCl pH 8.6 0.1 M 
 Luminol stock 4 ml 
 p-hydroxy-coumarin stock 0.1 ml 
ECL solution B (200 ml) Tris-HCl pH 8.6 0.1 M 
 H2O2 (30%) 0.2 ml 
Luminol stock solution (10 ml) Luminol in DMSO 0.44 g 
NCP 10x pH 8-8.2 NaCl 1.47 M 
 Tris base 0.4 M 
 Tween-20 0.5% 
 HCl 6 M app. 40-45 ml 
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p-hydroxy-coumarin stock  p-hydroxy-coumarin in DMSO 150 mg 
PLP-Sepharose beads acidic  Na-acetate pH 4.0 0.1 M 
washing solution NaCl 0.5 M 
PLP-Sepharose beads basic  Tris-HCl pH 8.0 0.1 M 
washing solution NaCl 0.5 M 
PLP-Sepharose beads storage  Tris-HCl pH 8.0 20 mM 
solution EDTA 5 mM 
 NaCl 100 mM 
 NaN3 0.1% 
 EtOH 20% 
Polyacrylamide resolving gel  H2O 26.7 ml 
8% (50 ml for 7 gels) Acrylamide (30%) 13.3 ml 
 Tris-HCl 2 M pH 8.8 9.5 ml 
 SDS (20%) 250 µl 
 APS (10%) 320 µl 
 TEMED 25 µl 
Polyacrylamide resolving gel  H2O 15 ml 
15% (50 ml for 7 gels) Acrylamide (30%) 25 ml 
 Tris-HCl 2 M pH 8.8 9.5 ml 
 SDS (20%) 250 µl 
 APS (10%) 320 µl 
 TEMED 25 µl 
Polyacrylamide stacking gel 4%  H2O 18.3 ml 
(30 ml for 7 gels) Acrylamide (30%) 3.9 ml 
 Tris-HCl 0.5 M pH 6.8 7.5 ml 
 SDS (20%) 150 µl 
 APS (10%) 180 µl 
 TEMED 14 µl 
SDS-loading buffer 5x  Tris-HCl pH 6.8 110 mM 
(SDS-sample buffer 5x) Glycerol 20% 
 SDS 3.8% 
 β-mercaptoethanol 8% 
 Bromphenole blue ad libitum 
SDS-running buffer 10x Tris base 0.25 M 
 Glycine 1.92 M 
 SDS (20%) 1% 
Sepharose beads blocking  PBS  1x 
solution for IP BSA (1 mg/ml) 0.1% 
Sepharose beads deblocking  HCl 37% 1 mM 
solution   
Silver stain AgNO3 solution AgNO3 2 g/l 
 Formaldehyde 37% 0.75 ml/l 
Silver stain fixation solution Methanol 50% 
 Acetic acid (glacial) 12% 
 Formaldehyde 37% 0.5 ml/l 
Silver stain Na2CO3 solution Na2CO3 2 g/l 
 Formaldehyde 37% 0.5 ml/l 
 Na2S2O3 4 mg/l 
Silver stain Na2S2O3 solution Na2S2O3 0.2 g/l 
Silver stain stopping solution Ethanol absolute 10% 
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 Acetic acid (glacial) 10% 
Streptag lysis buffer EDTA  5 mM 
 Triton-X 100 0.5% 
 sucrose 10% 
 Complete protease 
inhibitor, EDTA-free, Roche 
1x 
Streptag washing buffer Tris-HCl pH 8 100 mM 
 EDTA 1 mM 
 NaCl 150 mM 
Streptag elution buffer Tris-HCl pH 8 100 mM 
 EDTA 1 mM 
 NaCl 150 mM 
 D-Desthiobiotin 2.5 mM 
Streptag regeneration buffer Tris-HCl pH 10.5 100 mM 
 EDTA 1 mM 
 NaCl 150 mM 
 HABA 1 mM 
Triton lysis buffer (TLB) NaCl 150 mM 
 Tris-HCl pH 7.4- 8 50 mM 
 TritonX-100 1% 
 Complete protease 
inhibitor, EDTA-free, Roche 
1x 
Towbin transfer buffer 1x Tris base 25 mM 
 Glycine 192 mM 
 methanol 20% 
 
5.1.3 Solutions for histological analysis 
Name Substance concentration 
IF blocking solution TBS-T 1x 
for vibratome sections NGS 2-10% 
 DMSO 1-2% 
IF blocking solution TBS 1x 
for cultured neurons NGS 10% 
 Tween-20 0.2% 
Paraformaldehyde (PFA) 4% PBS 1x 60 ml 
(pH 7.2, 100 ml) PFA 4 g 
  dissolve at 65 ºC 
 PBS 1x adjust volume to 100 ml 
  sterile filtrate 
PBS (10x) pH 7.4 NaCl 1.5 M  
 Na2HPO4 162 mM 
 NaH2PO4 38 mM 
TBS 10x Tris-HCl pH 7.4 400 mM 
 NaCl 1.5 M 
TBS-T TBS 1x 
 TritonX-100 0.2% 
Autofluorescence quenching 
solution 
Ammoniumchloride (NH4Cl) 50 mM 
Glycerol mounting medium Glycerol 
Tris-HCl pH 8.5 
90% 
40 mM 
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 n-propyl-gallate (NPG) 5% 
 1,4-diazabicyclo[2.2.2]octane 
(DABCO) 
2.5% 
 p-phenyl-endiamine (PPD)   0.25% 
Mowiol mounting medium Mowiol 
Tris-HCl pH 8.5 
20% 
40 mM 
 n-propyl-gallate (NPG) 5% 
 1,4-diazabicyclo[2.2.2]octane 
(DABCO) 
2.5% 
 p-phenyl-endiamine (PPD)   0.25% 
 
5.1.4 Solutions for neuron culture 
Solution Substance Amount 
N2-medium Neuropan2 5 ml 
 Pyruvic acid 5 ml 
 Glucose (20%) 15 ml 
 NaHCO3 (5,5%) 20 ml 
 MEM (10x) 50 ml 
 H2O to 400 ml 
  adjust pH to 7.3 
  fill up to 500 ml  
  filter sterile 
MEM-HS/FCS MEM (10x) 50 ml 
 Glucose (20%) 15 ml 
 NaHCO3 (5,5%) 20 ml 
 L-glutamine (200 mM) 5 ml 
 MEM essential amino acids (50x) 10 ml 
 MEM non-essential amino acids (100x) 10 ml 
 Horse serum (HS)/fetal calf serum 
(FCS), heat-inactivated 
50 ml 
 H2O to 400 ml 
  adjust pH to 7.3 
  fill up to 500 ml  
  filter sterile 
HBSS/HEPES HBSS 500 ml 
 HEPES 1 M pH 7.25 3.5 ml 
Trypsin Trypsin/EDTA (0.05%) 100 ml 
 HEPES 1 M pH 7.25 700 µl 
Fixative for neurons PFA 4% 
 Glutaraldehyde  0.25% 
 Sucrose 2% 
AraC (200x) AraC 12 mg 
 H2O 50 ml 
Borate buffer Boric acid 1.24 g 
 Borax 1.90 g 
 H2O to 400 ml 
  to pH 8.5 
  filter sterile 
Poly-L-lysine Poly-L-lysine hydrobromide 100 mg 
 Borate buffer 100 ml 
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5.1.5 Solutions for neuron stimulation 
Solution Substance Concentration 
ACSF NaCl 124 mM 
 KCl 2.5 mM 
 NaH2PO4 1.2 mM 
 NaHCO3 24 mM 
 HEPES 5 mM 
 Glucose 12.5 mM 
 MgSO4 2 mM 
 CaCl2 2 mM 
ACSF for KCl NaCl 36.5 mM 
stimulation KCl 90 mM 
 NaH2PO4 1.2 mM 
 NaHCO3 24 mM 
 HEPES 5 mM 
 Glucose 12.5 mM 
 MgSO4 2 mM 
 CaCl2 2 mM 
ACSF for pre-synaptic NaCl 124 mM 
stimulation increasing KCl 2.5 mM 
the Ca2+/Mg2+ ratio to NaH2PO4 1.2 mM 
7:1 NaHCO3 24 mM 
 HEPES 5 mM 
 Glucose 12.5 mM 
 MgSO4 0.5 mM 
 CaCl2 3.5 mM 
 
 
5.1.5.1 Receptor agonist solutions for neuron stimulation 
Receptor agonist Substance Concentration 
NMDA ACSF 1x 
 NMDA 10 µM 
NMDA for chemical LTD ACSF 1x 
 NMDA 25 µM 
Glutamate ACSF 1x 
 Glutamate 10 µM 
Glutamate/glycine ACSF 1x 
 Glutamate 10 µM 
 Glycine 10 µM 
GABA ACSF 1x 
 GABA 50 µM 
 
 
 
 
 
 
 
 
5. Material 
 
 
 
154 
5.2 Commercial solutions, chemicals and reagents 
 
5.2.1 Commercial solutions for nucleic acid analysis 
Name Manufacturer 
dNTPs Promega 
DTT 0.1 M Invitrogen 
First strand buffer 5x Invitrogen 
Go-taq-polymerase Promega 
MgCl2 Invitrogen 
MgCl2  Promega 
PCR-flexi-buffer (5x) Promega 
 
5.2.2 Commercial solutions for protein analysis 
Name Manufacturer 
Bradford reagent (5x) Bio-Rad 
Broad Range marker Bio-Rad 
Clean-blot™ IP Detection Reagent (HRP) Thermo Scientific 
SeeBlue Plus2 Prestained marker Invitrogen 
 
5.2.3 Liquid chemicals 
Name Manufacturer 
1 kb Plus DNA Ladder  Invitrogen 
Acidic acid glacial Merck 
Acrylamide (30%) Bio-Rad 
β-Mercaptoethanol Sigma 
Bovine serum albumin (BSA), (10 mg/ml) New England Biolabs 
Broad Range marker BioRad 
Chloroform Merck 
Dimethyl sulfoxide (DMSO) Merck 
Ethanol (technical) Merck 
Ethanol for analysis Merck 
Ethidiumbromide (1%) Bio-Rad 
Formaldehyde 37% Sigma 
Formamide Sigma 
Glycerol Sigma 
Hydrochloric acid (HCL) (fuming, 37%) Merck 
Hydrogen peroxide (30%) Merck 
Isopropanol Merck 
Methanol  VWR 
Mowiol 4-88 Roth 
Normal goat serum (NGS) Vector Laboratories 
Nitrogen (liquid) German-Cryo 
Nonidet P-40 Sigma 
Phenol Merck 
Protein A sepharose 4 Fast Flow GE Healthcare 
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Protein G sepharose 4 Fast Flow GE Healthcare 
SeaBlue Plus2 Pre-Stained Standard  Invitrogen 
TEMED Sigma 
Triton-X 100 Roche 
Tween-20 Sigma 
 
5.2.4 Solid chemicals 
Name Manufacturer 
Agarose Sigma 
APS Fisher Scientific 
Borax Merck 
Boric acid Merck 
Bovine serum albumin (BSA) Merck 
Bromphenol blue Bio-Rad 
Coomassie Brilliant Blue Bio-Rad 
CNBr-activated sepharose beads 4 Fast Flow GE Healthcare 
DTT Sigma 
EDTA Sigma 
GABA Sigma 
Glucose Merck 
Glutamate Sigma 
Glycine Applichem 
Luminol Sigma 
Magnesium chloride (MgCl2) Sigma 
Milk powder (non-fat) Roth 
MOPS Serva 
NaH2PO4  Sigma 
Na2HPO4  Sigma 
NMDA Sigma 
NaOH pellets Sigma 
Paraffin, low-melting Merck 
PBS- Sigma 
p-hydroxy-Coumarin Sigma 
Poly-L-proline MW > 40,000 Sigma 
Propyl gallate Sigma 
Protease inhibitor cocktail tablets,  
Complete, EDTA-free  Roche 
Proteinase K Sigma 
Silvernitrate Applichem 
Sodium acetate Merck 
Sodium azide (NaN3) Merck 
Sodium carbonate (NaCO3) Merck 
Sodium chloride (NaCl) Merck 
Sodium deoxycholate Merck 
Sodium dodecylsulfate (SDS) Merck 
Sodium thiosulfate (NaS2O3) Sigma 
Tris Base Ultra Pure Quality  Roth 
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5.3 Laboratory material 
 
5.3.1 Plastic ware 
 
5.3.1.1 Plastic ware  
Name Manufacturer 
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf 
Tubes  (15 ml, 50 ml, 150 ml) Sarstedt 
PCR tubes Bioplastics 
Pipettes  (5 ml, 10 ml, 25 ml, 50 ml) BD Falcon 
Pipette tips (plugged) ART 
Pipette tips (20 µl, 200 µl, 1000 µl) Sarstedt 
24-well plates Corning 
Micro Bio-spin chromatography columns Bio-Rad 
Chromatography columns (2 ml/ 15 ml/ 50 ml) Bio-Rad 
 
5.3.1.2 Plastic ware for tissue culture 
Name Manufacturer 
24-well-plates Corning 
Eppendorf tubes (1.5 ml, 2 ml)  Eppendorf 
Tubes  (15 ml) Corning 
Pipettes  (5 ml, 10 ml, 25 ml, 50 ml) BD Falcon 
Dishes (3 cm Ø, 6 cm Ø) Nunc 
Flask (T-25, T-75) Nunc 
 
5.3.2 Glass ware 
Name Manufacturer 
Glass bottles (50 ml, 100 ml, 250 ml,  
500 ml, 1000 ml, 2000 ml) Schott 
Glass pipettes Brand 
Pasteur pipettes Brand 
 
5.3.3 Further material 
Name Manufacturer 
PVDF transfer membrane Immobilon-P Millipore 
Bio Max XAR Film Kodak 
 
 
 
 
5. Material 
 
 
 
157 
 
5.4 Technical equipment 
 
5.4.1 General technical equipment 
 
Name Manufacturer 
Accu-Jet/Pipet boy Brand 
Agarose gel electrophoresis running chamber European Molecular Biology Laboratory 
Centrifuge 5415 D  Eppendorf 
Centrifuge 5417 R  Eppendorf 
Centrifuge J2-HS  Beckman 
Centrifuge J2-MC Beckman 
Cover slips No. 1.5H Marienfeld 
ECL-Imager LAS Mini GE Healthcare 
Film developer Curix 60  AGFA 
Freezer (-80 °C)  Thermo Scientific 
Gel documentation machine UV Herolab 
Polyacrylamide gel electrophoresis running 
chamber  Hoefer  
Glass-Teflon tissue grinders Kimbel Kontes 
Heating block  Grant/QBT 
Homogenizer Bosch 
Magnetic stirring plate  Heidolph 
Microscope slides super premium VWR 
PCR machine PTC-200 Peltier thermal cycler  MJ Research 
pH-meter, pH Level 2 InoLab 
Pipettes  Gilson 
Power supply (for agarose gels) Pharmacia 
Power supply Power PAC 200/ 300 Bio-Rad 
Razor blades for vibratome cutting Gilette 
Rocker Heidolph 
Scale  Sartorius 
Scale (analytic)  Kern & Sohn 
SDS gel apparatus SE250  Pharmacia Biotech 
Semi-dry blotting chamber  Bio-Rad 
Shaker  New Brunswick Scientific 
Spectrophotometer UV-DU 640 Beckmann 
Ultracentrifuge Optima™ TL Beckmann 
UV-Table Bachofer 
Vibratome VT 1200S Leica 
Vortex-Genie 2   Scientific Industries 
Water purifier Millipore 
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5.4.2 Microscope 
Name Manufacturer 
Axioplan 2  Carl Zeiss 
Zeiss Meta detector PMT Carl Zeiss 
Zeiss LSM 510 laser set 
Argon/2 laser 488 nm/458 nm/477 nm/514 nm 
HeNe laser 543 nm 
HeNe laser 633 nm 
Carl Zeiss 
25 mW 
1 mW 
10 mW 
Zeiss LSM 510 Meta filter set  
 LP 505 
 BP 475-525 
 BP 500/20 
 BP 505-530 
 BP 530-600 
 BP 560-615 
Carl Zeiss 
Immersol™ 518 F Immersion Oil Carl Zeiss 
 
 
5.5 Oligonucleotides 
 
The oligonucleotides were produces by Eurofins MWG Operon. 
Oligo Sequence (5´-3´ direction) 
Pfn2-for (s) (229) GTC TTG GTC TTT GTA ATG GGA AAA G 
Pfn2-rev (as) (268) GGA GTA CAC AAG GAA AC 
PGFP-1 (as) (593) TTG AAG AAG TCG TGC TG 
PPI-1 (s) (614) TTT CGT CAA TGG GCT GAC AC 
PPI-9 (as) (616) AAG CTC AAA GCA AGA AGG GAC 
PPII-28 (s) (615) AGT CAA GGT GGG GAG CCA AC 
PPI-3 (as) AGC CCA TGT GGT TTT GGC AGC 
PPI-2 (as) GGAAGG GAC AGA TGA GG 
PPII-2 (s) AAA TAC GTC TGG GCA GCC AC 
CPII-1as (as) TGTGCCTGCGTGGACACC 
CPII-2as (as) ATAAAGGTTGGTTACAGACC 
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5.6 Newly generated bacterial expression constructs 
 
 
Fig. 28 Bacterial expression vectors for Pfn1-, Pfn2- and P2-GFP-Streptag fusion proteins 
The cDNA of mouse Pfn1, Pfn2a or P2-GFP was generated from isolated brain tissue RNA. The 
respective gene was integrated in the pMW172-Strepag expression vector (kindly provided by Julia 
Hecker) by SacI and NdeI mediated insertion. PMW172-Streptag vectors with the inserted gene of 
Pfn1 (A, Witke archive Nr. 574), Pfn2 (B, Witke archive Nr. 571) and P2-GFP (C, Witke archive Nr. 
573) were obtained from bacteria and the corresponding fusion proteins were purified from bacterial 
extracts. 
 
 
5.7 Antibodies 
 
5.7.1 Primary antibodies 
Antigen Host species Company Dilutions Conditions 
Abi1 Rb poly Sigma WB 1:2000 2 h, RT 
Abi2 Ms mono Sigma WB 1:200 o.n., 4°C 
Actin (clone C4) Ms mono ImmunO WB 1:2000 2 h, RT 
Arp3 Rb poly Anika Steffens WB 1:1800 2 h, RT 
DBH Sh poly Cell signaling IF 1:500 o.n., 4°C 
Calbindin Ms mono Sigma IF 1:400 o.n., 4°C 
ChAT Rb poly Abcam IF 1:200 24 h, RT 
ChT Ms mono SYSY IF 1:500 o.n., RT 
Cleaved-caspase3 Rb poly Millipore/ Chemicon IF 1:100 o.n., 4°C 
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Cleaved-caspase3- 
Alexa488 
Rb poly Cell signaling IF 1:100 o.n., 4°C 
CNPase Ms mono Millipore IF 1:100 o.n., 4°C 
Cortactin Ms mono Anika Steffens WB 1:1000 1 h, RT 
CyFIP1  Rb poly Upstate cell signaling WB 1:500 o.n., 4°C 
CyFIP2 (5C9)  Ms mono Walter Witke WB 1:2 o.n., 4°C 
CyFIP2 (5C9)- 
affinity purified  
Ms mono Walter Witke IF 1:100 o.n., 4°C 
DARPP32 Rb poly Cell signaling IF 1:100 o.n., 4°C 
Dopamine D1 receptor Rb poly Alomone IF 1:50 o.n., 4°C 
Dopamine D2 receptor Rb poly Alomone IF 1:50 o.n., 4°C 
Iba1 Rb poly WAKO Chemicals IF 1:750 o.n., 4°C 
Dynamin1 Ms mono Upstate cell signaling WB 1:1000 o.n., 4°C 
Endophilin1 Rb poly Walter Witke WB 1:500 o.n., 4°C 
GABA Rb poly Sigma IF 1:1000 o.n., 4°C 
GABAB-receptor Gp poly Sigma IF 1:1000 o.n., 4°C 
Gad1 Rb poly SYSY IF 1:200 o.n., 4°C 
Gephyrin Ms mono SYSY IF 1:200 o.n., 4°C 
GFAP Rb poly Sigma IF 1:150 
WB 1:100 
o.n., 4°C 
o.n., 4°C 
GFAP Ms mono Millipore WB 1:500 
IF 1:500 
o.n., 4°C 
o.n., 4°C 
GFP Chk poly Abcam WB 1:2000 
IF 1:1000 
o.n., 4°C 
o.n., 4°C 
GFP Chk poly Acris WB 1:500 
IF 1:500 
o.n., 4°C 
o.n., 4°C or RT 
GFP-Atto488 Llama mono Chromotek IF 1:100 o.n., 4°C 
GFP-Trap-A Llama mono Chromotek IP  
GluR1 Rb poly Upstate cell signaling IF 1:500 o.n., 4°C 
Grip Rb poly SYSY IF 1:100 24 h, RT 
Huntingtin Ms mono Chemicon WB 1:1000 o.n., 4°C 
Map2 Rb poly Millipore IF 1:500 o.n., 4°C 
Map2 Ms mono Transduct. Labs. IF 1:1000 o.n., 4°C 
MBP Rb poly Abcam IF 1:100 o.n., RT 
mDia1 Ms mono BD Transduct. Labs. WB 1:500 o.n., 4°C 
mDia2 Rb poly Anika Steffens WB 1:1000 o.n., 4°C 
Mena Rb poly Walter Witke WB 1:500 o.n., 4°C 
Nap1 Rb poly Upstate cell signaling WB 1:1000 o.n., 4°C 
Nestin Ms mono Millipore IF 1:100 o.n., 4°C 
NeuN (clone A60) Ms mono Millipore IF 1:100 o.n., 4°C 
Neurofilament 200 
(clone RT97) 
Ms mono Böhringer Mannheim IF 1:500 o.n., 4°C 
Neurofilament 200  Rb poly Sigma IF 1:500 o.n., 4°C 
NG2 Rb poly Millipore IF 1:100 o.n., RT 
NRGN Rb poly ProteinTech IF 1:500 o.n., 4°C 
Oct4a Rb poly Cell Signaling IF 1:200 o.n., 4°C 
Parvalbumin Ms mono Sigma IF 1:500 o.n., 4°C 
Pax6 Rb poly Covance IF 1:100 o.n., 4°C 
Pfn1 T Rb poly Walter Witke WB 1:1000 
IF 1:100 
o.n., 4°C 
o.n., 4°C 
Pfn2 T2 Rb poly Walter Witke WB 1:2000 2h, RT - o.n., 4°C 
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IF 1:100 o.n., RT 
Pfn2 3003 Rb poly Walter Witke WB 1:1000 
IF 1:100 
o.n., 4°C 
o.n., 4°C 
Pfn2 5A7 Ms mono Walter Witke IP 1:100  
Pfn2 DB2 Rb poly Walter Witke WB 1:100 
IF 1:100 
o.n., 4°C 
o.n., 4°C 
Pfn2 GD2 Rb poly Walter Witke WB 1:1000 
IF 1:100 
o.n., 4°C 
o.n., 4°C 
PSD95 Rb poly SYSY IF 1:100 o.n., 4°C 
PSD95 Ms mono Upstate cell signaling IF 1:200 o.n., RT 
Rac1 Ms mono Anika Steffens WB 1:2000 o.n., 4°C 
Reelin Ms mono Millipore WB 1:1000 
IF 1:100 
o.n., 4°C 
o.n., 4°C 
S100β Rb poly Abcam WB 1:1000 
IF 1:1000 
o.n., 4°C 
o.n., 4°C 
Snap25 Rb poly Sigma IF 1:500 o.n., 4°C 
Sox2 Rb poly Cell signaling IF 1:200 o.n., 4°C 
Sox2 Ms mono Cell signaling IF 1:200 o.n., 4°C 
Synapsin 1 Ms mono Chemicon IF 1:200 2 h, RT 
Synapsin 2a Ms mono Transduct. Labs. IF 1:2000 2 h, RT - o.n., 4°C 
Synaptophysin Ms mono Sigma IF 1:400 o.n., 4°C 
Synaptotagmin1 Rb poly SYSY IF 1:100 o.n., 4°C 
Tau1  
(clone PC1C6) 
Ms mono Millipore IF 1:1000 o.n., 4°C 
Tbr1 Rb poly Millipore IF 1:200 o.n., 4°C 
Tbr2 Rb poly Millipore IF 1:200 o.n., 4°C 
TH (clone TH-2) Ms mono Sigma IF 1:150 o.n., 4°C 
TH Gp poly SYSY IF 1:500 o.n., 4°C 
TPH Ms mono Sigma IF 1:200 o.n., 4°C 
β3-tubulin Ms mono Promega IF 1:1000 o.n., 4°C 
γ-tubulin Ms mono Sigma WB 1:500 o.n., 4°C 
VAMP2 Rb poly SYSY IF 1:1000 o.n., 4°C 
VASP Rb poly Anika Steffens WB 1:1000 o.n., 4°C 
VIAAT Rb poly Bruno Grasnier IF 1:500 o.n., 4°C 
VGluT1 Gp poly Millipore IF 1:500 o.n., RT 
VGluT2 Gp poly SYSY IF 1:500 o.n., 4°C 
Vimentin Rb poly Abcam IF 1:1000 o.n., 4°C 
Wave1 Ms mono BD Transduct. Labs. WB 1:1000 2 h, RT 
Wave2 Rb poly Upstate cell signaling WB 1:500 o.n., 4°C 
Wave3 Goat poly Santa Cruz WB 1:500 o.n., 4°C 
Wave3 Rb poly Abcam WB 1:1000 o.n., 4°C 
 
 
5.7.2 Secondary antibodies 
 
Antigen species Conjugate Host species Company dilution 
Chicken Alexa 488 Goat Life Technologies 1:1000 
Chicken Alexa 488 Goat Abcam 1:500 
Chicken Atto 488 Alpaca Creative Diagnostics 1:100 
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Chicken HRP Goat Dianova 1:5000 
Goat HRP Donkey Dianova 1:5000 
Guinea Pig CF 543 Donkey Biotium 1:1000 
Guinea pig Alexa 594 Goat Life Technologies 
(Molecular Probes) 
1:500 
Guinea pig HRP Rabbit Sigma 1:5000 
Mouse Alexa 488 Goat Life Technologies 
(Molecular Probes) 
1:1000 
Mouse Alexa 555 Goat Life Technologies 1:1000 
Mouse Alexa 594 Goat Life Technologies 
(Molecular Probes) 
1:1000 
Mouse Alexa 647 Goat Life Technologies 
(Invitrogen) 
1:500 
Mouse CF 633 Donkey Biotium 1:500 
Mouse HRP Goat Dianova 1:5000 
Rabbit Alexa 488 Goat Life Technologies 1:1000 
Rabbit Alexa 555 Goat Life Technologies 1:1000 
Rabbit Alexa 594 Goat Life Technologies 
(Molecular Probes) 
1:1000 
Rabbit Alexa 647 Goat Life Technologies 
(Invitrogen) 
1:500 
Rabbit CF 633 Donkey Biotium 1:500 
Rabbit HRP Goat Dianova 1:5000 
Sheep Alexa 555 Donkey Life Technologies 1:1000 
 
 
5.8 Dyes and staining reagents 
 
Dye type Conjugate Company 
DAPI  Sigma 
Draq5  Biostatus 
Phalloidin Alexa 488 Life Technologies 
Phalloidin Alexa 594 Life Technologies 
Phalloidin Alexa 680 Life Technologies 
Phalloidin Atto 488 AttoTec 
Phalloidin CF 542 Biotium 
Propidium iodide  Sigma 
Streptactin HRP Bio-Rad 
 
 
5.9 Animal lines 
 
Line Reference 
Pfn2-lacZ (Pfn2 KO) Walter Witke 
P2-GFP Pietro Pilo Boyl 
wt  Charles River 
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Supplementary Fig. 1 Schematic view of the projections originating from dopaminergic 
neurons Dopaminergic neurons can be found manly in regions of the mouse brain that can be further 
subdivided into several neuron groups. The depicted major dopaminergic groups comprise the 
substantia nigra (SN, group A9) and ventral tegmental area (VTA, group A10), the retrorubral field 
(RRF, group A8) and the olfactory bulb (group A16). These regions innervate various brain areas, as 
can be appreciated by the emerging projections that are shown here in purple (modified from Kandel 
et al., 2000). 
 
 
 
 
Supplementary Fig. 2 Schematic overview of the innervations originating from noradrenergic 
neurons of the locus coeruleus 
The noradrenergic system has widespread innervations throughout the entire brain, exclusively 
originating from the locus coeruleus (LC) of the brainstem. Although only small numbers of 
noradrenergic neurons exist in the mouse brain, they have a pronounced modulatory effect on nearly 
every neuronal pathway and brain region (modified from Kandel et al., 2000). 
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Supplementary Fig. 3 Schematic overview of serotonergic projections of the Raphe nuclei 
Serotonergic neurons are located dispersed throughout the Raphe nuclei of the brainstem. They 
innervate several regions of the basal ganglia (striatum and thalamus), the hippocampus, the 
cerebellum and cortical areas. Serotonin has a dual role, since it can modulate synaptic transmission 
through both excitation and inhibition depending on the expression of the different serotonin receptor 
subtypes (modified from Kandel et al., 2000). 
 
 
Supplementary Fig. 4 Schematic overview of cholinergic neurons and their projections in the 
mouse brain 
Cholinergic neurons are localized to three groups in the mouse brain. The biggest and most dispersed 
group is located in the medial septum and a slightly smaller group in the pontomesencephalic region 
near the cerebellum comprised of the ppt (pedunculopontine tegmental nucleus) and ldt (laterodorsal 
tegmental nucleus). These neurons send their axons to nearly all brain regions. In addition large 
cholinergic interneurons can be found isolated in the striatum (modified from Woolf, 1991). 
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Supplementary Fig. 5 Excitatory neuronal systems immunofluorescence control stainings of 
wildtype brain sections 
Co-Immunofluorescence studies were verified by several control stainings, including the control for the 
specificity of the P2-GFP signal using wildtype (wt) sections. Wt mice should not express the GFP 
protein and should therefore show no signal, if they were processed in the same way as the 
homozygous P2-GFP knock-in animals (G/G) were treated. 
A signal for GFP (green) could not be detected using the same settings for image acquisition and 
processing, confirming the specificity of the P2-GFP labelling approach. The respective controls for the 
brain regions and neuronal systems were chosen according to the regions of the excitatory neuronal 
systems that were shown in Fig. 14. (A) Glutamatergic neurons were specifically identified using 
neurogranin (NRGN, red) as a marker protein in the hippocampus and (B) the cortex. (C) 
Dopaminergic neurons of the substantia nigra (SN) and (D) the ventral tegmental area (VTA) were 
labelled with an antibody recognizing a specific antigen for TH (red). (E) Neurons positive for 
noradrenaline were analyzed in the locus coeruleus (LC) using DBH (red) as a marker. (F) 
Serotonergic neurons of the Raphe nuclei were stained with an anti-TPH (red) antibody and (G) 
cholinergic neurons were identified by their specific expression of the choline transporter (ChT, red) in 
the pedunculopontine tegmental nucleus (ppt) or (H) by their expression of choline acetyltransferase 
(ChAT, red) in the striatum. To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 
(Biostatus) was used. 
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Supplementary Fig. 6 GABAergic neuronal systems immunofluorescence control stainings of 
wildtype brain sections  
Co-Immunofluorescence studies were verified by several control stainings, including the control for the 
specificity of the P2-GFP signal using wildtype (wt) sections. Wt mice should not express the GFP 
protein and should therefore show no signal, if they were processed in the same way as the 
homozygous P2-GFP knock-in animals (G/G) were treated. 
A signal for GFP (green) could not be detected using the same settings for image acquisition and 
processing, confirming the specificity of the P2-GFP labelling approach. 
The respective controls for the GABAergic neurons in the mouse brain were chosen according to the 
regions of the GABAergic neuronal systems that were shown in Fig. 15. GABAergic neuronal subtypes 
were specifically identified using GABA (red) or the Ca2+-binding proteins parvalbumin (PV, red) and 
calbindin (CB, red) as markers. (A) Few GABAergic neurons co-express Pfn2, which are distributed 
throughout the cortex and can moreover be subcategorized using (B) PV and (C) CB to identify 
specific cell types of GABAergic neurons. The distribution of these marker proteins and therefore of 
the corresponding GABAergic neuronal subtypes were further studied (D, E) in the hippocampus and 
(F, G) the cerebellum. To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 (Biostatus) 
was used. 
 
7. Supplementary 
 
 
185 
 
Supplementary Fig. 7 Striatal system immunofluorescence control stainings of wildtype brain 
sections 
Co-Immunofluorescence studies were verified by several control stainings, including the control for the 
specificity of the P2-GFP signal using wildtype (wt) sections. Wt mice should not express the GFP 
protein and should therefore show no signal, if they were processed in the same way as the 
homozygous P2-GFP knock-in animals (G/G) were treated. 
A signal for GFP (green) could not be detected using the same settings for image acquisition and 
processing, confirming the specificity of the P2-GFP labelling approach. 
The respective controls for the neurons in the mouse striatum were chosen according to the images 
that were shown in Fig. 16. (A) GABAergic medium spiny neuron (MSN) subtypes were specifically 
identified using DARPP32 (red). (B) Aspiny interneurons were stained with the Ca2+-binding protein 
parvalbumin (PV, red). MSNs were further subdivided into either dopamine D1 receptor-expressing 
cells (D1R, red) for the (C) dorsal and (D) ventral striatum or dopamine D2 receptor-expressing (D2R, 
red) cells in the (E) dorsal and (F) ventral striatum. To visualize the cell nuclei (blue), the DNA-
intercalating dye Draq5 (Biostatus) was used. 
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Supplementary Fig. 8 Sensory systems immunofluorescence control stainings of wildtype 
brain sections 
Co-Immunofluorescence studies were verified by several control stainings, including the control for the 
specificity of the P2-GFP signal using wildtype (wt) sections. Wt mice should not express the GFP 
protein and should therefore show no signal, if they were processed in the same way as the 
homozygous P2-GFP knock-in animals (G/G) were treated. 
A signal for GFP (green) could not be detected using the same settings for image acquisition and 
processing, confirming the specificity of the P2-GFP labelling approach. 
The respective controls for the neurons in the mouse olfactory bulb were chosen according to the 
images that were shown in Fig. 18. (A) Olfactory granule cells (NeuN, red) next to Mitral cells (NeuN-
neg., unlabelled) (B) GABAergic periglomerular neurons and short axon cells around a glomerulus 
(GABA, red) (C) Dopaminergic short axon cells around a glomerulus (TH, red). 
To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 (Biostatus) was used. 
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Supplementary Fig. 9 Glial cells immunofluorescence control stainings of wildtype brain 
sections 
Co-Immunofluorescence studies were verified by several control stainings, including the control for the 
specificity of the P2-GFP signal using wildtype (wt) sections. Wt mice should not express the GFP 
protein and should therefore show no signal, if they were processed in the same way as the 
homozygous P2-GFP knock-in animals (G/G) were treated. 
A signal for GFP (green) could not be detected using the same settings for image acquisition and 
processing, confirming the specificity of the P2-GFP labelling approach. 
The respective controls for the glial cells were chosen according to the brain regions that were shown 
in Fig. 20.  
The four major types of glial cells in the brain were analyzed. Astrocytes can be in a dormant or a 
reactive state and express corresponding molecular markers. (A) Both types of astrocytes express 
S100β but (B) only reactive astrocytes express GFAP at high levels. (C) Also microglia can switch 
from an inactive to an active state, both states expressing Iba1 as a marker protein for microglia. (D) 
Oligodendrocytes express the enzyme CNPase mostly in their cell bodies, whereas (E) the myelin 
basic protein (MBP) is preferentially localized to myelin-sheaths of their processes. (F) The fourth type 
of glial cells are the NG2 cells, which exclusively produce the NG2 proteoglycan and transport it to 
their cell membranes. To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 (Biostatus) 
was used. 
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Supplementary Fig. 10 Adult neural stem cell and progenitor cell immunofluorescence control 
stainings of wildtype brain sections  
Co-Immunofluorescence studies were verified by several control stainings, including the control for the 
specificity of the P2-GFP signal using wildtype (wt) sections. Wt mice should not express the GFP 
protein and should therefore show no signal, if they were processed in the same way as the 
homozygous P2-GFP knock-in animals (G/G) were treated. 
A signal for GFP (green) could not be detected using the same settings for image acquisition and 
processing, confirming the specificity of the P2-GFP labelling approach. 
The respective controls for adult neural stem cells (aNSCs) and progenitor cells were chosen 
according to the brain regions that were shown in Fig. 21. (A) aNSCs are mainly localized to the 
subventricular zone (SVZ), where they express high levels of the intermediate filament nestin (red) 
and (B) the transcription factor Pax6 (red), which can also be found in aNSC-derived progenitor cells. 
(C) The progenitor cells remain Pax6-positive (red), while migrating from the SVZ towards the olfactory 
bulb through the rostral migratory stream (RMS). (D) Adult NSCs of the hippocampal dentate gyrus 
are located in the so-called subgranular zone (SGZ) and are enriched in the transcription factor Oct4 
(red). To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 (Biostatus) was used. 
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Supplementary Fig. 11 Immunofluorescence control stainings of wildtype brain sections for the 
specificity of the applied fluorescently-conjugated secondary antibodies  
Co-Immunofluorescence studies were verified by several control stainings, including the control for the 
specificity of the fluorescently-conjugated (Alexa488 or Alexa555) secondary antibody towards 
preferably the host species of the used primary antibodies. 
A signal for secondary antibody conjugated to a fluorescent dye without a corresponding primary 
antibody could not be detected. The same settings for image acquisition and processing were applied, 
confirming the specificity of the immunofluorescence approach. 
P2-GFP fluorescence was enhanced by an anti-GFP antibody derived from chicken yolk that was 
labelled by secondary anti-chicken antibodies conjugated to Alexa488 dye molecules (green). In 
addition several other primary antibodies against specific marker proteins were added, which were 
labelled with the corresponding secondary antibodies for the respective host species conjugated to the 
Alexa555 dye. Many primary antibodies are specifically raised in (A) rabbits or (B) mice as host 
species as well as other species, which are less frequently used, such as (C) guinea pig and (D) 
sheep. To visualize the cell nuclei (blue), the DNA-intercalating dye Draq5 (Biostatus) was used. 
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Neuronal System/ Cell type P2 expression
Glutamatergic neurons positive +++ 
Dopaminergic neurons positive +++ 
Serotonergic neurons positive ++ 
Noradrenergic neurons positive ++ 
Cholinergic neurons positive + 
GABAergic neurons mixed (++) 
Sensory neurons (e.g. Mitral cells) positive +++ 
Adult neural stem cells (aNSCs) positive ++ 
Progenitor cells negative - 
Astrocytes negative - 
Oligodendrocytes negative - 
Microglia negative - 
NG2 cells negative - 
 
 
Supplementary Fig. 12 Neuronal systems expressing Pfn2 in summary 
Most neuronal systems express Pfn2, nonetheless with varying levels. Among the excitatory neuronal 
systems, the glutamatergic and dopaminergic neurons express the highest levels of Pfn2 in the brain. 
Serotonergic and noradrenergic neurons are also highly positive for Pfn2, while cholinergic neurons 
merely produce moderate levels of Pfn2. GABAergic neurons express Pfn2 in specific cell types only 
but most GABAergic neurons are devoid of Pfn2. Sensory neurons are enriched in Pfn2 as well with 
the glutamatergic Mitral cells being one of the highest Pfn2-expressing cells in the brain. Pfn2 can also 
be found in adult neural stem cells of the SVZ, but is missing from aNSC-derived progenitor cells. Glial 
cells in general also lack the expression of Pfn2 in any of the investigated cell populations. 
 
Anti-Pfn2 antibody Host species Applications   
WB IF IP P2-GFP recognition
Anti-Pfn2 2T Rabbit x x x - 
Anti-Pfn2 GD2 Rabbit x (x) x 53% 
Anti-Pfn2 3003 Rabbit x - - 29% 
Anti-Pfn2 DB2 Rabbit (x) - - - 
Anti-Pfn2 5A7 Mouse - - x - 
 
Supplementary Fig. 13 Applications tested for the different anti-Pfn2 antibodies 
Different anti-Pfn2 antibodies (2T, GD2, 3003, DB2, 5A7) were raised in rabbits and mice before 
analyzing their efficiency in certain experimental applications. The anti-Pfn2 2T antibody could be used 
for all tested purposes, but failed to label also P2-GFP efficiently in Western blot assays. The anti-Pfn2 
antibody GD2 could be verified to bind most efficiently to P2-GFP in addition to Pfn2 (53% P2-GFP is 
labelled compared to Pfn2), but it is only of limited use in IF experiments. P2-GFP was also 
recognized in WB experiments by the anti-Pfn2 3003 antibody at a rate of 29% of the efficiency it 
labels Pfn2. This antibody was not operational in the other tested applications. The least effective 
antibody was anti-Pfn2 DB2, which only showed signals for Pfn2 in Western blots among a high 
aspecific background. The monoclonal anti-Pfn2 antibody produced by mouse hybridoma cells of the 
clone 5A7 was only operative in IP. WB= Western blot; IF= Immunofluorescence; IP= 
Immunoprecipitation 
